0001493152-21-019503.txt : 20210812 0001493152-21-019503.hdr.sgml : 20210812 20210812160613 ACCESSION NUMBER: 0001493152-21-019503 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210812 DATE AS OF CHANGE: 20210812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Co-Diagnostics, Inc. CENTRAL INDEX KEY: 0001692415 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 462609396 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38148 FILM NUMBER: 211167507 BUSINESS ADDRESS: STREET 1: 4049 SOUTH HIGHLAND DRIVE CITY: SALT LAKE CITY STATE: UT ZIP: 84124 BUSINESS PHONE: 8012789769 MAIL ADDRESS: STREET 1: 4049 SOUTH HIGHLAND DRIVE CITY: SALT LAKE CITY STATE: UT ZIP: 84124 10-Q 1 form10-q.htm
0001692415 false 2021 Q2 --12-31 P3Y P7Y5M9D P7Y2M1D P2Y9M18D Feb 29,2024 0001692415 2021-01-01 2021-06-30 0001692415 2021-08-10 0001692415 2021-06-30 0001692415 2020-12-31 0001692415 2021-04-01 2021-06-30 0001692415 2020-04-01 2020-06-30 0001692415 2020-01-01 2020-06-30 0001692415 2019-12-31 0001692415 2020-06-30 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001692415 us-gaap:CommonStockMember 2020-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001692415 us-gaap:RetainedEarningsMember 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001692415 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001692415 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001692415 2021-01-01 2021-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2021-03-31 0001692415 us-gaap:CommonStockMember 2021-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001692415 us-gaap:RetainedEarningsMember 2021-03-31 0001692415 2021-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2021-04-01 2021-06-30 0001692415 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001692415 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001692415 us-gaap:ConvertiblePreferredStockMember 2021-06-30 0001692415 us-gaap:CommonStockMember 2021-06-30 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001692415 us-gaap:RetainedEarningsMember 2021-06-30 0001692415 us-gaap:ConvertiblePreferredStockMember 2019-12-31 0001692415 us-gaap:CommonStockMember 2019-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001692415 us-gaap:RetainedEarningsMember 2019-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001692415 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001692415 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001692415 2020-01-01 2020-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-03-31 0001692415 us-gaap:CommonStockMember 2020-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001692415 us-gaap:RetainedEarningsMember 2020-03-31 0001692415 2020-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-04-01 2020-06-30 0001692415 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001692415 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-06-30 0001692415 us-gaap:CommonStockMember 2020-06-30 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001692415 us-gaap:RetainedEarningsMember 2020-06-30 0001692415 srt:MinimumMember 2021-01-01 2021-06-30 0001692415 srt:MaximumMember 2021-01-01 2021-06-30 0001692415 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember CODX:TwoCustomersTogetherMember 2021-01-01 2021-06-30 0001692415 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember CODX:TwoCustomersTogetherMember 2021-01-01 2021-06-30 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001692415 srt:AmericasMember 2021-04-01 2021-06-30 0001692415 srt:AmericasMember 2020-04-01 2020-06-30 0001692415 srt:AmericasMember 2021-01-01 2021-06-30 0001692415 srt:AmericasMember 2020-01-01 2020-06-30 0001692415 CODX:RestOfWorldMember 2021-04-01 2021-06-30 0001692415 CODX:RestOfWorldMember 2020-04-01 2020-06-30 0001692415 CODX:RestOfWorldMember 2021-01-01 2021-06-30 0001692415 CODX:RestOfWorldMember 2020-01-01 2020-06-30 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-04-01 2021-06-30 0001692415 srt:AmericasMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-04-01 2020-06-30 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-06-30 0001692415 CODX:RestOfWorldMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-04-01 2021-06-30 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-04-01 2020-06-30 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-06-30 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2021-06-30 0001692415 CODX:StockOptionsMember 2021-01-01 2021-06-30 0001692415 CODX:StockOptionsMember 2021-06-30 0001692415 CODX:StockOptionsMember 2021-01-31 0001692415 CODX:StockOptionsMember srt:MaximumMember 2021-01-31 0001692415 CODX:StockOptionsMember srt:MinimumMember 2021-01-31 0001692415 CODX:StockOptionsMember 2021-01-01 2021-01-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-06-30 0001692415 us-gaap:WarrantMember 2021-06-30 0001692415 CODX:ThirdPartiesMember us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001692415 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001692415 us-gaap:EmployeeStockOptionMember 2020-04-01 2021-06-30 0001692415 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001692415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001692415 us-gaap:WarrantMember 2021-04-01 2021-06-30 0001692415 us-gaap:WarrantMember 2020-04-01 2020-06-30 0001692415 us-gaap:WarrantMember 2021-01-01 2021-06-30 0001692415 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001692415 us-gaap:StockCompensationPlanMember 2021-04-01 2021-06-30 0001692415 us-gaap:StockCompensationPlanMember 2020-04-01 2020-06-30 0001692415 us-gaap:StockCompensationPlanMember 2021-01-01 2021-06-30 0001692415 us-gaap:StockCompensationPlanMember 2020-01-01 2020-06-30 0001692415 CODX:ExclusiveLicenseAgreementMember CODX:DrSatterfieldMember 2017-01-01 0001692415 CODX:ExclusiveLicenseAgreementMember CODX:DrSatterfieldMember CODX:PerMonthMember 2016-12-28 2017-01-01 0001692415 CODX:ExclusiveLicenseAgreementMember CODX:DrBrentSatterfieldMember 2021-06-30 0001692415 2020-02-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:acre

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2021

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File No. 001-38148

 

CO-DIAGNOSTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Utah   3841   46-2609396
(State or other jurisdiction of
incorporation or organization)		   (Primary Standard Industrial
Classification Code Number)		   (I.R.S. Employer
Identification Number)

 

2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address of principal executive offices and zip code)

 

(801) 438-1036

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CODX   NASDAQ-CM

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐ Accelerated filer ☐
  Non-accelerated filer ☐ Smaller reporting company ☐
      Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

As of August 10, 2021, there were 28,889,890 shares of common stock, par value $0.001 per share, outstanding.

 

 

 

 
 

 

CO-DIAGNOSTICS, INC.

 

TABLE OF CONTENTS

 

PART I FINANCIAL INFORMATION:  
     
Item 1. Financial Statements (unaudited): 3
     
  Condensed Consolidated Balance Sheets 3
     
  Condensed Consolidated Statements of Operations 4
     
  Condensed Consolidated Statements of Cash Flows 5
     
  Condensed Consolidated Statements of Stockholders’ Equity 6
     
  Notes to Condensed Consolidated Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 21
     
Item 4. Controls and Procedures 21
     
PART II OTHER INFORMATION:  
     
Item 1. Legal Proceedings 22
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22
     
Item 3. Defaults Upon Senior Securities 22
     
Item 4. Mine Safety Disclosures 22
     
Item 5. Other Information 22
     
Item 6. Exhibits 22
     
  Signatures 23

 

2
 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

CO – DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

 

   June 30, 2021   December 31, 2020 
Assets          
Current assets          
Cash and cash equivalents  $70,274,078   $42,976,713 
Marketable investment securities   2,109,675    4,335,446 
Accounts receivable, net   12,755,952    12,136,833 
Inventory   4,120,704    7,995,189 
Prepaid expenses   1,039,506    369,028 
Deferred tax asset   20,443    547,224 
Total current assets   90,320,358    68,360,433 
Property and equipment, net   1,192,901    949,639 
Investment in joint venture   1,276,202    1,927,125 
Total assets  $92,789,461   $71,237,197 
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable  $427,144   $598,318 
Accrued expenses, current   4,001,445    2,849,503 
Accrued expenses (related party), current   90,000    120,000 
Income taxes payable   47,180    637,560 
Deferred revenue   163,134    305,307 
Total current liabilities   4,728,903    4,510,688 
Long-term liabilities          
Accrued expenses, noncurrent   794,615    - 
Accrued expenses (related party), noncurrent   -    30,000 
Total long-term liabilities   794,615    30,000 
Total liabilities   5,523,518    4,540,688 
Commitments and contingencies (Note 9)    -    - 
Stockholders’ equity          
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2021 and December 31, 2020   -    - 
Common stock, $0.001 par value; 100,000,000 shares authorized; 28,889,890 and 28,558,033 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively   28,890    28,558 
Additional paid-in capital   52,042,150    49,157,236 
Accumulated earnings   35,194,903    17,510,715 
Total stockholders’ equity   87,265,943    66,696,509 
Total liabilities and stockholders’ equity  $92,789,461   $71,237,197 

 

See accompanying notes to unaudited condensed consolidated financial statements

 

3
 

 

CO – DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   2021   2020   2021   2020 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
Revenue  $27,358,140   $24,040,274   $47,382,909   $25,588,802 
Cost of revenue   2,504,355    5,975,305    5,776,920    6,457,045 
Gross profit   24,853,785    18,064,969    41,605,989    19,131,757 
Operating expenses                    
Sales and marketing   5,853,313    390,191    7,050,859    658,674 
General and administrative   2,468,433    2,191,034    5,404,122    3,650,518 
Research and development   4,669,160    750,249    6,886,223    1,150,271 
Depreciation and amortization   71,714    25,218    138,719    45,966 
Total operating expenses   13,062,620    3,356,692    19,479,923    5,505,429 
Income from operations   11,791,165    14,708,277    22,126,066    13,626,328 
Other income (expense)                    
Interest income   10,529    38,173    25,186    45,748 
Gain (loss) on equity method investment in joint venture   128,595    258,559    (336,348)   267,740 
Total other income (expense)   139,124    296,732    (311,162)   313,488 
Income before income taxes   11,930,289    15,005,009    21,814,904    13,939,816 
Income tax provision   2,145,076    -    4,130,716    - 
Net income  $9,785,213   $15,005,009   $17,684,188   $13,939,816 
Earnings per common share:                    
Basic  $0.34   $0.54   $0.61   $0.50 
Diluted  $0.33   $0.51   $0.59   $0.48 
Weighted average shares outstanding:                    
Basic   28,794,047    27,582,229    28,921,140    27,605,137 
Diluted   29,741,265    29,152,222    29,833,955    29,094,475 

 

See accompanying notes to unaudited condensed consolidated financial statements

 

4
 

 

CO – DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2021   2020 
   Six Months Ended June 30, 
   2021   2020 
Cash flows from operating activities          
Net income   $17,684,188   $13,939,816 
Adjustments to reconcile net income to cash used in operating activities:          
Depreciation and amortization   138,719    45,966 
Stock-based compensation expense   2,440,347    1,124,242 
Loss (gain) from equity method investment   336,348    (267,740)
Deferred income taxes   526,781    - 
Bad debt expense   147,775    524,389 
Changes in assets and liabilities:          
Accounts receivable   (766,894)   (5,742,883)
Prepaid expenses   (670,478)   (2,527,983)
Inventory   3,874,485    (10,030,838)
Deferred revenue   (142,173)   1,044,225 
Income taxes payable   (590,380)   - 
Accounts payable and accrued expenses   1,715,383    1,542,347 
Net cash provided by (used in) operating activities   24,694,101    (348,459)
Cash flows from investing activities          
Purchases of property and equipment   (381,981)   (205,290)
Proceeds from maturities of marketable investment securities   2,225,771    - 
Investment in joint venture   314,575    (714,500)
Net cash provided by (used in) investing activities   2,158,365    (919,790)
Cash flows from financing activities          
Proceeds from sale of common stock   -    19,470,005 
Proceeds from exercise of options and warrants   444,899    913,465 
Payment of offering costs   -    (1,457,922)
Net cash provided by financing activities   444,899    18,925,548 
Net increase in cash and cash equivalents   27,297,365    17,657,299 
Cash and cash equivalents at beginning of period   42,976,713    893,138 
Cash and cash equivalents at end of period  $70,274,078   $18,550,437 
Supplemental disclosure of cash flow information          
Interest paid  $-   $- 
Income taxes paid  $3,423,700   $- 
Supplemental disclosure of non-cash investing and financing transactions          
Inventory moved to property, plant and equipment  $-   $117,220 

 

See accompanying notes to unaudited condensed consolidated financial statements

 

5
 


 

CO – DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

 

   Shares   Amount   Shares   Amount   Capital   (Deficit)   Equity 
   Convertible Preferred Stock   Common Stock   Additional Paid-in   Accumulated Earnings   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   (Deficit)   Equity 
Balance as of December 31, 2020   -   $-    28,558,033   $28,558   $49,157,236   $17,510,715   $66,696,509 
Common stock issued for option exercises   -    -    65,891    66    148,914    -    148,980 
Stock-based compensation   -    -    41,790    42    1,512,970    -    1,513,012 
Net income   -    -    -    -    -    7,898,975    7,898,975 
Balance as of March 31, 2021   -   $-    28,665,714   $28,666   $50,819,120   $25,409,690   $76,257,476 
Common stock issued for option exercises   -    -    118,334    118    295,799    -    295,917 
Stock-based compensation   -    -    105,842    106    927,231    -    927,337 
Net income   -    -    -    -    -   $9,785,213    9,785,213 
Balance as of June 30, 2021   -   $-    28,889,890   $28,890   $52,042,150   $35,194,903   $87,265,943 
                                    
Balance as of December 31, 2019   25,600   $26    17,342,922   $17,343   $26,687,701   $(24,967,814)  $1,737,256 
Public offering, net of offering costs of $1,457,922   -    -    7,242,954    7,243    18,004,840    -    18,012,083 
Common stock issued for warrant exercises   -    -    719,492    720    49,280    -    50,000 
Stock-based compensation expense   -    -    12,363    12    432,811    -    432,823 
Conversion of preferred stock to common   (25,600)   (26)   2,133,333    2,133    (2,107)   -    - 
Net loss   -    -    -    -    -    (1,065,193)   (1,065,193)
Balance as of March 31, 2020   -   $-    27,451,064   $27,451   $45,172,525   $(26,033,007)  $19,166,969 
Common stock issued for option and warrant exercises   -    -    530,289    530    862,935    -    863,465 
Stock-based compensation expense   -    -    9,689    10    691,409    -    691,419 
Net income   -    -    -    -    -    15,005,009    15,005,009 
Balance as of June 30, 2020   -   $-    27,991,042   $27,991   $46,726,869   $(11,027,998)  $35,726,862 

 

See accompanying notes to unaudited condensed consolidated financial statements

 

6
 

 

CO – DIAGNOSTICS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1 – Overview and Basis of Presentation

 

Description of Business

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CDI”), is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The Company develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of these tests, the Company may sell diagnostic equipment and supplies from other manufacturers.

 

Unaudited Condensed Consolidated Financial Statements

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed on March 25, 2021.

 

Certain 2020 financial statement amounts have been reclassified to conform to 2021 presentations.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

 

Note 2 – Summary of Significant Accounting Policies

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of June 30, 2021 and December 31, 2020. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and re-evaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the condensed consolidated balance sheets. Any unrealized gains or losses are immaterial.

 

7
 

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At June 30, 2021, total accounts receivable was $13,686,152 with an allowance for uncollectable accounts of $930,200 resulting in a net amount of $12,755,952. At December 31, 2020 total accounts receivable was $12,928,633 with an allowance for uncollectable accounts of $791,800 resulting in a net amount of $12,136,833.

 

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying condensed consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying condensed consolidated statements of operations.

 

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At June 30, 2021, the Company had $4,120,704 in inventory, of which $659,737 was finished goods and $3,460,967 was raw materials. At December 31, 2020, the Company had $7,995,189 in inventory, of which $598,881 was finished goods and $7,396,308 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.

 

8
 

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

Research and Development

 

Research and development costs are expensed when incurred. For the three and six months ended June 30, 2021, the Company expensed $4,669,160 and $6,886,223 of research and development costs, respectively. For the three and six months ended June 30, 2020, the Company expensed $750,249 and $1,150,271, respectively.

 

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended June 30, 2021. Two customers together accounted for approximately 67% of total revenue for the three months ended June 30, 2021.

 

Two customers each accounted for more than 10% of accounts receivable at June 30, 2021. These two customers together accounted for approximately 48% of accounts receivable at June 30, 2021.

 

9
 

 

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company expects to use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company expects its balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheet but does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.

 

Note 3 – Fair Value Measurements

 

The Company measures and records certain financial assets at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds. The following three levels of inputs are used to measure the fair value of financial instruments:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

10
 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit. The following table summarizes the assets measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, by level within the fair value hierarchy:

 

   June 30, 2021 
   (Level 1)   (Level 2)   (Level 3)   Total 
Marketable investment securities:                    
Certificates of deposit  $-   $2,109,675   $-   $2,109,675 

 

   December 31, 2020
   (Level 1)   (Level 2)   (Level 3)   Total 
Marketable investment securities:                    
Certificates of deposit  $-   $4,335,446   $-   $4,335,446 

 

Note 4 – Revenue

 

The following table sets forth revenue by geographic area:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
United States  $5,365,323   $13,383,761   $17,859,273   $13,997,786 
Rest of World   21,992,817    10,656,513    29,523,636    11,591,016 
Total  $27,358,140   $24,040,274   $47,382,909   $25,588,802 
Percentage of revenue by area:                    
United States   20%   56%   38%   55%
Rest of World   80%   44%   62%   45%

 

Deferred Revenue

 

Changes in the Company’s deferred revenue balance for the six months ended June 30, 2021 were as follows:

 

Balance as of December 31, 2020  $305,307 
Revenue recognized included in deferred revenue balance at the beginning of the period   (194,060)
Increase due to prepayments from customers   51,887 
Balance as of June 30, 2021  $163,134 

 

The Company expects to perform its performance obligation and recognize the deferred revenue as revenue during the year ended December 31, 2021.

 

11
 

 

Note 5 – Earnings Per Share

 

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three and six months ended June 30, 2021 and 2020:

 

 

             
   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
Numerator                
Net income (loss), as reported  $9,785,213   $15,005,009   $17,684,188   $13,939,816 
                     
Denominator                    
Weighted average shares, basic   28,794,047    27,582,229    28,728,828    27,605,137 
Dilutive effect of stock options, warrants and RSUs   947,218    1,569,993    1,105,127    1,489,338 
Shares used to compute diluted earnings per share   29,741,265    29,152,222    29,833,955    29,094,475 
                     
Basic earnings per share  $0.34   $0.54   $0.62   $0.50 
Diluted earnings per share  $0.33   $0.51   $0.59   $0.48 

 

For the three and six months ended June 30, 2021, potentially dilutive securities of 931,341 and 146,133 were excluded from the calculation because their effect would have been anti-dilutive. No securities were excluded from the calculation for the three and six months ended June 30, 2020.

 

Note 6 – Stock-Based Compensation

 

Stock Incentive Plans

 

The Co-Diagnostics, Inc. 2015 Long Term Incentive Plan (the “Incentive Plan”) reserves an aggregate of 6,000,000 shares of common stock issuable upon the grant of awards under the Incentive Plan. The number of awards available for issuance under the Incentive Plan was 2,798,683 at June 30, 2021.

 

Stock Options

 

The following table summarizes option activity during the six months ended June 30, 2021:

 

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2020   1,300,588   $2.44   $1.24      
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (184,225)   2.41    1.14      
Outstanding at June 30, 2021   1,116,363   $2.12   $1.31    7.44 
Exercisable at June 30, 2021   828,036   $2.20   $1.19    7.17 

 

The total intrinsic value of options exercised during the six months ended June 30, 2021 was approximately $1.3 million. The aggregate intrinsic value of outstanding options at June 30, 2021 was approximately $6.9 million.

 

Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted.

 

12
 

 

In January 2021, the Company modified the exercise price of 100,000 of the options from $16.49 to $9.30. Due to the modification, the Company will recognize incremental stock-based compensation cost of $65,000. Of this amount, the Company has recognized approximately $45,000 and the remaining will be recognized over the remaining service period.

  

As of June 30, 2021, there were 288,327 of unvested options and $186,144 of unrecognized stock-based compensation expense. The unrecognized stock-based compensation expense is expected to be recognized over 0.9 years.

 

Restricted Stock Units

 

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the six months ended June 30, 2021:

 

 

   Number of RSUs   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2020   522,500   $10.49 
Granted   480,000    9.90 
Vested   (192,084)   10.39 
Forfeited/Cancelled   -    - 
Unvested at June 30, 2021   810,416   $10.18 

 

As of June 30, 2021, there was approximately $7.8 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.7 years.

 

Warrants

 

The Company has issued warrants related to past financings and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

 

The following table summarizes warrant activity during the six months ended June 30, 2021:

 

   Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2020   70,000   $1.83   $5.21      
Granted   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at June 30, 2021   70,000   $1.83   $5.21    2.8 

 

The aggregate intrinsic value of outstanding warrants at June 30, 2021 was approximately $450,000. All outstanding warrants are exercisable at June 30, 2021 and there was no unrecognized stock-based compensation expense related to warrants.

 

13
 

 

Stock Issued for Services

 

The Company has issued restricted stock to third parties for services provided. The grant date fair value of the restricted stock granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the stock awards. The Company has issued 5,548 shares of restricted stock for services during the six months ended June 30, 2021 and there was no unrecognized stock-based compensation expense related to restricted stock issued.

  

Stock-Based Compensation Expense

 

The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
Options  $76,114   $301,568   $152,786   $703,198 
Restricted stock units   839,224    -    2,235,661    - 
Warrants   -    303,802    -    303,802 
Stock   12,000    86,049    51,900    117,242 
Total stock-based compensation expense  $927,338   $691,419   $2,440,347   $1,124,242 

 

Note 7 – Income Taxes

 

For the three months ended June 30, 2021, the Company recognized an expense from income taxes of $2,145,076, representing an effective tax rate of 18.0%. For the six months ended June 30, 2021, the Company recognized an expense from income taxes of $4,130,716, representing an effective tax rate of 18.9%. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of 21.0% due to state taxes, permanent items, and discrete items. For the three and six months ended June 30, 2020, no benefit from income taxes was recorded due to the Company being in a full valuation allowance position, resulting in an effective tax rate of 0.0%.

 

Note 8 – Related Party Transactions

 

The Company acquired the exclusive rights to the CoPrimer technology pursuant to an exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between the Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, a former executive officer, prior to the Company’s acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provides in part that all accrued royalties under the License cease as of January 1, 2017, and the Company began in January 2017 to pay to Dr. Satterfield $700,000 of accrued royalties at the rate of $10,000 per month. At June 30, 2021, the aggregate balance of this related party liability was $90,000.

 

Note 9 – Commitments and Contingencies

 

Lease Obligations

 

The Company’s offices are located at 2401 S. Foothill Dr., Suite D, Salt Lake City, Utah 84109-1479. In February 2020, the Company entered into a 4-year lease agreement for its office space and in March 2020, the Company entered into an addendum with our landlord for additional space. The new aggregate space consists of approximately 13,687 square feet at a monthly rate of $28,825 and expires in February 2024. For the three and six months ended June 30, 2021 the Company expensed $86,588 and $173,175 for rent, respectively. For the three and six months ended June 30, 2020, the Company expensed $86,969 and $138,786 for rent, respectively. The Company’s future minimum lease payments were as follows as of June 30, 2021:

 

Year Ending December 31,    
2021 (remainder)  $142,950 
2022   293,595 
2023   303,059 
2024   50,774 
Total lease payments  $790,378 

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

In July and September 2020, securities class action complaints were filed by certain stockholders of the Company against the Company claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

 

Note 10 – Subsequent Events

 

The Company evaluated subsequent events pursuant to ASC Topic 855 and has determined that there are no events that need to be reported.

 

14
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report and the documents incorporated by reference herein, including statements regarding future events, our future financial performance, business strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors and the documents incorporated by reference herein, which may affect our or our industry’s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements.

 

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations, and financial needs. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Quarterly Report, and in particular, the risks discussed below and under the heading “Risk Factors” in other documents we file with the SEC. The following discussion should be read in conjunction with the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 25, 2021 and the audited financial statements and notes included therein.

 

15
 

 

You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Quarterly Report. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Quarterly Report to conform our statements to actual results or changed expectations.

 

You are advised, however, to consult any further disclosures we make on related subjects in our periodic and current reports filed with the SEC. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider this list to be a complete set of all potential risks or uncertainties.

 

Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:

 

  ● the results of clinical trials and the regulatory approval process;
     
  ● market acceptance of any products that may be approved for commercialization;
     
  ● our ability to protect our intellectual property rights;
     
  ● the impact of any infringement actions or other litigation brought against us;
     
  ● competition from other providers and products;
     
  ● our ability to develop and commercialize new and improved products and services;
     
  ● changes in government regulation; and
     
  ● and other factors (including the risks contained in the section entitled “Risk Factors” in other documents we file with the SEC) relating to our industry, our operations and results of operations.

 

Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

 

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

 

As used in this Quarterly Report, the terms “we”, “us”, “our”, and “Co-Diagnostics” means Co-Diagnostics, Inc., a Utah corporation and its consolidated subsidiaries (the “Company”), unless otherwise indicated.

 

Executive Overview

 

The following management’s discussion and analysis of financial condition and results of operations describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition. This discussion should be read in conjunction with the accompanying unaudited financial statements and notes thereto included elsewhere in this report. The information contained in this discussion is subject to a number of risks and uncertainties. We urge you to review carefully the section of this report entitled “Cautionary Note Regarding Forward-Looking Statements” for a summary of the risks and uncertainties associated with an investment in our securities.

 

16
 

 

Business Overview

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CDI”), is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. We develop, manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”).

 

Our diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. CDI’s technical advance involves a novel approach to Polymerase Chain Reaction (“PCR”) test design of primer and probe structure (“CoPrimers”) that eliminates one of the key vexing issues of PCR amplification, the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA/RNA.

 

We believe our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. Because we own our platform, we believe we will be able to accomplish this faster and more economically, allowing for significant margins while still positioning the Company to be a low-cost provider of molecular diagnostics and screening services.

 

In addition, continued development has demonstrated the unique properties of our CoPrimer technology that make it ideally suited for a variety of applications where specificity is key to optimal results, including multiplexing several targets, enhanced Single Nucleotide Polymorphism (“SNP”) detection and enrichment for next gen sequencing.

 

Our scientists use the complex mathematics of DNA/RNA test design, to engineer and optimize a DNA/RNA test and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. Dr. Satterfield, our founder, developed the Company’s intellectual property consisting of the predictive mathematical algorithms and proprietary reagents used in the testing process, which together represent a major advance in PCR testing systems. CDI technologies are now protected by eight granted or pending US and foreign patents, as well as certain trade secrets and copyrights. Ownership of our proprietary platform permits us the advantage of avoiding payment of patent royalties required by other PCR test systems, which enables the sale of diagnostic tests at a lower price than competitors, while enabling us to maintain profit margins.

 

We design our tests by identifying the optimal locations on the target gene for amplification and pair the location with the optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research. This is done by following planned and documented processes, procedures and validation protocols. In other words, the data resulting from our tests verify that we succeeded in designing what we intended at the outset. Verification is a series of testing that concludes that the product is ready to proceed to validation in an evaluation either in our lab or in an independent laboratory setting using initial production tests to confirm that the product as designed meets the user needs.

 

In addition to testing for infectious disease, the technology lends itself to identifying any section of a DNA or RNA strand that describe any type of genetic trait, which creates a number of significant applications. We, in conjunction with our customers, are active in designing and licensing tests that identify genetic traits in plant and animal genomes. We also have three multiplexed tests developed to test mosquitos for the identification of diseases carried by the mosquitos to enable municipalities to concentrate their efforts in spraying mosquito populations on the specific areas known to be breeding the mosquitos that carry deadly viruses.

 

Recent Developments

 

Because we believe that testing for the COVID-19 virus is going to be a consideration for public health worldwide even after the current pandemic has subsided, we have initiated a project to facilitate frequent testing in schools, businesses, the hospitality industry, and at home. We believe this may be accomplished through the development of a low cost, easy to use by non-professionals, testing device that can provide PCR quality test results in less than an hour. This project is possible due to the fact that in 2020 we were able to successfully lyophilize our Logix Smart COVID-19 test reagents and additionally developed a saliva-based collection system that does not require the RNA/DNA extraction. While the final result is the same as if done through a lab-based IVD process, it has the advantages of increased speed and ease of handling thanks to lyophilization. We have engaged the services of a group of professionals who have the expertise and track record to develop the hardware for such a device using our CoPrimers as the reagent chemistry. The device will be available to homes, offices, event facilities, and the travel industry at a cost that will allow screening frequently to prevent spread of the COVID-19 virus and its variants in the future. The device would also be available to test for other pathogens detectable through saliva samples as we develop those tests and offer them to the marketplace.

 

17
 

 

RESULTS OF OPERATIONS

 

The Three Months Ended June 30, 2021 Compared to the Three Months ended June 30, 2020

 

Revenues

 

For the three months ended June 30, 2021, we generated revenues of $27,358,140 compared to revenues of $24,040,274 for the three months ended June 30, 2020. The increase in revenue of $3,317,866 was primarily due to sales of our LogixSmart COVID-19 test developed in response to the current COVID-19 pandemic. Of the total revenue in the three months ended June 30, 2021, $164,470 related to the sale of third party manufactured equipment and consumables, which we sourced and sold to customers to facilitate the sales of our COVID-19 test compared to $1,676,820 of revenue from the sales of such equipment for the three months ended June 30, 2020.

 

Cost of Revenues

 

We recorded cost of revenues of $2,504,355 for the three months ended June 30, 2021, compared to $5,975,305 for the three months ended June 30, 2020. This decrease is due to a reduction of product production costs, reduction in sales of third-party equipment, which have a higher cost of sales than tests, and the commission structure of certain sales of tests completed during the period. Of the total cost of sales during the three months ended June 30, 2021, $131,403 was from equipment sold to our customers compared to $1,580,968 for equipment sold to customers for the three months ended June 30, 2020.

 

Expenses

 

We incurred total operating expenses of $13,062,620 for the three months ended June 30, 2021, compared to total operating expenses of $3,356,692 for the three months ended June 30, 2020. The increase in operating expenses was due to the increase in business activities experienced as a result of our increase in revenue, increased third party sales commissions, reflected in sales and marketing, and increased investment in research and development.

 

General and administrative expenses increased $277,399, from $2,191,034 for the three months ended June 30, 2020 to $2,468,433 for the three months ended June 30, 2021. The increase in general and administrative expenses was primarily due to increased activity to support the growth of our business. The primary drivers of the increased expenses related to increases in compensation including stock-based compensation, insurance expense, contributions to retirement plans and increased expenses for professional services.

 

Our sales and marketing expenses for the three months ended June 30, 2021 were $5,853,313, compared to $390,191 for the three months ended June 30, 2020. The increase of $5,463,122 was primarily a result of increased third-party sales commissions, personnel related expenses, including commissions paid to our sales team, and increased stock-based compensation due to the growth in revenue.

 

Our research and development expenses increased by $3,918,911, from $750,249 for the three months ended June 30, 2020 to $4,669,160 for the three months ended June 30, 2021. The primary increase in expenses was research expenditures of greater than $3,500,000 for our point-of-care device in addition to increases in salaries and related benefits, including stock-based compensation, as we have added additional employees to our research and development team to increase our product development activities. Additionally, there has been an increase in professional and lab services utilized to further help us in our research and product development activities.

 

18
 

 

Other Income (Expense)

 

For the three months ended June 30, 2021 we had total other income of $139,124, compared to total other income of $296,732 for the three months ended June 30, 2020. The decrease was due primarily due to a decreased gain from our India joint venture.

 

Net Income

 

We realized net income for the three months ended June 30, 2021 of $9,785,213, compared with a net income for the three months ended June 30, 2020 of $15,005,009. The decrease in net income of $5,219,796 was primarily the result of an increase in operating expenses, offset by an increase of product revenues and resulting margins from those sales. Additionally, we recorded income tax expense of $2,145,076 for the three months ended June 30, 2021.

 

The Six Months Ended June 30, 2021 Compared to the Six Months ended June 30, 2020

 

Revenues

 

For the six months ended June 30, 2021, we generated revenues of $47,382,909 compared to revenues of $25,588,802 for the six months ended June 30, 2020. The increase in revenue of $21,794,107 was primarily due to sales of our LogixSmart COVID-19 test developed in response to the current COVID-19 pandemic. Of the total revenue in the six months ended June 30, 2021, $430,985 related to the sale of third party manufactured equipment and consumables, which we sourced and sold to customers to facilitate the sales of our COVID-19 test compared to $1,782,312 of revenue from the sales of such equipment for the six months ended June 30, 2020.

 

Cost of Revenues

 

We recorded cost of revenues of $5,776,920 for the six months ended June 30, 2021, compared to $6,457,045 for the six months ended June 30, 2020. This decrease is due to a reduction of product production costs, reduction in sales of third-party equipment, which have a higher cost of sales than tests, and the commission structure of certain sales of tests completed during the period. Of the total cost of sales during the six months ended June 30, 2021, $334,039 was from equipment sold to our customers compared to $1,651,395 for equipment sold to customers for the six months ended June 30, 2020.

 

Expenses

 

We incurred total operating expenses of $19,479,923 for the six months ended June 30, 2021, compared to total operating expenses of $5,505,429 for the six months ended June 30, 2020. The increase in operating expenses was due to the increase in business activities experienced as a result of our increase in revenue, increased third party sales commissions, reflected in sales and marketing, and increased investment in research and development.

 

General and administrative expenses increased $1,753,604, from $3,650,518 for the six months ended June 30, 2020 to $5,404,122 for the six months ended June 30, 2021. The primary drivers of the increased expenses related to increases in compensation including stock-based compensation, insurance expense, contributions to retirement plans and increased expenses for professional services.

 

Our sales and marketing expenses for the six months ended June 30, 2021 were $7,050,859, compared to $658,674 for the six months ended June 30, 2020. The increase of $6,392,185 was primarily a result of increased third-party sales commissions, personnel related expenses, including commissions paid to our sales team, and increased stock-based compensation due to the growth in revenue.

 

Our research and development expenses increased by $5,735,952, from $1,150,271 for the six months ended June 30, 2020 to $6,886,223 for the six months ended June 30, 2021. The primary increase in expenses was research expenditures of greater than $4,500,000 for our point-of-care device in addition to increases in salaries and related benefits, including stock-based compensation, as we have added additional employees to our research and development team to increase our product development activities. Additionally, there has been an increase in professional and lab services utilized to further help us in our research and product development activities.

 

19
 

 

Other Income (Expense)

 

For the six months ended June 30, 2021 we had total other expense of $311,162, compared to total other income of $313,488 for the six months ended June 30, 2020. The decrease in other income was due primarily due to recording a loss of $336,348 from our India joint venture compared to income of $267,740 from our joint venture in the same period in 2020.

 

Net Income

 

We realized net income for the six months ended June 30, 2021 of $17,684,188, compared to net income for the six months ended June 30, 2020 of $13,939,816. The increase in net income of $3,744,372 was primarily the result of sales of our LogixSmart COVID-19 test and resulting margins from those sales offset by increased operating expenses. Additionally, we recorded income tax expense of $4,130,716 for the six months ended June 30, 2021.

 

Liquidity and Capital Resources

 

At June 30, 2021, we had cash and cash equivalents of $70,274,078 and marketable investment securities of $2,109,675 that could readily be converted into cash if needed. Additionally, our total current assets of June 30, 2021, were $90,320,358 compared to total current liabilities of $4,728,903.

 

Net cash provided by operating activities during the six months ended June 30, 2021 was $24,694,101, compared to cash used in operating activities of $348,549 for the six months ended June 30, 2020. The increase in cash from operating activities was primarily due to our increased revenue.

 

We received $2,158,365 of cash from investing activities during the six months ended June 30, 2021 from maturity of marketable investments and repayment of advances from our India joint venture as compared use of cash of $919,790 during the six months ended June 30, 2020.

 

Net cash provided by financing activities was $444,899 for the six months ended June 30, 2021 realized from the exercise of options, compared to $18,925,548 for the same period in the prior year. The decrease is primarily due to net proceeds of $18,012,083 received from a series of three registered direct offerings in January and February 2020 pursuant to our shelf registration in addition to receiving $50,000 from the exercise of warrants and options for the six months ended June 30, 2020.

 

Since commencing sales of our Logix Smart COVID-19 test in March 2020, we have used our cash generated from those sales to fund the increase in our inventories and receivables and pay our operating expenses. We have increased our work force primarily in the area of research and development to complete development of additional tests to enable us to use our distributor network to sell other products throughout the world and remain profitable in the future.

 

We believe that our existing capital resources and the cash generated from future sales will be sufficient to meet our projected operating requirements for the next 12 months. However, our available capital resources may be consumed more rapidly than currently expected and we may need or want to raise additional financing for strategic opportunities.

If needed, we expect additional investment capital to come from (i) additional issuances of our common stock with existing and new investors or (ii) the private placement of other securities with investors similar to those that have provided funding in the past. We may not be able to secure such financing in a timely manner or on favorable terms, if at all.

 

On October 30, 2020, we filed a Registration Statement on Form S-3 (File No: 333-249651) with the Securities and Exchange Commission (the “SEC”). The SEC declared the Form S-3 effective on November 5, 2020. Pursuant to a prospectus supplement to the Form S-3, we may offer and sell up to $100 million of the following securities separately or together, in one or more series or classes and in amounts, at prices and on terms described in one or more offerings: common stock; preferred stock; warrants to purchase our securities, each of which may be convertible into equity securities; or units comprised of, or other combinations of, the foregoing securities through underwriting syndicates managed or co-managed by one or more underwriters or dealers, through agents or directly to purchasers. Each time our securities are offered, we will provide a prospectus supplement to the Form S-3 containing more specific information about the particular offering. We have not sold any securities pursuant to the Form S-3.

 

20
 

 

The foregoing estimates, expectations and forward-looking statements are subject to change as we make strategic operating decisions from time to time and as our revenue and expenses fluctuate from period to period.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not required under Regulation S-K for “smaller reporting companies.”

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2021. Based on the evaluation of our disclosure controls and procedures as of June 30, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls were effective.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during the three months ended June 30, 2021, that has materially affected or, are reasonably likely to materially affect, our internal control over financial reporting.

 

21
 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

There have been no material developments to the legal proceedings previously disclosed under Item 3 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

 

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. Although we have received inquiries from FINRA, NASDAQ and the SEC, to which we have responded, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties or businesses are subject, which would reasonably be likely to have a material adverse effect on the Company.

 

Item 2A. Risk Factors.

 

Not required under Regulation S-K for “smaller reporting companies.”

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

We issued the unregistered securities below. For the issuances of unregistered securities, we relied on the exemption from registration requirements of the Securities Act of 1933, as amended, available under Section 4(a)(2) promulgated thereunder due to the fact that such issuances did not involve a public offering of securities.

 

  ● On April 6, 2021, we issued an aggregate of 1,258 shares of our common stock for services rendered pursuant to a consulting agreement.

 

Dividends

 

We have never declared or paid any cash dividends on our capital stock. The payment of dividends on our common stock in the future will depend on our earnings, capital requirements, operating and financial condition and such other factors as our Board of Directors may consider appropriate. We currently expect to use all available funds to finance the future development and expansion of our business and do not anticipate paying dividends on our common stock in the foreseeable future.

 

Pursuant to Section 16-10a-640 of the Utah Revised Business Corporation Act, no distribution may be made if, after giving it effect:

 

  (a) the corporation would not be able to pay its debts as they become due in the usual course of business; or
     
  (b) the corporation’s total assets would be less than the sum of its total liabilities plus, unless the articles of incorporation permit otherwise, the amount that would be needed, if the corporation were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of shareholders whose preferential rights are superior to those receiving the distribution.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

Exhibit Index

 

(a) Exhibits

 

Exhibit   Number Description
     
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema Document
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File

 

* Filed herewith.

 

22
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CO-DIAGNOSTICS, INC.
     
Date: August 12, 2021 By: /s/ Dwight H. Egan
  Name: Dwight H. Egan
  Title: Chief Executive Officer, President and Principal Executive Officer
     
Date: August 12, 2021 By: /s/ Brian Brown
  Name: Brian Brown
  Title: Chief Financial Officer and Principal Financial and Accounting Officer

 

23

 

 

 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13a-14 OF THE EXCHANGE ACT OF 1934

 

I, Dwight H. Egan, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Co-Diagnostics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepting accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 12, 2021 By: /s/ Dwight H. Egan
    Dwight H. Egan
    Chief Executive Officer, President and Principal Executive Officer

 

 

  

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13a-14 OF THE EXCHANGE ACT OF 1934

 

I, Brian Brown, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Co-Diagnostics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepting accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date August 12, 2021 By: /s/ Brian Brown
    Brian Brown
    Chief Financial Officer and Principal Financial and Accounting Officer

 

 

 

 EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Co-Diagnostics, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof, I, Dwight H. Egan, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 12, 2021 By: /s/ Dwight H. Egan
    Dwight H. Egan
    Chief Executive Officer, President and Principal Executive Officer

 

 

  

 EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Co-Diagnostics, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof, I, Brian Brown, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 12, 2021 By: /s/ Brian Brown
    Brian Brown
    Chief Financial Officer and Principal Financial and Accounting Officer

 

 

  

 EX-101.SCH 6 codx-20210630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Overview and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Assets Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Revenue by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Schedule of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Earnings Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 codx-20210630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 codx-20210630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 codx-20210630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Convertible Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Two Customers Together [Member] Accounts Receivable [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Geographical [Axis] Americas [Member] Rest Of World [Member] Geographic Concentration Risk [Member] Plan Name [Axis] 2015 Long-term Incentive Plan [Member] Award Type [Axis] Stock Options [Member] Restricted Stock Units (RSUs) [Member] Warrant [Member] Title of Individual [Axis] Third Parties [Member] Restricted Stock [Member] Share-based Payment Arrangement, Option [Member] Share-based Payment Arrangement [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Exclusive License Agreement [Member] Dr Satterfield [Member] Scenario [Axis] Per Month [Member] Dr Brent Satterfield [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Marketable investment securities Accounts receivable, net Inventory Prepaid expenses Deferred tax asset Total current assets Property and equipment, net Investment in joint venture Total assets Liabilities and stockholders’ equity Current liabilities Accounts payable Accrued expenses, current Accrued expenses (related party), current Income taxes payable Deferred revenue Total current liabilities Long-term liabilities Accrued expenses, noncurrent Accrued expenses (related party), noncurrent Total long-term liabilities Total liabilities Commitments and contingencies (Note 9) Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2021 and December 31, 2020 Common stock, $0.001 par value; 100,000,000 shares authorized; 28,889,890 and 28,558,033 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively Additional paid-in capital Accumulated earnings Total stockholders’ equity Total liabilities and stockholders’ equity Convertible preferred stock, par value Convertible preferred stock , shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of revenue Gross profit Operating expenses Sales and marketing General and administrative Research and development Depreciation and amortization Total operating expenses Income from operations Other income (expense) Interest income Gain (loss) on equity method investment in joint venture Total other income (expense) Income before income taxes Income tax provision Net income Earnings per common share: Basic Diluted Weighted average shares outstanding: Basic Diluted Statement of Cash Flows [Abstract] Cash flows from operating activities Net income Adjustments to reconcile net income to cash used in operating activities: Stock-based compensation expense Loss (gain) from equity method investment Deferred income taxes Bad debt expense Changes in assets and liabilities: Accounts receivable Prepaid expenses Inventory Deferred revenue Income taxes payable Accounts payable and accrued expenses Net cash provided by (used in) operating activities Cash flows from investing activities Purchases of property and equipment Proceeds from maturities of marketable investment securities Investment in joint venture Net cash provided by (used in) investing activities Cash flows from financing activities Proceeds from sale of common stock Proceeds from exercise of options and warrants Payment of offering costs Net cash provided by financing activities Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information Interest paid Income taxes paid Supplemental disclosure of non-cash investing and financing transactions Inventory moved to property, plant and equipment Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Public offering, net of offering costs of $1,457,922 Public offering, net of offering costs of $1,457,922, shares Common stock issued for warrant exercises Common stock issued for warrant exercises, shares Common stock issued for option exercises Common stock issued for option exercises, shares Common stock issued for option and warrant exercises Common stock issued for option and warrant exercises, shares Stock-based compensation expense Stock-based compensation expense, shares Conversion of preferred stock to common Conversion of preferred stock to common, shares Net income (loss) Ending balance, value Ending balance, shares Statement of Stockholders' Equity [Abstract] Public offering costs Accounting Policies [Abstract] Overview and Basis of Presentation Summary of Significant Accounting Policies Fair Value Disclosures [Abstract] Fair Value Measurements Revenue from Contract with Customer [Abstract] Revenue Earnings Per Share [Abstract] Earnings Per Share Share-based Payment Arrangement [Abstract] Stock-Based Compensation Income Tax Disclosure [Abstract] Income Taxes Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Cash and Cash Equivalents Marketable Investment Securities Accounts Receivable Equity-Method Investments Inventory Property and Equipment Revenue Recognition Deferred Revenue Research and Development Stock-based Compensation Income Taxes Concentrations Risk and Significant Customers Net Income (Loss) per Share Recent Accounting Pronouncements Summary of Assets Measured at Fair Value on Recurring Basis Summary of Revenue by Geographic Area Schedule of Deferred Revenue Schedule of Basic and Diluted Earnings Per Share Schedule of Option Activity Schedule of Outstanding Restricted Stock Units and Related Activity Schedule of Warrant Activity Schedule of Recognized Stock-based Compensation Expense Schedule of Future Minimum Lease Payments Schedule of Product Information [Table] Product Information [Line Items] Accounts receivable Doubtful accounts Inventory finished goods Inventory raw materials Estimated useful life of property Research and development costs Concentration risk percentage Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of assets Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue Percentage of revenue Deferred revenue, beginning balance Revenue recognized included in deferred revenue balance at the beginning of the period Increase due to prepayments from customers Deferred revenue, ending balance Net income (loss), as reported Weighted average shares, basic Dilutive effect of stock options, warrants and RSUs Shares used to compute diluted earnings per share Basic earnings per share Diluted earnings per share Securities excluded from computation of diluted earnings per share Number of Options Outstanding, Beginning Weighted Average Exercise Price Outstanding, Beginning Weighted Average Fair Value Outstanding, Beginning Number of Options Outstanding, Granted Weighted Average Exercise Price Granted Weighted Average Fair Value Granted Number of Options Outstanding, Expired Weighted Average Exercise Price Expired Weighted Average Fair Value Expired Number of Options Outstanding, Forfeited/Cancelled Weighted Average Exercise Price Forfeited/Cancelled Weighted Average Fair Value Forfeited/Cancelled Number of Options Outstanding, Exercised Weighted Average Exercise Price Exercised Weighted Average Fair Value Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance Weighted Average Exercise Price Outstanding, Ending Weighted Average Fair Value Outstanding, Ending Weighted-average Remaining Contractual Life (years) Outstanding, Ending Number of Options Exercisable Ending Weighted Average Exercise Price, Exercisable Ending Weighted Average Fair Value, Exercisable Ending Weighted-average Remaining Contractual Life (years), Exercisable Ending Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Restricted Stock Units, Outstanding Beginning Weighted Average Grant Date Fair Value, Outstanding Beginning Number of Restricted Stock Units, Granted Weighted Average Grant Date Fair Value, Granted Number of Restricted Stock Units, Vested Weighted Average Grant Date Fair Value, Vested Number of Restricted Stock Units, Forfeited/Cancelled Weighted Average Grant Date Fair Value, Forfeited/Cancelled Number of Restricted Stock Units, Outstanding Ending Weighted Average Grant Date Fair Value, Outstanding Ending Number of Warrants Outstanding, Beginning Weighted Average Exercise Price, Beginning Weighted Average Fair Value, Beginning Number of Warrants Outstanding, Granted Weighted Average Exercise Price, Granted Weighted Average Fair Value, Granted Number of Warrants Outstanding, Forfeited/Cancelled Weighted Average Exercise Price, Forfeited/Cancelled Weighted Average Fair Value, Forfeited/Cancelled Number of Warrants Outstanding, Exercised Weighted Average Exercise Price, Exercised Weighted Average Fair Value, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance [custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice-2] Shareholder [Member] Weighted-average Remaining Contractual Life (Years) Outstanding, Ending Total stock-based compensation expense Aggregate number of common shares reserved Number of common shares availalble for issuance Intrinsic value of options execised Intrinsic value of options outstanding Number of options Option exercise price Stock-based compensation Recognized share based compensation Unvested option shares outstanding Unrecognized stock-based compensation Unrecognized stock-based compensation recognition period Number of shares issued for services Income tax expenses Effective income tax rate effective income tax u.s. federal statutory rate effective income tax rate, valuation allowance Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accrued royalties Payment for royalties Due to related party 2021 (remainder) 2022 2023 2024 Total lease payments Lease term Area of land Payments for rent Lease expiration date Rent expenses Deferred tax asset current. Accrued expenses noncurrent. Payments to acquire interest In joint ventures. Proceeds from exercise of options and warrants. Noncash or part noncash inventory moved to property plant and equipment. Issuance of common stock for option and warrant exercises. Issuance of common stock for option and warrant exercises shares. Three Customers Together [Member] Two Customers Together [Member] Rest of World [Member] Increase due to prepayments from customers. 2015 Long-term Incentive Plan [Member] Stock Options [Member] Recognized share based compensation. Third Parties [Member] Exclusive License Agreement [Member] Dr. Satterfield [Member] Per Month [Member] Dr. Brent Satterfield [Member] Share based compensation arrangement by share based payment award equity instruments other than options exercised weighted average grant date fair value. Weighted Average Fair Value Exercised. Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option plan. Share-based compensation arrangements by share-based payment award, non-options, grants in period, weighted average exercise price. Weighted average price at which grantees could have acquired the underlying shares with respect to non-options that were terminated. Share-based compensation arrangements by share-based payment award, non-options, exercise in period, weighted average exercise price Share-based compensation arrangement by share-based payment award, non-option, weighted average exercise price Share-based compensation arrangement by share-based payment award, non-option, granted in period, weighted average exercise price. Share-based compensation arrangement by share-based payment award, non-option, forfeitures, weighted average exercise price. Share-based compensation arrangement by share-based payment award, non-option, exercise in period, weighted average exercise price. Share-based compensation arrangement by share-based payment award, non-options, outstanding, weighted average remaining contractual term. Options [Member] Restricted Stock Units [Member] Stock [Member] The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Assets, Current Assets [Default Label] Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Weighted Average Number of Shares Outstanding, Basic Gain (Loss) on Sale of Equity Investments Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense Increase (Decrease) in Inventories Increase (Decrease) in Deferred Income Taxes Increase (Decrease) in Income Taxes Payable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment PaymentsToAcquireInterestInJointVentures Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Shares, Outstanding Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture Revenue from Contract with Customer [Text Block] Inventory, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Revenue from Contract with Customer, Including Assessed Tax Contract with Customer, Liability Contract with Customer, Liability, Revenue Recognized Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price Securities Purchase Agreements [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Fair Value, Exercisable Ending Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice Shareholder [Member] EX-101.PRE 10 codx-20210630_pre.xml XBRL PRESENTATION FILE XML 11 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001692415 2021-01-01 2021-06-30 0001692415 2021-08-10 0001692415 2021-06-30 0001692415 2020-12-31 0001692415 2021-04-01 2021-06-30 0001692415 2020-04-01 2020-06-30 0001692415 2020-01-01 2020-06-30 0001692415 2019-12-31 0001692415 2020-06-30 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001692415 us-gaap:CommonStockMember 2020-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001692415 us-gaap:RetainedEarningsMember 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001692415 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001692415 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001692415 2021-01-01 2021-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2021-03-31 0001692415 us-gaap:CommonStockMember 2021-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001692415 us-gaap:RetainedEarningsMember 2021-03-31 0001692415 2021-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2021-04-01 2021-06-30 0001692415 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001692415 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001692415 us-gaap:ConvertiblePreferredStockMember 2021-06-30 0001692415 us-gaap:CommonStockMember 2021-06-30 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001692415 us-gaap:RetainedEarningsMember 2021-06-30 0001692415 us-gaap:ConvertiblePreferredStockMember 2019-12-31 0001692415 us-gaap:CommonStockMember 2019-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001692415 us-gaap:RetainedEarningsMember 2019-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001692415 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001692415 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001692415 2020-01-01 2020-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-03-31 0001692415 us-gaap:CommonStockMember 2020-03-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001692415 us-gaap:RetainedEarningsMember 2020-03-31 0001692415 2020-03-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-04-01 2020-06-30 0001692415 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001692415 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-06-30 0001692415 us-gaap:CommonStockMember 2020-06-30 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001692415 us-gaap:RetainedEarningsMember 2020-06-30 0001692415 srt:MinimumMember 2021-01-01 2021-06-30 0001692415 srt:MaximumMember 2021-01-01 2021-06-30 0001692415 CODX:TwoCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001692415 CODX:TwoCustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001692415 srt:AmericasMember 2021-04-01 2021-06-30 0001692415 srt:AmericasMember 2020-04-01 2020-06-30 0001692415 srt:AmericasMember 2021-01-01 2021-06-30 0001692415 srt:AmericasMember 2020-01-01 2020-06-30 0001692415 CODX:RestOfWorldMember 2021-04-01 2021-06-30 0001692415 CODX:RestOfWorldMember 2020-04-01 2020-06-30 0001692415 CODX:RestOfWorldMember 2021-01-01 2021-06-30 0001692415 CODX:RestOfWorldMember 2020-01-01 2020-06-30 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-04-01 2021-06-30 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-04-01 2020-06-30 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-06-30 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-04-01 2021-06-30 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-04-01 2020-06-30 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-06-30 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2021-06-30 0001692415 CODX:StockOptionsMember 2021-01-01 2021-06-30 0001692415 CODX:StockOptionsMember 2021-06-30 0001692415 CODX:StockOptionsMember 2021-01-31 0001692415 srt:MaximumMember CODX:StockOptionsMember 2021-01-31 0001692415 srt:MinimumMember CODX:StockOptionsMember 2021-01-31 0001692415 CODX:StockOptionsMember 2021-01-01 2021-01-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-06-30 0001692415 us-gaap:WarrantMember 2021-06-30 0001692415 CODX:ThirdPartiesMember us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001692415 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001692415 us-gaap:EmployeeStockOptionMember 2020-04-01 2021-06-30 0001692415 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001692415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001692415 us-gaap:WarrantMember 2021-04-01 2021-06-30 0001692415 us-gaap:WarrantMember 2020-04-01 2020-06-30 0001692415 us-gaap:WarrantMember 2021-01-01 2021-06-30 0001692415 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001692415 us-gaap:StockCompensationPlanMember 2021-04-01 2021-06-30 0001692415 us-gaap:StockCompensationPlanMember 2020-04-01 2020-06-30 0001692415 us-gaap:StockCompensationPlanMember 2021-01-01 2021-06-30 0001692415 us-gaap:StockCompensationPlanMember 2020-01-01 2020-06-30 0001692415 CODX:DrSatterfieldMember CODX:ExclusiveLicenseAgreementMember 2017-01-01 0001692415 CODX:PerMonthMember CODX:DrSatterfieldMember CODX:ExclusiveLicenseAgreementMember 2016-12-28 2017-01-01 0001692415 CODX:DrBrentSatterfieldMember CODX:ExclusiveLicenseAgreementMember 2021-06-30 0001692415 2020-02-29 iso4217:USD shares iso4217:USD shares pure utr:acre 0001692415 false 2021 Q2 --12-31 P3Y P7Y5M9D P7Y2M1D P2Y9M18D 2024-02-29 10-Q true 2021-06-30 false 001-38148 CO-DIAGNOSTICS, INC. UT 46-2609396 2401 S. Foothill Drive Suite D Salt Lake City UT 84109 (801) 438-1036 Common Stock CODX NASDAQ Yes Yes Non-accelerated Filer false true false false 28889890 70274078 42976713 2109675 4335446 12755952 12136833 4120704 7995189 1039506 369028 20443 547224 90320358 68360433 1192901 949639 1276202 1927125 92789461 71237197 427144 598318 4001445 2849503 90000 120000 47180 637560 163134 305307 4728903 4510688 794615 30000 794615 30000 5523518 4540688 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 100000000 100000000 28889890 28889890 28558033 28558033 28890 28558 52042150 49157236 35194903 17510715 87265943 66696509 92789461 71237197 27358140 24040274 47382909 25588802 2504355 5975305 5776920 6457045 24853785 18064969 41605989 19131757 5853313 390191 7050859 658674 2468433 2191034 5404122 3650518 4669160 750249 6886223 1150271 71714 25218 138719 45966 13062620 3356692 19479923 5505429 11791165 14708277 22126066 13626328 10529 38173 25186 45748 128595 258559 -336348 267740 139124 296732 -311162 313488 11930289 15005009 21814904 13939816 2145076 4130716 9785213 15005009 17684188 13939816 0.34 0.54 0.61 0.50 0.33 0.51 0.59 0.48 28794047 27582229 28921140 27605137 29741265 29152222 29833955 29094475 17684188 13939816 138719 45966 2440347 1124242 -336348 267740 526781 147775 524389 766894 5742883 670478 2527983 -3874485 10030838 142173 -1044225 -590380 1715383 1542347 24694101 -348459 381981 205290 2225771 -314575 714500 2158365 -919790 19470005 444899 913465 1457922 444899 18925548 27297365 17657299 42976713 893138 70274078 18550437 3423700 117220 28558033 28558 49157236 17510715 66696509 65891 66 148914 148980 41790 42 1512970 1513012 7898975 7898975 28665714 28666 50819120 25409690 76257476 118334 118 295799 295917 105842 106 927231 927337 9785213 9785213 28889890 28890 52042150 35194903 87265943 25600 26 17342922 17343 26687701 -24967814 1737256 1457922 7242954 7243 18004840 18012083 719492 720 49280 50000 12363 12 432811 432823 -25600 -26 2133333 2133 -2107 -1065193 -1065193 27451064 27451 45172525 -26033007 19166969 530289 530 862935 863465 9689 10 691409 691419 15005009 15005009 15005009 15005009 27991042 27991 46726869 -11027998 35726862 <p id="xdx_80D_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zKn68am7DoMl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 1 – <span id="xdx_821_zH8cPjGa4C4g">Overview and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description of Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 27.35pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CDI”), is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The Company develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of these tests, the Company may sell diagnostic equipment and supplies from other manufacturers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Unaudited Condensed Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed on March 25, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain 2020 financial statement amounts have been reclassified to conform to 2021 presentations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zaGXcPvzZyA1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 2 – <span id="xdx_822_zXsRi0neI0Gj">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zakc3bO1g9bk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_860_z02STIhgd0Qj">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of June 30, 2021 and December 31, 2020. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_846_eus-gaap--MarketableSecuritiesPolicy_zqkvnk7q4RN7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zvyvhTtKkHEd">Marketable Investment Securities</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and re-evaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the condensed consolidated balance sheets. Any unrealized gains or losses are immaterial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zo4ToaOllSF5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zNlDByTh1sx5">Accounts Receivable</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At June 30, 2021, total accounts receivable was $<span id="xdx_901_eus-gaap--AccountsReceivableGrossCurrent_c20210630_pp0p0" title="Accounts receivable">13,686,152</span> with an allowance for uncollectable accounts of $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_c20210630_pp0p0" title="Doubtful accounts">930,200</span> resulting in a net amount of $<span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_c20210630_pp0p0" title="Accounts receivable, net">12,755,952</span>. At December 31, 2020 total accounts receivable was $<span id="xdx_90C_eus-gaap--AccountsReceivableGrossCurrent_c20201231_pp0p0" title="Accounts receivable">12,928,633</span> with an allowance for uncollectable accounts of $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_c20201231_pp0p0" title="Doubtful accounts">791,800</span> resulting in a net amount of $<span id="xdx_905_eus-gaap--AccountsReceivableNetCurrent_c20201231_pp0p0" title="Accounts receivable, net">12,136,833</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zuYQ7hD3Dja4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zJ5U0tYZtKu2">Equity-Method Investments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying condensed consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zmPAyrkZrY44" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86D_z7TN3doqwVC2">Inventory</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At June 30, 2021, the Company had $<span id="xdx_90E_eus-gaap--InventoryNet_c20210630_pp0p0" title="Inventory">4,120,704</span> in inventory, of which $<span id="xdx_900_eus-gaap--InventoryFinishedGoods_c20210630_pp0p0" title="Inventory finished goods">659,737</span> was finished goods and $<span id="xdx_908_eus-gaap--InventoryRawMaterials_c20210630_pp0p0" title="Inventory raw materials">3,460,967</span> was raw materials. At December 31, 2020, the Company had $<span id="xdx_903_eus-gaap--InventoryNet_c20201231_pp0p0" title="Inventory">7,995,189</span> in inventory, of which $<span id="xdx_90F_eus-gaap--InventoryFinishedGoods_c20201231_pp0p0" title="Inventory finished goods">598,881</span> was finished goods and $<span id="xdx_90B_eus-gaap--InventoryRawMaterials_c20201231_pp0p0" title="Inventory raw materials">7,396,308</span> was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z4OFPDzDSau7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zcx8WpnIt9dg">Property and Equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20210101__20210630__srt--RangeAxis__srt--MinimumMember_zgEOVOL9xlGb" title="Estimated useful life of property::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0666">three</span></span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20210630__srt--RangeAxis__srt--MaximumMember_zUJwsWJpWFIj" title="Estimated useful life of property">five years</span>. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zOfDZYl92ZCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zXpHX1HXNiOa">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zKrXCsyg77n9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zzostnZJDFJc">Deferred Revenue</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zD02F5GZfri3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zS7zjySSAMEb">Research and Development</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research and development costs are expensed when incurred. For the three and six months ended June 30, 2021, the Company expensed $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210401__20210630_zHKd9BJj5rq3" title="Research and development costs">4,669,160</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20210630_zQYyQQSvCyoa" title="Research and development costs">6,886,223</span> of research and development costs, respectively. For the three and six months ended June 30, 2020, the Company expensed $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200401__20200630_ze02XyVaAuVi" title="Research and development costs">750,249</span> and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630_pp0p0" title="Research and development costs">1,150,271</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zuwj2TlPOVJ3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_z58vg1hPcLdl">Stock-based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_znpYmYhSPSpf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_z5x1tCgM1Ioj">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zlSo6eZlhCU7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zsjdEP4BqO16">Concentrations Risk and Significant Customers</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended June 30, 2021. Two customers together accounted for approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember_zq8WCdihcCV1" title="Concentration risk percentage">67</span>% of total revenue for the three months ended June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Two customers each accounted for more than 10% of accounts receivable at June 30, 2021. These two customers together accounted for approximately <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember_z05iLb1s52Md" title="Concentration risk percentage">48</span>% of accounts receivable at June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i/></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z8V6mFlrpd0h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zCowsILVoUbb">Net Income (Loss) per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMDPQxutL3ti" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zHajT4z5yxD">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company expects to use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company expects its balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheet but does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.</span></p> <p id="xdx_858_zM5nYjNscJ3b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zakc3bO1g9bk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_860_z02STIhgd0Qj">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of June 30, 2021 and December 31, 2020. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_846_eus-gaap--MarketableSecuritiesPolicy_zqkvnk7q4RN7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zvyvhTtKkHEd">Marketable Investment Securities</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and re-evaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the condensed consolidated balance sheets. Any unrealized gains or losses are immaterial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zo4ToaOllSF5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zNlDByTh1sx5">Accounts Receivable</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At June 30, 2021, total accounts receivable was $<span id="xdx_901_eus-gaap--AccountsReceivableGrossCurrent_c20210630_pp0p0" title="Accounts receivable">13,686,152</span> with an allowance for uncollectable accounts of $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_c20210630_pp0p0" title="Doubtful accounts">930,200</span> resulting in a net amount of $<span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_c20210630_pp0p0" title="Accounts receivable, net">12,755,952</span>. At December 31, 2020 total accounts receivable was $<span id="xdx_90C_eus-gaap--AccountsReceivableGrossCurrent_c20201231_pp0p0" title="Accounts receivable">12,928,633</span> with an allowance for uncollectable accounts of $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_c20201231_pp0p0" title="Doubtful accounts">791,800</span> resulting in a net amount of $<span id="xdx_905_eus-gaap--AccountsReceivableNetCurrent_c20201231_pp0p0" title="Accounts receivable, net">12,136,833</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 13686152 930200 12755952 12928633 791800 12136833 <p id="xdx_841_eus-gaap--EquityMethodInvestmentsPolicy_zuYQ7hD3Dja4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zJ5U0tYZtKu2">Equity-Method Investments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying condensed consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zmPAyrkZrY44" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86D_z7TN3doqwVC2">Inventory</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At June 30, 2021, the Company had $<span id="xdx_90E_eus-gaap--InventoryNet_c20210630_pp0p0" title="Inventory">4,120,704</span> in inventory, of which $<span id="xdx_900_eus-gaap--InventoryFinishedGoods_c20210630_pp0p0" title="Inventory finished goods">659,737</span> was finished goods and $<span id="xdx_908_eus-gaap--InventoryRawMaterials_c20210630_pp0p0" title="Inventory raw materials">3,460,967</span> was raw materials. At December 31, 2020, the Company had $<span id="xdx_903_eus-gaap--InventoryNet_c20201231_pp0p0" title="Inventory">7,995,189</span> in inventory, of which $<span id="xdx_90F_eus-gaap--InventoryFinishedGoods_c20201231_pp0p0" title="Inventory finished goods">598,881</span> was finished goods and $<span id="xdx_90B_eus-gaap--InventoryRawMaterials_c20201231_pp0p0" title="Inventory raw materials">7,396,308</span> was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 4120704 659737 3460967 7995189 598881 7396308 <p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z4OFPDzDSau7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zcx8WpnIt9dg">Property and Equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20210101__20210630__srt--RangeAxis__srt--MinimumMember_zgEOVOL9xlGb" title="Estimated useful life of property::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0666">three</span></span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20210630__srt--RangeAxis__srt--MaximumMember_zUJwsWJpWFIj" title="Estimated useful life of property">five years</span>. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> P5Y <p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zOfDZYl92ZCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zXpHX1HXNiOa">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zKrXCsyg77n9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zzostnZJDFJc">Deferred Revenue</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zD02F5GZfri3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zS7zjySSAMEb">Research and Development</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research and development costs are expensed when incurred. For the three and six months ended June 30, 2021, the Company expensed $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210401__20210630_zHKd9BJj5rq3" title="Research and development costs">4,669,160</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20210630_zQYyQQSvCyoa" title="Research and development costs">6,886,223</span> of research and development costs, respectively. For the three and six months ended June 30, 2020, the Company expensed $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200401__20200630_ze02XyVaAuVi" title="Research and development costs">750,249</span> and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630_pp0p0" title="Research and development costs">1,150,271</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 4669160 6886223 750249 1150271 <p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zuwj2TlPOVJ3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_z58vg1hPcLdl">Stock-based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_znpYmYhSPSpf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_z5x1tCgM1Ioj">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zlSo6eZlhCU7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zsjdEP4BqO16">Concentrations Risk and Significant Customers</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended June 30, 2021. Two customers together accounted for approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember_zq8WCdihcCV1" title="Concentration risk percentage">67</span>% of total revenue for the three months ended June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Two customers each accounted for more than 10% of accounts receivable at June 30, 2021. These two customers together accounted for approximately <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember_z05iLb1s52Md" title="Concentration risk percentage">48</span>% of accounts receivable at June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i/></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 0.67 0.48 <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z8V6mFlrpd0h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zCowsILVoUbb">Net Income (Loss) per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zMDPQxutL3ti" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zHajT4z5yxD">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.35pt; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company expects to use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company expects its balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheet but does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.</span></p> <p id="xdx_803_eus-gaap--FairValueDisclosuresTextBlock_zYcnXMBLgkn4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 3 – <span id="xdx_827_zs7J6yg7cnW4">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company measures and records certain financial assets at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds. The following three levels of inputs are used to measure the fair value of financial instruments:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Level 3: Unobservable inputs that are not corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_890_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zuxqTEh4JaE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit. The following table summarizes the assets measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B1_zLB5eSKVjcDf" style="display: none">Summary of Assets Measured at Fair Value on Recurring Basis</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Marketable investment securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%">Certificates of deposit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets">2,109,675</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets">2,109,675</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="15" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Marketable investment securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-left: 10pt">Certificates of deposit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets">4,335,446</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets">4,335,446</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p id="xdx_8A5_zpF5iNd8wKZi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_890_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zuxqTEh4JaE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit. The following table summarizes the assets measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B1_zLB5eSKVjcDf" style="display: none">Summary of Assets Measured at Fair Value on Recurring Basis</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Marketable investment securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%">Certificates of deposit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets">2,109,675</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets">2,109,675</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="15" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Marketable investment securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; padding-left: 10pt">Certificates of deposit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets">4,335,446</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pp0p0" style="width: 10%; text-align: right" title="Fair value of assets">4,335,446</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> 2109675 2109675 4335446 4335446 <p id="xdx_80F_eus-gaap--RevenueFromContractWithCustomerTextBlock_zU9GfPNF5t5c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 4 – <span id="xdx_827_z0q2xr96H7vi">Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_897_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zZrbdsHL0ZX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table sets forth revenue by geographic area:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B8_z3gzqkn7XYTi" style="display: none">Summary of Revenue by Geographic Area</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20210401__20210630__srt--StatementGeographicalAxis__srt--AmericasMember_zaH0FT7gJiCi" style="width: 10%; text-align: right" title="Revenue">5,365,323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200401__20200630__srt--StatementGeographicalAxis__srt--AmericasMember_zqyYPbbxDov3" style="width: 10%; text-align: right" title="Revenue">13,383,761</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210630__srt--StatementGeographicalAxis__srt--AmericasMember_pp0p0" style="width: 10%; text-align: right" title="Revenue">17,859,273</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20200630__srt--StatementGeographicalAxis__srt--AmericasMember_pp0p0" style="width: 10%; text-align: right" title="Revenue">13,997,786</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Rest of World</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20210401__20210630__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zj2i3RpE6Xc6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">21,992,817</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200401__20200630__srt--StatementGeographicalAxis__custom--RestOfWorldMember_z5ilHgelMT69" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">10,656,513</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210630__srt--StatementGeographicalAxis__custom--RestOfWorldMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">29,523,636</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20200630__srt--StatementGeographicalAxis__custom--RestOfWorldMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">11,591,016</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20210401__20210630_zohjZVf4Gs5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">27,358,140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200401__20200630_zrcwnme67oQ" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">24,040,274</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">47,382,909</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">25,588,802</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of revenue by area:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zoYlQmyuY0ga" style="text-align: right" title="Percentage of revenue">20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200401__20200630__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJoARYHngdxg" style="text-align: right" title="Percentage of revenue">56</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20210630__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zrlfsIvhM7nk" style="text-align: right" title="Percentage of revenue">38</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200630__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zKcScM077zf2" style="text-align: right" title="Percentage of revenue">55</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Rest of World</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210401__20210630__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zou6ODNYJOY9" style="text-align: right" title="Percentage of revenue">80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200401__20200630__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zZOL9KwO8SOd" style="text-align: right" title="Percentage of revenue">44</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20210630__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zKu9wDde2VYc" style="text-align: right" title="Percentage of revenue">62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200630__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zLLQYsHYZ9gl" style="text-align: right" title="Percentage of revenue">45</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p id="xdx_8A1_zGciKKcEKbP5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Deferred Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zowLAwqLjJg5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Changes in the Company’s deferred revenue balance for the six months ended June 30, 2021 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zK5MZUzoAL59" style="display: none">Schedule of Deferred Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerLiability_iS_c20210101__20210630_zlQYgKx9NDKc" style="width: 16%; text-align: right" title="Deferred revenue, beginning balance">305,307</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Revenue recognized included in deferred revenue balance at the beginning of the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_pp0p0_di_c20210101__20210630_zjZUPaTX4AJb" style="text-align: right" title="Revenue recognized included in deferred revenue balance at the beginning of the period">(194,060</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Increase due to prepayments from customers</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--IncreaseDueToPrepaymentsFromCustomers_c20210101__20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Increase due to prepayments from customers">51,887</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_iE_pp0p0_c20210101__20210630_zDuNxg6FDlH7" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred revenue, ending balance">163,134</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p id="xdx_8A5_zMuYVNFYZWxk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company expects to perform its performance obligation and recognize the deferred revenue as revenue during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_897_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zZrbdsHL0ZX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table sets forth revenue by geographic area:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B8_z3gzqkn7XYTi" style="display: none">Summary of Revenue by Geographic Area</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20210401__20210630__srt--StatementGeographicalAxis__srt--AmericasMember_zaH0FT7gJiCi" style="width: 10%; text-align: right" title="Revenue">5,365,323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200401__20200630__srt--StatementGeographicalAxis__srt--AmericasMember_zqyYPbbxDov3" style="width: 10%; text-align: right" title="Revenue">13,383,761</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210630__srt--StatementGeographicalAxis__srt--AmericasMember_pp0p0" style="width: 10%; text-align: right" title="Revenue">17,859,273</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20200630__srt--StatementGeographicalAxis__srt--AmericasMember_pp0p0" style="width: 10%; text-align: right" title="Revenue">13,997,786</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Rest of World</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20210401__20210630__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zj2i3RpE6Xc6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">21,992,817</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200401__20200630__srt--StatementGeographicalAxis__custom--RestOfWorldMember_z5ilHgelMT69" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">10,656,513</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210630__srt--StatementGeographicalAxis__custom--RestOfWorldMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">29,523,636</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20200630__srt--StatementGeographicalAxis__custom--RestOfWorldMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">11,591,016</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20210401__20210630_zohjZVf4Gs5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">27,358,140</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200401__20200630_zrcwnme67oQ" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">24,040,274</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">47,382,909</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">25,588,802</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of revenue by area:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zoYlQmyuY0ga" style="text-align: right" title="Percentage of revenue">20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200401__20200630__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJoARYHngdxg" style="text-align: right" title="Percentage of revenue">56</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20210630__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zrlfsIvhM7nk" style="text-align: right" title="Percentage of revenue">38</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200630__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zKcScM077zf2" style="text-align: right" title="Percentage of revenue">55</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Rest of World</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210401__20210630__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zou6ODNYJOY9" style="text-align: right" title="Percentage of revenue">80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200401__20200630__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zZOL9KwO8SOd" style="text-align: right" title="Percentage of revenue">44</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20210630__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zKu9wDde2VYc" style="text-align: right" title="Percentage of revenue">62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200630__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zLLQYsHYZ9gl" style="text-align: right" title="Percentage of revenue">45</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> 5365323 13383761 17859273 13997786 21992817 10656513 29523636 11591016 27358140 24040274 47382909 25588802 0.20 0.56 0.38 0.55 0.80 0.44 0.62 0.45 <p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zowLAwqLjJg5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Changes in the Company’s deferred revenue balance for the six months ended June 30, 2021 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zK5MZUzoAL59" style="display: none">Schedule of Deferred Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerLiability_iS_c20210101__20210630_zlQYgKx9NDKc" style="width: 16%; text-align: right" title="Deferred revenue, beginning balance">305,307</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Revenue recognized included in deferred revenue balance at the beginning of the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_pp0p0_di_c20210101__20210630_zjZUPaTX4AJb" style="text-align: right" title="Revenue recognized included in deferred revenue balance at the beginning of the period">(194,060</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Increase due to prepayments from customers</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--IncreaseDueToPrepaymentsFromCustomers_c20210101__20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Increase due to prepayments from customers">51,887</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiability_iE_pp0p0_c20210101__20210630_zDuNxg6FDlH7" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred revenue, ending balance">163,134</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> 305307 194060 51887 163134 <p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zVRr5wk0wXH5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 5 –<span id="xdx_827_z1KncdBtvi8c"> Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zj0XaPU3tnYg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three and six months ended June 30, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zdzYlmG1Fm54" style="display: none">Schedule of Basic and Diluted Earnings Per Share</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20210401__20210630_zCMa08R67m14" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2021</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20200401__20200630_z49j0wloOfsh" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210101__20210630_zctDlP9IpYU4" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2021</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20200101__20200630_zWz3zl3HsCv6" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_z5waM2a88rR9" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Net income (loss), as reported</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">9,785,213</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">15,005,009</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">17,684,188</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">13,939,816</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--WeightedAverageNumberOfBasicSharesOutstanding_zfQbNTRUP9gg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,794,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,582,229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,728,828</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,605,137</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of stock options, warrants and RSUs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">947,218</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,569,993</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,105,127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,489,338</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Shares used to compute diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,741,265</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,152,222</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,833,955</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,094,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--EarningsBasicPerShare_ze4FaSKB39E9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i_pdd" style="vertical-align: bottom; background-color: White"> <td>Diluted earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.48</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p id="xdx_8AB_z7fxoOaFokb1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For the three and six months ended June 30, 2021, potentially dilutive securities of <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630_z86FBbCpOII3" title="Securities excluded from computation of diluted earnings per share">931,341</span> and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630_zN7bv57IN2eb" title="Securities excluded from computation of diluted earnings per share">146,133</span> were excluded from the calculation because their effect would have been anti-dilutive. <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20200401__20200630_zaH5GL1UYAEk" title="Securities excluded from computation of diluted earnings per share"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20200101__20200630_zx5opzVWRUgk" title="Securities excluded from computation of diluted earnings per share">No</span></span> securities were excluded from the calculation for the three and six months ended June 30, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zj0XaPU3tnYg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three and six months ended June 30, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zdzYlmG1Fm54" style="display: none">Schedule of Basic and Diluted Earnings Per Share</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20210401__20210630_zCMa08R67m14" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2021</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20200401__20200630_z49j0wloOfsh" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210101__20210630_zctDlP9IpYU4" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2021</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20200101__20200630_zWz3zl3HsCv6" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_z5waM2a88rR9" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Net income (loss), as reported</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">9,785,213</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">15,005,009</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">17,684,188</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">13,939,816</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--WeightedAverageNumberOfBasicSharesOutstanding_zfQbNTRUP9gg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,794,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,582,229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,728,828</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,605,137</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of stock options, warrants and RSUs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">947,218</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,569,993</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,105,127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,489,338</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Shares used to compute diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,741,265</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,152,222</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,833,955</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,094,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--EarningsBasicPerShare_ze4FaSKB39E9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i_pdd" style="vertical-align: bottom; background-color: White"> <td>Diluted earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.48</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> 9785213 15005009 17684188 13939816 28794047 27582229 28728828 27605137 947218 1569993 1105127 1489338 29741265 29152222 29833955 29094475 0.34 0.54 0.62 0.50 0.33 0.51 0.59 0.48 931341 146133 0 0 <p id="xdx_80A_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ztZF9F3ii9yj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 6 – <span id="xdx_829_z47mwQNG9t1i">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock Incentive Plans</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Co-Diagnostics, Inc. 2015 Long Term Incentive Plan (the “Incentive Plan”) reserves an aggregate of <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210630__us-gaap--PlanNameAxis__custom--TwoThousandFifteenLongTermIncentivePlanMember_pdd" title="Aggregate number of common shares reserved">6,000,000</span> shares of common stock issuable upon the grant of awards under the Incentive Plan. The number of awards available for issuance under the Incentive Plan was <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210630__us-gaap--PlanNameAxis__custom--TwoThousandFifteenLongTermIncentivePlanMember_pdd" title="Number of common shares availalble for issuance">2,798,683</span> at June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock Options</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z64rskcvRPj3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes option activity during the six months ended June 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_znGna78n4jeg" style="display: none">Schedule of Option Activity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630_zn98eFMFEpO1" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning">1,300,588</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_zpLwZfJhBqRd" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210101__20210630_zfLGNU2naXqg" style="width: 12%; text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.24</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20210630_zVYbJXDC5qp5" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210101__20210630_zhWx1kOY8R35" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20210630_ziT5M6rxXlzg" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0840">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20210630_zNCCqdx2JTV1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised">(184,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630_zWZsIfXdkVE5" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised">2.41</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_iE_c20210101__20210630_zRHnKBQvjJab" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised">1.14</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630_zClKOsaELtEc" style="border-bottom: Black 2.5pt double; text-align: right">1,116,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_zDRakXcrOGG8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20210101__20210630_zTbBwrFetlWg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value Outstanding, Ending">1.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20210630_zGBqU4CJtrD" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average Remaining Contractual Life (years) Outstanding, Ending::XDX::P7Y5M9D"><span style="-sec-ix-hidden: xdx2ixbrl0857">7.44</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20210630_zNEgVMq69Jb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">828,036</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210630_z0C7YhKSaHfd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">2.20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_iE_c20210101__20210630_zNt21Y9NU1tj" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Exercisable Ending">1.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtYxL_c20210101__20210630_zUx5bFGEiZ2f" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average Remaining Contractual Life (years), Exercisable Ending::XDX::P7Y2M1D"><span style="-sec-ix-hidden: xdx2ixbrl0865">7.17</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"/> <p id="xdx_8A9_zciZBFqKz8ah" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The total intrinsic value of options exercised during the six months ended June 30, 2021 was approximately $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zlUzwLfIXIaa" title="Intrinsic value of options execised">1.3</span> million. The aggregate intrinsic value of outstanding options at June 30, 2021 was approximately $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zxua3qSiYP8j" title="Intrinsic value of options outstanding">6.9</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In January 2021, the Company modified the exercise price of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210131__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Number of options">100,000</span> of the options from $<span id="xdx_906_eus-gaap--SharePrice_c20210131__us-gaap--AwardTypeAxis__custom--StockOptionsMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Option exercise price">16.49</span> to $<span id="xdx_909_eus-gaap--SharePrice_c20210131__us-gaap--AwardTypeAxis__custom--StockOptionsMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Option exercise price">9.30</span>. Due to the modification, the Company will recognize incremental stock-based compensation cost of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20210101__20210131__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Stock-based compensation">65,000</span>. Of this amount, the Company has recognized approximately $<span id="xdx_90F_ecustom--RecognizedShareBasedCompensation_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Recognized share based compensation">45,000</span> and the remaining will be recognized over the remaining service period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021, there were <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pdd" title="Unvested option shares outstanding">288,327</span> of unvested options and $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_pp0p0" title="Unrecognized stock-based compensation">186,144</span> of unrecognized stock-based compensation expense. The unrecognized stock-based compensation expense is expected to be recognized over <span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zkYG1ABgwWW3" title="Unrecognized stock-based compensation recognition period">0.9</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Restricted Stock Units</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zBKZhm3i9Paj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the six months ended June 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b><span id="xdx_8BF_ziiEQqmc8jNc" style="display: none">Schedule of Outstanding Restricted Stock Units and Related Activity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%">Unvested at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zr1iXEaJOFG3" style="width: 16%; text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">522,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOixZToiFhMc" style="width: 18%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">10.49</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Number of Restricted Stock Units, Granted">480,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">9.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkcelR0qT8ub" style="text-align: right" title="Number of Restricted Stock Units, Vested">(192,084</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">10.39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEkB9nLgyR7b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Restricted Stock Units, Outstanding Ending">810,416</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z76f5G8p96E8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Ending">10.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"/> <p id="xdx_8A0_zSoHXHJ9x83f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2021, there was approximately $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziPJlm21URBh" title="Unrecognized stock-based compensation">7.8</span> million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4yC5Zi9wVl" title="Unrecognized stock-based compensation recognition period">2.7</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has issued warrants related to past financings and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHhoFLN02tH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes warrant activity during the six months ended June 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BA_zo4bebjqb23f" style="display: none">Schedule of Warrant Activity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; color: Red"/> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630_ztyssDIfoV48" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">70,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_zZRQ0UWd7IQ8" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning">1.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iS_c20210101__20210630_zaUCqWDFgCdh" style="width: 12%; text-align: right" title="Weighted Average Fair Value, Beginning">5.21</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630_pdd" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0923">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630_pdd" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630_zBDapKIhwWFi" style="border-bottom: Black 2.5pt double; text-align: right">70,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_zO6x52KJZBc2" style="padding-bottom: 2.5pt; text-align: right">1.83</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iE_c20210101__20210630_zQjWfUonzF16" style="padding-bottom: 2.5pt; text-align: right">5.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm21_dtYxL_c20210101__20210630_znx0HOielox9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average Remaining Contractual Life (Years) Outstanding, Ending::XDX::P2Y9M18D"><span style="-sec-ix-hidden: xdx2ixbrl0942">2.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"/> <p id="xdx_8A4_zTs1Le4QYGe6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The aggregate intrinsic value of outstanding warrants at June 30, 2021 was approximately $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Intrinsic value of options outstanding">450,000</span>. All outstanding warrants are exercisable at June 30, 2021 and there was no unrecognized stock-based compensation expense related to warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock Issued for Services</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has issued restricted stock to third parties for services provided. The grant date fair value of the restricted stock granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the stock awards. The Company has issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210630__srt--TitleOfIndividualAxis__custom--ThirdPartiesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" title="Number of shares issued for services">5,548</span> shares of restricted stock for services during the six months ended June 30, 2021 and there was no unrecognized stock-based compensation expense related to restricted stock issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock-Based Compensation Expense</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zhChDVTmlBkc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B2_zHIy7sFb3shb" style="display: none">Schedule of Recognized Stock-based Compensation Expense</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6hHmVh3AGB6" style="width: 12%; text-align: right">76,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCb2XmgpxwBg" style="width: 12%; text-align: right">301,568</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaLiQwFEwjBd" style="width: 12%; text-align: right" title="Total stock-based compensation expense">152,786</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQvJWbILvil7" style="width: 12%; text-align: right">703,198</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAj2wnCXgOVe" style="text-align: right">839,224</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zI7mcmZMHQQ6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6t3Eh6oljA" style="text-align: right" title="Total stock-based compensation expense">2,235,661</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8E4hGVgVOF" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z60ubq7hwBrj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxg1K7GOmBzh" style="text-align: right">303,802</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" style="text-align: right" title="Total stock-based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbGFvQ6VFBRh" style="text-align: right">303,802</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zJ6ekKG4HcEl" style="border-bottom: Black 1.5pt solid; text-align: right">12,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zdEVzSv1sJkh" style="border-bottom: Black 1.5pt solid; text-align: right">86,049</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zh4tNMKgB0Tl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">51,900</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zEBI3S5Gwdjj" style="border-bottom: Black 1.5pt solid; text-align: right">117,242</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630_zoXUDYnj0GJk" style="border-bottom: Black 2.5pt double; text-align: right">927,338</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630_zTHxnMDAe8R8" style="border-bottom: Black 2.5pt double; text-align: right">691,419</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630_zkcfIJcZLZEi" style="border-bottom: Black 2.5pt double; text-align: right">2,440,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630_zMy6n34uYB4b" style="border-bottom: Black 2.5pt double; text-align: right">1,124,242</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p id="xdx_8A5_zvKiSI5TrHNl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 6000000 2798683 <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z64rskcvRPj3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes option activity during the six months ended June 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_znGna78n4jeg" style="display: none">Schedule of Option Activity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630_zn98eFMFEpO1" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning">1,300,588</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_zpLwZfJhBqRd" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210101__20210630_zfLGNU2naXqg" style="width: 12%; text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.24</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20210630_zVYbJXDC5qp5" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210101__20210630_zhWx1kOY8R35" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20210630_ziT5M6rxXlzg" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0840">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20210630_zNCCqdx2JTV1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised">(184,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630_zWZsIfXdkVE5" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised">2.41</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_iE_c20210101__20210630_zRHnKBQvjJab" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised">1.14</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630_zClKOsaELtEc" style="border-bottom: Black 2.5pt double; text-align: right">1,116,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_zDRakXcrOGG8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20210101__20210630_zTbBwrFetlWg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value Outstanding, Ending">1.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20210630_zGBqU4CJtrD" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average Remaining Contractual Life (years) Outstanding, Ending::XDX::P7Y5M9D"><span style="-sec-ix-hidden: xdx2ixbrl0857">7.44</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20210630_zNEgVMq69Jb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">828,036</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210630_z0C7YhKSaHfd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">2.20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_iE_c20210101__20210630_zNt21Y9NU1tj" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Exercisable Ending">1.19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtYxL_c20210101__20210630_zUx5bFGEiZ2f" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average Remaining Contractual Life (years), Exercisable Ending::XDX::P7Y2M1D"><span style="-sec-ix-hidden: xdx2ixbrl0865">7.17</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"/> 1300588 2.44 1.24 184225 2.41 1.14 1116363 2.12 1.31 828036 2.20 1.19 1300000 6900000 100000 16.49 9.30 65000 45000 288327 186144 P0Y10M24D <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zBKZhm3i9Paj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the six months ended June 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b><span id="xdx_8BF_ziiEQqmc8jNc" style="display: none">Schedule of Outstanding Restricted Stock Units and Related Activity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%">Unvested at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zr1iXEaJOFG3" style="width: 16%; text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">522,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOixZToiFhMc" style="width: 18%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">10.49</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Number of Restricted Stock Units, Granted">480,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">9.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkcelR0qT8ub" style="text-align: right" title="Number of Restricted Stock Units, Vested">(192,084</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">10.39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Unvested at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEkB9nLgyR7b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Restricted Stock Units, Outstanding Ending">810,416</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z76f5G8p96E8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Ending">10.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"/> 522500 10.49 480000 9.90 192084 10.39 810416 10.18 7800000 P2Y8M12D <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHhoFLN02tH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes warrant activity during the six months ended June 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BA_zo4bebjqb23f" style="display: none">Schedule of Warrant Activity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; color: Red"/> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630_ztyssDIfoV48" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">70,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_zZRQ0UWd7IQ8" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning">1.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iS_c20210101__20210630_zaUCqWDFgCdh" style="width: 12%; text-align: right" title="Weighted Average Fair Value, Beginning">5.21</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630_pdd" style="text-align: right" title="Number of Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0923">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Fair Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited/Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630_pdd" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210630_pdd" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20210101__20210630_pdd" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630_zBDapKIhwWFi" style="border-bottom: Black 2.5pt double; text-align: right">70,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_zO6x52KJZBc2" style="padding-bottom: 2.5pt; text-align: right">1.83</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iE_c20210101__20210630_zQjWfUonzF16" style="padding-bottom: 2.5pt; text-align: right">5.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm21_dtYxL_c20210101__20210630_znx0HOielox9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average Remaining Contractual Life (Years) Outstanding, Ending::XDX::P2Y9M18D"><span style="-sec-ix-hidden: xdx2ixbrl0942">2.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"/> 70000 1.83 5.21 70000 1.83 5.21 450000 5548 <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zhChDVTmlBkc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B2_zHIy7sFb3shb" style="display: none">Schedule of Recognized Stock-based Compensation Expense</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6hHmVh3AGB6" style="width: 12%; text-align: right">76,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCb2XmgpxwBg" style="width: 12%; text-align: right">301,568</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaLiQwFEwjBd" style="width: 12%; text-align: right" title="Total stock-based compensation expense">152,786</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQvJWbILvil7" style="width: 12%; text-align: right">703,198</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAj2wnCXgOVe" style="text-align: right">839,224</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zI7mcmZMHQQ6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6t3Eh6oljA" style="text-align: right" title="Total stock-based compensation expense">2,235,661</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8E4hGVgVOF" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z60ubq7hwBrj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxg1K7GOmBzh" style="text-align: right">303,802</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" style="text-align: right" title="Total stock-based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbGFvQ6VFBRh" style="text-align: right">303,802</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zJ6ekKG4HcEl" style="border-bottom: Black 1.5pt solid; text-align: right">12,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zdEVzSv1sJkh" style="border-bottom: Black 1.5pt solid; text-align: right">86,049</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zh4tNMKgB0Tl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">51,900</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zEBI3S5Gwdjj" style="border-bottom: Black 1.5pt solid; text-align: right">117,242</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210401__20210630_zoXUDYnj0GJk" style="border-bottom: Black 2.5pt double; text-align: right">927,338</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630_zTHxnMDAe8R8" style="border-bottom: Black 2.5pt double; text-align: right">691,419</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210630_zkcfIJcZLZEi" style="border-bottom: Black 2.5pt double; text-align: right">2,440,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200630_zMy6n34uYB4b" style="border-bottom: Black 2.5pt double; text-align: right">1,124,242</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> 76114 301568 152786 703198 839224 2235661 303802 303802 12000 86049 51900 117242 927338 691419 2440347 1124242 <p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_z4iy1p0SoKa4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 7 – <span id="xdx_82F_zgcO3k3dNpql">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For the three months ended June 30, 2021, the Company recognized an expense from income taxes of $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20210401__20210630_zvlP0lJlvQRb" title="Income tax expenses">2,145,076</span>, representing an effective tax rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_c20210401__20210630_zPC37QK1j8ea" title="Effective income tax rate">18.0</span>%. For the six months ended June 30, 2021, the Company recognized an expense from income taxes of $<span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20210630_pp0p0" title="Income tax expenses">4,130,716</span>, representing an effective tax rate of <span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_c20210101__20210630_zgWy8swvOm72" title="Effective income tax rate">18.9</span>%. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_c20210101__20210630_zKNEtmuQiEM6" title="effective income tax u.s. federal statutory rate">21.0</span>% due to state taxes, permanent items, and discrete items. For the three and six months ended June 30, 2020, no benefit from income taxes was recorded due to the Company being in a full valuation allowance position, resulting in an effective tax rate of <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_c20200401__20200630_zXjuw17M6OJ5" title="effective income tax rate, valuation allowance"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_c20200101__20200630_zf4yL3VJ8rx1" title="effective income tax rate, valuation allowance">0.0</span></span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 2145076 0.180 4130716 0.189 0.210 0.000 0.000 <p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z4mkocwlaAIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 8 – <span id="xdx_821_zGmpLyMpF0Lf">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company acquired the exclusive rights to the CoPrimer technology pursuant to an exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between the Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, a former executive officer, prior to the Company’s acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provides in part that all accrued royalties under the License cease as of January 1, 2017, and the Company began in January 2017 to pay to Dr. Satterfield $<span id="xdx_90C_eus-gaap--AccruedRoyaltiesCurrent_c20170101__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--DrSatterfieldMember_pp0p0" title="Accrued royalties">700,000</span> of accrued royalties at the rate of $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20161228__20170101__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--DrSatterfieldMember__srt--StatementScenarioAxis__custom--PerMonthMember_pp0p0" title="Payment for royalties">10,000</span> per month. At June 30, 2021, the aggregate balance of this related party liability was $<span id="xdx_900_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_c20210630__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--DrBrentSatterfieldMember_pp0p0" title="Due to related party">90,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 700000 10000 90000 <p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z1feQpoJbX41" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 9 – <span id="xdx_82D_zUt6TFGKJHLh">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Lease Obligations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s offices are located at 2401 S. Foothill Dr., Suite D, Salt Lake City, Utah 84109-1479. In February 2020, the Company entered into a <span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20200229_ztQBdQTrPScj" title="Lease term">4</span>-year lease agreement for its office space and in March 2020, the Company entered into an addendum with our landlord for additional space. The new aggregate space consists of approximately <span id="xdx_90E_eus-gaap--AreaOfLand_iI_pid_uSqft_c20210630_z47VA1C820m2" title="Area of land">13,687</span> square feet at a monthly rate of $<span id="xdx_908_eus-gaap--PaymentsForRent_c20210101__20210630_pp0p0" title="Payments for rent">28,825</span> and expires in <span id="xdx_90E_eus-gaap--LeaseExpirationDate1_dxL_c20210101__20210630_zpA9nudOUIJj" title="Lease expiration date::XDX::Feb%2029%2C2024"><span style="-sec-ix-hidden: xdx2ixbrl1006">February 2024</span></span>. For the three and six months ended June 30, 2021 the Company expensed $<span id="xdx_902_eus-gaap--LeaseAndRentalExpense_pp0p0_c20210401__20210630_zOR8gNpybetg" title="Rent expenses">86,588</span> and $<span id="xdx_905_eus-gaap--LeaseAndRentalExpense_c20210101__20210630_pp0p0" title="Rent expenses">173,175</span> for rent, respectively. For the three and six months ended June 30, 2020, the Company expensed $<span id="xdx_905_eus-gaap--LeaseAndRentalExpense_pp0p0_c20200401__20200630_z4zmeBbuJWV4" title="Rent expenses">86,969</span> and $<span id="xdx_90A_eus-gaap--LeaseAndRentalExpense_pp0p0_c20200101__20200630_zguqbNyWgfz7" title="Rent expenses">138,786</span> for rent, respectively. The Company’s future minimum lease payments were as follows as of June 30, 2021:</span></p> <p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zaox4d2q5WTf" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span><span id="xdx_8B8_zBfcPJ9zj2Yk" style="display: none">Schedule of Future Minimum Lease Payments</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year Ending December 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; width: 78%">2021 (remainder)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c20210630_pp0p0" style="width: 18%; text-align: right" title="2021 (remainder)">142,950</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20210630_pp0p0" style="text-align: right" title="2022">293,595</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20210630_pp0p0" style="text-align: right" title="2023">303,059</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="2024">50,774</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease payments">790,378</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z7s4qsEcdG3b" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Litigation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In July and September 2020, securities class action complaints were filed by certain stockholders of the Company against the Company claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> P4Y 13687 28825 86588 173175 86969 138786 <p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zaox4d2q5WTf" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span><span id="xdx_8B8_zBfcPJ9zj2Yk" style="display: none">Schedule of Future Minimum Lease Payments</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year Ending December 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; width: 78%">2021 (remainder)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c20210630_pp0p0" style="width: 18%; text-align: right" title="2021 (remainder)">142,950</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20210630_pp0p0" style="text-align: right" title="2022">293,595</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20210630_pp0p0" style="text-align: right" title="2023">303,059</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="2024">50,774</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease payments">790,378</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 142950 293595 303059 50774 790378 <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zLJvrUoNii97" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 10 – <span id="xdx_823_zSrDeg5txDS6">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company evaluated subsequent events pursuant to ASC Topic 855 and has determined that there are no events that need to be reported.</span></p> XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
 6 Months Ended
Jun. 30, 2021
Aug. 10, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2021  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --12-31  
Entity File Number 001-38148  
Entity Registrant Name CO-DIAGNOSTICS, INC.  
Entity Central Index Key 0001692415  
Entity Tax Identification Number 46-2609396  
Entity Incorporation, State or Country Code UT  
Entity Address, Address Line One 2401 S. Foothill Drive  
Entity Address, Address Line Two Suite D  
Entity Address, City or Town Salt Lake City  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84109  
City Area Code (801)  
Local Phone Number 438-1036  
Title of 12(b) Security Common Stock  
Trading Symbol CODX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   28,889,890
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 70,274,078 $ 42,976,713
Marketable investment securities 2,109,675 4,335,446
Accounts receivable, net 12,755,952 12,136,833
Inventory 4,120,704 7,995,189
Prepaid expenses 1,039,506 369,028
Deferred tax asset 20,443 547,224
Total current assets 90,320,358 68,360,433
Property and equipment, net 1,192,901 949,639
Investment in joint venture 1,276,202 1,927,125
Total assets 92,789,461 71,237,197
Current liabilities    
Accounts payable 427,144 598,318
Accrued expenses, current 4,001,445 2,849,503
Accrued expenses (related party), current 90,000 120,000
Income taxes payable 47,180 637,560
Deferred revenue 163,134 305,307
Total current liabilities 4,728,903 4,510,688
Long-term liabilities    
Accrued expenses, noncurrent 794,615
Accrued expenses (related party), noncurrent 30,000
Total long-term liabilities 794,615 30,000
Total liabilities 5,523,518 4,540,688
Commitments and contingencies (Note 9)
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2021 and December 31, 2020
Common stock, $0.001 par value; 100,000,000 shares authorized; 28,889,890 and 28,558,033 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively 28,890 28,558
Additional paid-in capital 52,042,150 49,157,236
Accumulated earnings 35,194,903 17,510,715
Total stockholders’ equity 87,265,943 66,696,509
Total liabilities and stockholders’ equity $ 92,789,461 $ 71,237,197
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Convertible preferred stock, par value $ 0.001 $ 0.001
Convertible preferred stock , shares authorized 5,000,000 5,000,000
Convertible preferred stock, shares issued 0 0
Convertible preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 28,889,890 28,558,033
Common stock, shares outstanding 28,889,890 28,558,033
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Statement [Abstract]        
Revenue $ 27,358,140 $ 24,040,274 $ 47,382,909 $ 25,588,802
Cost of revenue 2,504,355 5,975,305 5,776,920 6,457,045
Gross profit 24,853,785 18,064,969 41,605,989 19,131,757
Operating expenses        
Sales and marketing 5,853,313 390,191 7,050,859 658,674
General and administrative 2,468,433 2,191,034 5,404,122 3,650,518
Research and development 4,669,160 750,249 6,886,223 1,150,271
Depreciation and amortization 71,714 25,218 138,719 45,966
Total operating expenses 13,062,620 3,356,692 19,479,923 5,505,429
Income from operations 11,791,165 14,708,277 22,126,066 13,626,328
Other income (expense)        
Interest income 10,529 38,173 25,186 45,748
Gain (loss) on equity method investment in joint venture 128,595 258,559 (336,348) 267,740
Total other income (expense) 139,124 296,732 (311,162) 313,488
Income before income taxes 11,930,289 15,005,009 21,814,904 13,939,816
Income tax provision 2,145,076 4,130,716
Net income $ 9,785,213 $ 15,005,009 $ 17,684,188 $ 13,939,816
Earnings per common share:        
Basic $ 0.34 $ 0.54 $ 0.61 $ 0.50
Diluted $ 0.33 $ 0.51 $ 0.59 $ 0.48
Weighted average shares outstanding:        
Basic 28,794,047 27,582,229 28,921,140 27,605,137
Diluted 29,741,265 29,152,222 29,833,955 29,094,475
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Cash flows from operating activities    
Net income $ 17,684,188 $ 13,939,816
Adjustments to reconcile net income to cash used in operating activities:    
Depreciation and amortization 138,719 45,966
Stock-based compensation expense 2,440,347 1,124,242
Loss (gain) from equity method investment 336,348 (267,740)
Deferred income taxes 526,781
Bad debt expense 147,775 524,389
Changes in assets and liabilities:    
Accounts receivable (766,894) (5,742,883)
Prepaid expenses (670,478) (2,527,983)
Inventory 3,874,485 (10,030,838)
Deferred revenue (142,173) 1,044,225
Income taxes payable (590,380)
Accounts payable and accrued expenses 1,715,383 1,542,347
Net cash provided by (used in) operating activities 24,694,101 (348,459)
Cash flows from investing activities    
Purchases of property and equipment (381,981) (205,290)
Proceeds from maturities of marketable investment securities 2,225,771
Investment in joint venture 314,575 (714,500)
Net cash provided by (used in) investing activities 2,158,365 (919,790)
Cash flows from financing activities    
Proceeds from sale of common stock 19,470,005
Proceeds from exercise of options and warrants 444,899 913,465
Payment of offering costs (1,457,922)
Net cash provided by financing activities 444,899 18,925,548
Net increase in cash and cash equivalents 27,297,365 17,657,299
Cash and cash equivalents at beginning of period 42,976,713 893,138
Cash and cash equivalents at end of period 70,274,078 18,550,437
Supplemental disclosure of cash flow information    
Interest paid
Income taxes paid 3,423,700
Supplemental disclosure of non-cash investing and financing transactions    
Inventory moved to property, plant and equipment $ 117,220
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 26 $ 17,343 $ 26,687,701 $ (24,967,814) $ 1,737,256
Beginning balance, shares at Dec. 31, 2019 25,600 17,342,922      
Public offering, net of offering costs of $1,457,922 $ 7,243 18,004,840 18,012,083
Public offering, net of offering costs of $1,457,922, shares 7,242,954      
Common stock issued for warrant exercises $ 720 49,280 50,000
Common stock issued for warrant exercises, shares 719,492      
Stock-based compensation expense $ 12 432,811 432,823
Stock-based compensation expense, shares 12,363      
Conversion of preferred stock to common $ (26) $ 2,133 (2,107)
Conversion of preferred stock to common, shares (25,600) 2,133,333      
Net income (loss) (1,065,193) (1,065,193)
Ending balance, value at Mar. 31, 2020 $ 27,451 45,172,525 (26,033,007) 19,166,969
Ending balance, shares at Mar. 31, 2020 27,451,064      
Beginning balance, value at Dec. 31, 2019 $ 26 $ 17,343 26,687,701 (24,967,814) 1,737,256
Beginning balance, shares at Dec. 31, 2019 25,600 17,342,922      
Net income (loss)         13,939,816
Ending balance, value at Jun. 30, 2020 $ 27,991 46,726,869 (11,027,998) 35,726,862
Ending balance, shares at Jun. 30, 2020 27,991,042      
Beginning balance, value at Mar. 31, 2020 $ 27,451 45,172,525 (26,033,007) 19,166,969
Beginning balance, shares at Mar. 31, 2020 27,451,064      
Common stock issued for option and warrant exercises $ 530 862,935 863,465
Common stock issued for option and warrant exercises, shares 530,289      
Stock-based compensation expense $ 10 691,409 691,419
Stock-based compensation expense, shares 9,689      
Net income (loss) 15,005,009 15,005,009
Ending balance, value at Jun. 30, 2020 $ 27,991 46,726,869 (11,027,998) 35,726,862
Ending balance, shares at Jun. 30, 2020 27,991,042      
Beginning balance, value at Dec. 31, 2020 $ 28,558 49,157,236 17,510,715 66,696,509
Beginning balance, shares at Dec. 31, 2020 28,558,033      
Common stock issued for option exercises $ 66 148,914 148,980
Common stock issued for option exercises, shares 65,891      
Stock-based compensation expense $ 42 1,512,970 1,513,012
Stock-based compensation expense, shares 41,790      
Net income (loss) 7,898,975 7,898,975
Ending balance, value at Mar. 31, 2021 $ 28,666 50,819,120 25,409,690 76,257,476
Ending balance, shares at Mar. 31, 2021 28,665,714      
Beginning balance, value at Dec. 31, 2020 $ 28,558 49,157,236 17,510,715 $ 66,696,509
Beginning balance, shares at Dec. 31, 2020 28,558,033      
Common stock issued for option exercises, shares         184,225
Net income (loss)         $ 17,684,188
Ending balance, value at Jun. 30, 2021 $ 28,890 52,042,150 35,194,903 87,265,943
Ending balance, shares at Jun. 30, 2021 28,889,890      
Beginning balance, value at Mar. 31, 2021 $ 28,666 50,819,120 25,409,690 76,257,476
Beginning balance, shares at Mar. 31, 2021 28,665,714      
Common stock issued for option exercises $ 118 295,799 295,917
Common stock issued for option exercises, shares 118,334      
Stock-based compensation expense $ 106 927,231 927,337
Stock-based compensation expense, shares 105,842      
Net income (loss) 9,785,213 9,785,213
Ending balance, value at Jun. 30, 2021 $ 28,890 $ 52,042,150 $ 35,194,903 $ 87,265,943
Ending balance, shares at Jun. 30, 2021 28,889,890      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Statement of Stockholders' Equity [Abstract]      
Public offering costs $ 1,457,922 $ 1,457,922
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Overview and Basis of Presentation
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Overview and Basis of Presentation

Note 1 – Overview and Basis of Presentation

 

Description of Business

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CDI”), is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The Company develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of these tests, the Company may sell diagnostic equipment and supplies from other manufacturers.

 

Unaudited Condensed Consolidated Financial Statements

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed on March 25, 2021.

 

Certain 2020 financial statement amounts have been reclassified to conform to 2021 presentations.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of June 30, 2021 and December 31, 2020. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and re-evaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the condensed consolidated balance sheets. Any unrealized gains or losses are immaterial.

 

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At June 30, 2021, total accounts receivable was $13,686,152 with an allowance for uncollectable accounts of $930,200 resulting in a net amount of $12,755,952. At December 31, 2020 total accounts receivable was $12,928,633 with an allowance for uncollectable accounts of $791,800 resulting in a net amount of $12,136,833.

 

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying condensed consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying condensed consolidated statements of operations.

 

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At June 30, 2021, the Company had $4,120,704 in inventory, of which $659,737 was finished goods and $3,460,967 was raw materials. At December 31, 2020, the Company had $7,995,189 in inventory, of which $598,881 was finished goods and $7,396,308 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.

 

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

Research and Development

 

Research and development costs are expensed when incurred. For the three and six months ended June 30, 2021, the Company expensed $4,669,160 and $6,886,223 of research and development costs, respectively. For the three and six months ended June 30, 2020, the Company expensed $750,249 and $1,150,271, respectively.

 

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended June 30, 2021. Two customers together accounted for approximately 67% of total revenue for the three months ended June 30, 2021.

 

Two customers each accounted for more than 10% of accounts receivable at June 30, 2021. These two customers together accounted for approximately 48% of accounts receivable at June 30, 2021.

 

 

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company expects to use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company expects its balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheet but does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
 6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 3 – Fair Value Measurements

 

The Company measures and records certain financial assets at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds. The following three levels of inputs are used to measure the fair value of financial instruments:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit. The following table summarizes the assets measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, by level within the fair value hierarchy:

 

   June 30, 2021 
   (Level 1)   (Level 2)   (Level 3)   Total 
Marketable investment securities:                    
Certificates of deposit  $-   $2,109,675   $-   $2,109,675 

 

   December 31, 2020
   (Level 1)   (Level 2)   (Level 3)   Total 
Marketable investment securities:                    
Certificates of deposit  $-   $4,335,446   $-   $4,335,446 

 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue
 6 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenue

Note 4 – Revenue

 

The following table sets forth revenue by geographic area:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
United States  $5,365,323   $13,383,761   $17,859,273   $13,997,786 
Rest of World   21,992,817    10,656,513    29,523,636    11,591,016 
Total  $27,358,140   $24,040,274   $47,382,909   $25,588,802 
Percentage of revenue by area:                    
United States   20%   56%   38%   55%
Rest of World   80%   44%   62%   45%

 

Deferred Revenue

 

Changes in the Company’s deferred revenue balance for the six months ended June 30, 2021 were as follows:

 

Balance as of December 31, 2020  $305,307 
Revenue recognized included in deferred revenue balance at the beginning of the period   (194,060)
Increase due to prepayments from customers   51,887 
Balance as of June 30, 2021  $163,134 

 

The Company expects to perform its performance obligation and recognize the deferred revenue as revenue during the year ended December 31, 2021.

 

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Share
 6 Months Ended
Jun. 30, 2021
Earnings Per Share [Abstract]  
Earnings Per Share

Note 5 – Earnings Per Share

 

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three and six months ended June 30, 2021 and 2020:

 

 

             
   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
Numerator                
Net income (loss), as reported  $9,785,213   $15,005,009   $17,684,188   $13,939,816 
                     
Denominator                    
Weighted average shares, basic   28,794,047    27,582,229    28,728,828    27,605,137 
Dilutive effect of stock options, warrants and RSUs   947,218    1,569,993    1,105,127    1,489,338 
Shares used to compute diluted earnings per share   29,741,265    29,152,222    29,833,955    29,094,475 
                     
Basic earnings per share  $0.34   $0.54   $0.62   $0.50 
Diluted earnings per share  $0.33   $0.51   $0.59   $0.48 

 

For the three and six months ended June 30, 2021, potentially dilutive securities of 931,341 and 146,133 were excluded from the calculation because their effect would have been anti-dilutive. No securities were excluded from the calculation for the three and six months ended June 30, 2020.

 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 6 – Stock-Based Compensation

 

Stock Incentive Plans

 

The Co-Diagnostics, Inc. 2015 Long Term Incentive Plan (the “Incentive Plan”) reserves an aggregate of 6,000,000 shares of common stock issuable upon the grant of awards under the Incentive Plan. The number of awards available for issuance under the Incentive Plan was 2,798,683 at June 30, 2021.

 

Stock Options

 

The following table summarizes option activity during the six months ended June 30, 2021:

 

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2020   1,300,588   $2.44   $1.24      
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (184,225)   2.41    1.14      
Outstanding at June 30, 2021   1,116,363   $2.12   $1.31    7.44 
Exercisable at June 30, 2021   828,036   $2.20   $1.19    7.17 

 

The total intrinsic value of options exercised during the six months ended June 30, 2021 was approximately $1.3 million. The aggregate intrinsic value of outstanding options at June 30, 2021 was approximately $6.9 million.

 

Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted.

 

 

In January 2021, the Company modified the exercise price of 100,000 of the options from $16.49 to $9.30. Due to the modification, the Company will recognize incremental stock-based compensation cost of $65,000. Of this amount, the Company has recognized approximately $45,000 and the remaining will be recognized over the remaining service period.

  

As of June 30, 2021, there were 288,327 of unvested options and $186,144 of unrecognized stock-based compensation expense. The unrecognized stock-based compensation expense is expected to be recognized over 0.9 years.

 

Restricted Stock Units

 

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the six months ended June 30, 2021:

 

 

   Number of RSUs   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2020   522,500   $10.49 
Granted   480,000    9.90 
Vested   (192,084)   10.39 
Forfeited/Cancelled   -    - 
Unvested at June 30, 2021   810,416   $10.18 

 

As of June 30, 2021, there was approximately $7.8 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.7 years.

 

Warrants

 

The Company has issued warrants related to past financings and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

 

The following table summarizes warrant activity during the six months ended June 30, 2021:

 

   Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2020   70,000   $1.83   $5.21      
Granted   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at June 30, 2021   70,000   $1.83   $5.21    2.8 

 

The aggregate intrinsic value of outstanding warrants at June 30, 2021 was approximately $450,000. All outstanding warrants are exercisable at June 30, 2021 and there was no unrecognized stock-based compensation expense related to warrants.

 

 

Stock Issued for Services

 

The Company has issued restricted stock to third parties for services provided. The grant date fair value of the restricted stock granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the stock awards. The Company has issued 5,548 shares of restricted stock for services during the six months ended June 30, 2021 and there was no unrecognized stock-based compensation expense related to restricted stock issued.

  

Stock-Based Compensation Expense

 

The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
Options  $76,114   $301,568   $152,786   $703,198 
Restricted stock units   839,224    -    2,235,661    - 
Warrants   -    303,802    -    303,802 
Stock   12,000    86,049    51,900    117,242 
Total stock-based compensation expense  $927,338   $691,419   $2,440,347   $1,124,242 

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
 6 Months Ended
Jun. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

Note 7 – Income Taxes

 

For the three months ended June 30, 2021, the Company recognized an expense from income taxes of $2,145,076, representing an effective tax rate of 18.0%. For the six months ended June 30, 2021, the Company recognized an expense from income taxes of $4,130,716, representing an effective tax rate of 18.9%. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of 21.0% due to state taxes, permanent items, and discrete items. For the three and six months ended June 30, 2020, no benefit from income taxes was recorded due to the Company being in a full valuation allowance position, resulting in an effective tax rate of 0.0%.

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions
 6 Months Ended
Jun. 30, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

Note 8 – Related Party Transactions

 

The Company acquired the exclusive rights to the CoPrimer technology pursuant to an exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between the Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, a former executive officer, prior to the Company’s acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provides in part that all accrued royalties under the License cease as of January 1, 2017, and the Company began in January 2017 to pay to Dr. Satterfield $700,000 of accrued royalties at the rate of $10,000 per month. At June 30, 2021, the aggregate balance of this related party liability was $90,000.

 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 9 – Commitments and Contingencies

 

Lease Obligations

 

The Company’s offices are located at 2401 S. Foothill Dr., Suite D, Salt Lake City, Utah 84109-1479. In February 2020, the Company entered into a 4-year lease agreement for its office space and in March 2020, the Company entered into an addendum with our landlord for additional space. The new aggregate space consists of approximately 13,687 square feet at a monthly rate of $28,825 and expires in February 2024. For the three and six months ended June 30, 2021 the Company expensed $86,588 and $173,175 for rent, respectively. For the three and six months ended June 30, 2020, the Company expensed $86,969 and $138,786 for rent, respectively. The Company’s future minimum lease payments were as follows as of June 30, 2021:

 

Year Ending December 31,    
2021 (remainder)  $142,950 
2022   293,595 
2023   303,059 
2024   50,774 
Total lease payments  $790,378 

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

In July and September 2020, securities class action complaints were filed by certain stockholders of the Company against the Company claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
 6 Months Ended
Jun. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 10 – Subsequent Events

 

The Company evaluated subsequent events pursuant to ASC Topic 855 and has determined that there are no events that need to be reported.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of June 30, 2021 and December 31, 2020. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 
Marketable Investment Securities

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and re-evaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the condensed consolidated balance sheets. Any unrealized gains or losses are immaterial.

 

 
Accounts Receivable

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At June 30, 2021, total accounts receivable was $13,686,152 with an allowance for uncollectable accounts of $930,200 resulting in a net amount of $12,755,952. At December 31, 2020 total accounts receivable was $12,928,633 with an allowance for uncollectable accounts of $791,800 resulting in a net amount of $12,136,833.

 
Equity-Method Investments

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying condensed consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying condensed consolidated statements of operations.

 
Inventory

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At June 30, 2021, the Company had $4,120,704 in inventory, of which $659,737 was finished goods and $3,460,967 was raw materials. At December 31, 2020, the Company had $7,995,189 in inventory, of which $598,881 was finished goods and $7,396,308 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 
Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 
Revenue Recognition

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.

 

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 
Deferred Revenue

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 
Research and Development

Research and Development

 

Research and development costs are expensed when incurred. For the three and six months ended June 30, 2021, the Company expensed $4,669,160 and $6,886,223 of research and development costs, respectively. For the three and six months ended June 30, 2020, the Company expensed $750,249 and $1,150,271, respectively.

 
Stock-based Compensation

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 
Concentrations Risk and Significant Customers

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended June 30, 2021. Two customers together accounted for approximately 67% of total revenue for the three months ended June 30, 2021.

 

Two customers each accounted for more than 10% of accounts receivable at June 30, 2021. These two customers together accounted for approximately 48% of accounts receivable at June 30, 2021.

 

 
Net Income (Loss) per Share

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company expects to use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company expects its balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheet but does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Summary of Assets Measured at Fair Value on Recurring Basis

The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit. The following table summarizes the assets measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, by level within the fair value hierarchy:

 

   June 30, 2021 
   (Level 1)   (Level 2)   (Level 3)   Total 
Marketable investment securities:                    
Certificates of deposit  $-   $2,109,675   $-   $2,109,675 

 

   December 31, 2020
   (Level 1)   (Level 2)   (Level 3)   Total 
Marketable investment securities:                    
Certificates of deposit  $-   $4,335,446   $-   $4,335,446 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue (Tables)
 6 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Revenue by Geographic Area

The following table sets forth revenue by geographic area:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
United States  $5,365,323   $13,383,761   $17,859,273   $13,997,786 
Rest of World   21,992,817    10,656,513    29,523,636    11,591,016 
Total  $27,358,140   $24,040,274   $47,382,909   $25,588,802 
Percentage of revenue by area:                    
United States   20%   56%   38%   55%
Rest of World   80%   44%   62%   45%
Schedule of Deferred Revenue

Changes in the Company’s deferred revenue balance for the six months ended June 30, 2021 were as follows:

 

Balance as of December 31, 2020  $305,307 
Revenue recognized included in deferred revenue balance at the beginning of the period   (194,060)
Increase due to prepayments from customers   51,887 
Balance as of June 30, 2021  $163,134 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Share (Tables)
 6 Months Ended
Jun. 30, 2021
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings Per Share

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three and six months ended June 30, 2021 and 2020:

 

 

             
   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
Numerator                
Net income (loss), as reported  $9,785,213   $15,005,009   $17,684,188   $13,939,816 
                     
Denominator                    
Weighted average shares, basic   28,794,047    27,582,229    28,728,828    27,605,137 
Dilutive effect of stock options, warrants and RSUs   947,218    1,569,993    1,105,127    1,489,338 
Shares used to compute diluted earnings per share   29,741,265    29,152,222    29,833,955    29,094,475 
                     
Basic earnings per share  $0.34   $0.54   $0.62   $0.50 
Diluted earnings per share  $0.33   $0.51   $0.59   $0.48 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Option Activity

The following table summarizes option activity during the six months ended June 30, 2021:

 

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2020   1,300,588   $2.44   $1.24      
Granted   -    -    -      
Expired   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   (184,225)   2.41    1.14      
Outstanding at June 30, 2021   1,116,363   $2.12   $1.31    7.44 
Exercisable at June 30, 2021   828,036   $2.20   $1.19    7.17 
Schedule of Outstanding Restricted Stock Units and Related Activity

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the six months ended June 30, 2021:

 

 

   Number of RSUs   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2020   522,500   $10.49 
Granted   480,000    9.90 
Vested   (192,084)   10.39 
Forfeited/Cancelled   -    - 
Unvested at June 30, 2021   810,416   $10.18 
Schedule of Warrant Activity

The following table summarizes warrant activity during the six months ended June 30, 2021:

 

   Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2020   70,000   $1.83   $5.21      
Granted   -    -    -      
Forfeited/Cancelled   -    -    -      
Exercised   -    -    -      
Outstanding at June 30, 2021   70,000   $1.83   $5.21    2.8 
Schedule of Recognized Stock-based Compensation Expense

The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
Options  $76,114   $301,568   $152,786   $703,198 
Restricted stock units   839,224    -    2,235,661    - 
Warrants   -    303,802    -    303,802 
Stock   12,000    86,049    51,900    117,242 
Total stock-based compensation expense  $927,338   $691,419   $2,440,347   $1,124,242 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies (Tables)
 6 Months Ended
Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Lease Payments

 

Year Ending December 31,    
2021 (remainder)  $142,950 
2022   293,595 
2023   303,059 
2024   50,774 
Total lease payments  $790,378 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Product Information [Line Items]          
Accounts receivable $ 13,686,152   $ 13,686,152   $ 12,928,633
Doubtful accounts 930,200   930,200   791,800
Accounts receivable, net 12,755,952   12,755,952   12,136,833
Inventory 4,120,704   4,120,704   7,995,189
Inventory finished goods 659,737   659,737   598,881
Inventory raw materials 3,460,967   3,460,967   $ 7,396,308
Research and development costs $ 4,669,160 $ 750,249 $ 6,886,223 $ 1,150,271  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customers Together [Member]          
Product Information [Line Items]          
Concentration risk percentage     67.00%    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers Together [Member]          
Product Information [Line Items]          
Concentration risk percentage     48.00%    
Minimum [Member]          
Product Information [Line Items]          
Estimated useful life of property     3 years    
Maximum [Member]          
Product Information [Line Items]          
Estimated useful life of property     5 years    
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets $ 2,109,675 $ 4,335,446
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 2,109,675 4,335,446
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Revenue by Geographic Area (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Disaggregation of Revenue [Line Items]        
Revenue $ 27,358,140 $ 24,040,274 $ 47,382,909 $ 25,588,802
Americas [Member]        
Disaggregation of Revenue [Line Items]        
Revenue $ 5,365,323 $ 13,383,761 $ 17,859,273 $ 13,997,786
Americas [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]        
Disaggregation of Revenue [Line Items]        
Percentage of revenue 20.00% 56.00% 38.00% 55.00%
Rest Of World [Member]        
Disaggregation of Revenue [Line Items]        
Revenue $ 21,992,817 $ 10,656,513 $ 29,523,636 $ 11,591,016
Rest Of World [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]        
Disaggregation of Revenue [Line Items]        
Percentage of revenue 80.00% 44.00% 62.00% 45.00%
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Deferred Revenue (Details)
 6 Months Ended
Jun. 30, 2021
USD ($)
Revenue from Contract with Customer [Abstract]  
Deferred revenue, beginning balance $ 305,307
Revenue recognized included in deferred revenue balance at the beginning of the period (194,060)
Increase due to prepayments from customers 51,887
Deferred revenue, ending balance $ 163,134
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Earnings Per Share [Abstract]            
Net income (loss), as reported $ 9,785,213 $ 7,898,975 $ 15,005,009 $ (1,065,193) $ 17,684,188 $ 13,939,816
Weighted average shares, basic 28,794,047   27,582,229   28,728,828 27,605,137
Dilutive effect of stock options, warrants and RSUs 947,218   1,569,993   1,105,127 1,489,338
Shares used to compute diluted earnings per share 29,741,265   29,152,222   29,833,955 29,094,475
Basic earnings per share $ 0.34   $ 0.54   $ 0.62 $ 0.50
Diluted earnings per share $ 0.33   $ 0.51   $ 0.59 $ 0.48
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Share (Details Narrative) - shares
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Earnings Per Share [Abstract]        
Securities excluded from computation of diluted earnings per share 931,341 0 146,133 0
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Option Activity (Details)
 6 Months Ended
Jun. 30, 2021
$ / shares
shares
Share-based Payment Arrangement [Abstract]  
Number of Options Outstanding, Beginning | shares 1,300,588
Weighted Average Exercise Price Outstanding, Beginning $ 2.44
Weighted Average Fair Value Outstanding, Beginning $ 1.24
Number of Options Outstanding, Granted | shares
Weighted Average Exercise Price Granted
Weighted Average Fair Value Granted
Number of Options Outstanding, Expired | shares
Weighted Average Exercise Price Expired
Weighted Average Fair Value Expired
Number of Options Outstanding, Forfeited/Cancelled | shares
Weighted Average Exercise Price Forfeited/Cancelled
Weighted Average Fair Value Forfeited/Cancelled
Number of Options Outstanding, Exercised | shares (184,225)
Weighted Average Exercise Price Exercised $ 2.41
Weighted Average Fair Value Exercised $ 1.14
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | shares 1,116,363
Weighted Average Exercise Price Outstanding, Ending $ 2.12
Weighted Average Fair Value Outstanding, Ending $ 1.31
Weighted-average Remaining Contractual Life (years) Outstanding, Ending 7 years 5 months 9 days
Number of Options Exercisable Ending | shares 828,036
Weighted Average Exercise Price, Exercisable Ending $ 2.20
Weighted Average Fair Value, Exercisable Ending $ 1.19
Weighted-average Remaining Contractual Life (years), Exercisable Ending 7 years 2 months 1 day
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Outstanding Restricted Stock Units and Related Activity (Details) - Restricted Stock Units (RSUs) [Member]
 6 Months Ended
Jun. 30, 2021
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Restricted Stock Units, Outstanding Beginning | shares 522,500
Weighted Average Grant Date Fair Value, Outstanding Beginning | $ / shares $ 10.49
Number of Restricted Stock Units, Granted | shares 480,000
Weighted Average Grant Date Fair Value, Granted | $ / shares $ 9.90
Number of Restricted Stock Units, Vested | shares (192,084)
Weighted Average Grant Date Fair Value, Vested | $ / shares $ 10.39
Number of Restricted Stock Units, Forfeited/Cancelled | shares
Weighted Average Grant Date Fair Value, Forfeited/Cancelled | $ / shares
Number of Restricted Stock Units, Outstanding Ending | shares 810,416
Weighted Average Grant Date Fair Value, Outstanding Ending | $ / shares $ 10.18
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Warrant Activity (Details)
 6 Months Ended
Jun. 30, 2021
$ / shares
shares
Share-based Payment Arrangement [Abstract]  
Number of Warrants Outstanding, Beginning | shares 70,000
Weighted Average Exercise Price, Beginning $ 1.83
Weighted Average Fair Value, Beginning $ 5.21
Number of Warrants Outstanding, Granted | shares
Weighted Average Exercise Price, Granted
Weighted Average Fair Value, Granted
Number of Warrants Outstanding, Forfeited/Cancelled | shares
Weighted Average Exercise Price, Forfeited/Cancelled
Weighted Average Fair Value, Forfeited/Cancelled
Number of Warrants Outstanding, Exercised | shares
Weighted Average Exercise Price, Exercised
Weighted Average Fair Value, Exercised
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance | shares 70,000
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice-2] $ 1.83
Shareholder [Member] $ 5.21
Weighted-average Remaining Contractual Life (Years) Outstanding, Ending 2 years 9 months 18 days
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Recognized Stock-based Compensation Expense (Details) - USD ($)
 3 Months Ended 6 Months Ended 15 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total stock-based compensation expense $ 927,338 $ 691,419 $ 2,440,347 $ 1,124,242  
Warrant [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total stock-based compensation expense 303,802 303,802  
Share-based Payment Arrangement, Option [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total stock-based compensation expense 76,114   152,786 703,198 $ 301,568
Restricted Stock Units (RSUs) [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total stock-based compensation expense 839,224 2,235,661  
Share-based Payment Arrangement [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total stock-based compensation expense $ 12,000 $ 86,049 $ 51,900 $ 117,242  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended
Jan. 31, 2021
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of options   1,116,363   1,300,588
Stock-based compensation   $ 2,440,347 $ 1,124,242  
Warrant [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Intrinsic value of options outstanding   450,000    
Stock Options [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Intrinsic value of options execised   1,300,000    
Intrinsic value of options outstanding   6,900,000    
Number of options 100,000      
Stock-based compensation $ 65,000      
Recognized share based compensation   $ 45,000    
Unvested option shares outstanding   288,327    
Unrecognized stock-based compensation   $ 186,144    
Unrecognized stock-based compensation recognition period   10 months 24 days    
Stock Options [Member] | Maximum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Option exercise price $ 16.49      
Stock Options [Member] | Minimum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Option exercise price $ 9.30      
Restricted Stock Units (RSUs) [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized stock-based compensation   $ 7,800,000    
Unrecognized stock-based compensation recognition period   2 years 8 months 12 days    
Restricted Stock [Member] | Third Parties [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares issued for services   5,548    
2015 Long-term Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Aggregate number of common shares reserved   6,000,000    
Number of common shares availalble for issuance   2,798,683    
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Tax Disclosure [Abstract]        
Income tax expenses $ 2,145,076 $ 4,130,716
Effective income tax rate 18.00%   18.90%  
effective income tax u.s. federal statutory rate     21.00%  
effective income tax rate, valuation allowance   0.00%   0.00%
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions (Details Narrative) - Exclusive License Agreement [Member] - USD ($)
Jan. 01, 2017
Jun. 30, 2021
Dr Satterfield [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Accrued royalties $ 700,000  
Dr Satterfield [Member] | Per Month [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Payment for royalties $ 10,000  
Dr Brent Satterfield [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Due to related party   $ 90,000
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Future Minimum Lease Payments (Details)
Jun. 30, 2021
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2021 (remainder) $ 142,950
2022 293,595
2023 303,059
2024 50,774
Total lease payments $ 790,378
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies (Details Narrative)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
USD ($)
a
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
a
Jun. 30, 2020
USD ($)
Feb. 29, 2020
Commitments and Contingencies Disclosure [Abstract]          
Lease term         4 years
Area of land | a 13,687   13,687    
Payments for rent     $ 28,825    
Lease expiration date     Feb. 29, 2024    
Rent expenses $ 86,588 $ 86,969 $ 173,175 $ 138,786  
EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 112 302 1 false 29 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://codiagnostics.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://codiagnostics.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://codiagnostics.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://codiagnostics.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://codiagnostics.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://codiagnostics.com/role/StatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://codiagnostics.com/role/StatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 00000008 - Disclosure - Overview and Basis of Presentation Sheet http://codiagnostics.com/role/OverviewAndBasisOfPresentation Overview and Basis of Presentation Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Fair Value Measurements Sheet http://codiagnostics.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 00000011 - Disclosure - Revenue Sheet http://codiagnostics.com/role/Revenue Revenue Notes 11 false false R12.htm 00000012 - Disclosure - Earnings Per Share Sheet http://codiagnostics.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 00000013 - Disclosure - Stock-Based Compensation Sheet http://codiagnostics.com/role/Stock-basedCompensation Stock-Based Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Income Taxes Sheet http://codiagnostics.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 00000015 - Disclosure - Related Party Transactions Sheet http://codiagnostics.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://codiagnostics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://codiagnostics.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Fair Value Measurements (Tables) Sheet http://codiagnostics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://codiagnostics.com/role/FairValueMeasurements 19 false false R20.htm 00000020 - Disclosure - Revenue (Tables) Sheet http://codiagnostics.com/role/RevenueTables Revenue (Tables) Tables http://codiagnostics.com/role/Revenue 20 false false R21.htm 00000021 - Disclosure - Earnings Per Share (Tables) Sheet http://codiagnostics.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://codiagnostics.com/role/EarningsPerShare 21 false false R22.htm 00000022 - Disclosure - Stock-Based Compensation (Tables) Sheet http://codiagnostics.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://codiagnostics.com/role/Stock-basedCompensation 22 false false R23.htm 00000023 - Disclosure - Commitments and Contingencies (Tables) Sheet http://codiagnostics.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://codiagnostics.com/role/CommitmentsAndContingencies 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies 24 false false R25.htm 00000025 - Disclosure - Summary of Assets Measured at Fair Value on Recurring Basis (Details) Sheet http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails Summary of Assets Measured at Fair Value on Recurring Basis (Details) Details 25 false false R26.htm 00000026 - Disclosure - Summary of Revenue by Geographic Area (Details) Sheet http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails Summary of Revenue by Geographic Area (Details) Details 26 false false R27.htm 00000027 - Disclosure - Schedule of Deferred Revenue (Details) Sheet http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails Schedule of Deferred Revenue (Details) Details 27 false false R28.htm 00000028 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details) Sheet http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails Schedule of Basic and Diluted Earnings Per Share (Details) Details 28 false false R29.htm 00000029 - Disclosure - Earnings Per Share (Details Narrative) Sheet http://codiagnostics.com/role/EarningsPerShareDetailsNarrative Earnings Per Share (Details Narrative) Details http://codiagnostics.com/role/EarningsPerShareTables 29 false false R30.htm 00000030 - Disclosure - Schedule of Option Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfOptionActivityDetails Schedule of Option Activity (Details) Details 30 false false R31.htm 00000031 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails Schedule of Outstanding Restricted Stock Units and Related Activity (Details) Details 31 false false R32.htm 00000032 - Disclosure - Schedule of Warrant Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails Schedule of Warrant Activity (Details) Details 32 false false R33.htm 00000033 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails Schedule of Recognized Stock-based Compensation Expense (Details) Details 33 false false R34.htm 00000034 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://codiagnostics.com/role/Stock-basedCompensationTables 34 false false R35.htm 00000035 - Disclosure - Income Taxes (Details Narrative) Sheet http://codiagnostics.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://codiagnostics.com/role/IncomeTaxes 35 false false R36.htm 00000036 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://codiagnostics.com/role/RelatedPartyTransactions 36 false false R37.htm 00000037 - Disclosure - Schedule of Future Minimum Lease Payments (Details) Sheet http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails Schedule of Future Minimum Lease Payments (Details) Details 37 false false R38.htm 00000038 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://codiagnostics.com/role/CommitmentsAndContingenciesTables 38 false false All Reports Book All Reports form10-q.htm codx-20210630.xsd codx-20210630_cal.xml codx-20210630_def.xml codx-20210630_lab.xml codx-20210630_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true true JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 14, "contextCount": 112, "dts": { "calculationLink": { "local": [ "codx-20210630_cal.xml" ] }, "definitionLink": { "local": [ "codx-20210630_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "codx-20210630_lab.xml" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "codx-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml" ] }, "schema": { "local": [ "codx-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 363, "entityCount": 1, "hidden": { "http://codiagnostics.com/20210630": 12, "http://fasb.org/us-gaap/2021-01-31": 92, "http://xbrl.sec.gov/dei/2021": 5, "total": 109 }, "keyCustom": 22, "keyStandard": 280, "memberCustom": 9, "memberStandard": 20, "nsprefix": "CODX", "nsuri": "http://codiagnostics.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://codiagnostics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Fair Value Measurements", "role": "http://codiagnostics.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Revenue", "role": "http://codiagnostics.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Earnings Per Share", "role": "http://codiagnostics.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Stock-Based Compensation", "role": "http://codiagnostics.com/role/Stock-basedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Income Taxes", "role": "http://codiagnostics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Related Party Transactions", "role": "http://codiagnostics.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Commitments and Contingencies", "role": "http://codiagnostics.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Subsequent Events", "role": "http://codiagnostics.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Fair Value Measurements (Tables)", "role": "http://codiagnostics.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://codiagnostics.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Revenue (Tables)", "role": "http://codiagnostics.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Earnings Per Share (Tables)", "role": "http://codiagnostics.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://codiagnostics.com/role/Stock-basedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://codiagnostics.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Summary of Assets Measured at Fair Value on Recurring Basis (Details)", "role": "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Summary of Assets Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Summary of Revenue by Geographic Area (Details)", "role": "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "shortName": "Summary of Revenue by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Schedule of Deferred Revenue (Details)", "role": "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails", "shortName": "Schedule of Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details)", "role": "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "shortName": "Schedule of Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "INF", "lang": null, "name": "CODX:WeightedAverageNumberOfBasicSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Earnings Per Share (Details Narrative)", "role": "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "shortName": "Earnings Per Share (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://codiagnostics.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Schedule of Option Activity (Details)", "role": "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails", "shortName": "Schedule of Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details)", "role": "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "shortName": "Schedule of Outstanding Restricted Stock Units and Related Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Warrant Activity (Details)", "role": "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails", "shortName": "Schedule of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details)", "role": "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "shortName": "Schedule of Recognized Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Stock-Based Compensation (Details Narrative)", "role": "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "Stock-Based Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30_us-gaap_WarrantMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Income Taxes (Details Narrative)", "role": "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2017-01-01_custom_ExclusiveLicenseAgreementMember_custom_DrSatterfieldMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedRoyaltiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2017-01-01_custom_ExclusiveLicenseAgreementMember_custom_DrSatterfieldMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedRoyaltiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Future Minimum Lease Payments (Details)", "role": "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails", "shortName": "Schedule of Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-02-29", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-02-29", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://codiagnostics.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://codiagnostics.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:GainLossOnSaleOfEquityInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-31_us-gaap_ConvertiblePreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://codiagnostics.com/role/StatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-03-31_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "role": "http://codiagnostics.com/role/StatementsOfStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Overview and Basis of Presentation", "role": "http://codiagnostics.com/role/OverviewAndBasisOfPresentation", "shortName": "Overview and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 29, "tag": { "CODX_AccruedExpensesNoncurrent": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses noncurrent.", "label": "Accrued expenses, noncurrent" } } }, "localname": "AccruedExpensesNoncurrent", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "CODX_DeferredTaxAssetCurrent": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax asset current.", "label": "Deferred tax asset" } } }, "localname": "DeferredTaxAssetCurrent", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "CODX_DrBrentSatterfieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dr. Brent Satterfield [Member]", "label": "Dr Brent Satterfield [Member]" } } }, "localname": "DrBrentSatterfieldMember", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_DrSatterfieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dr. Satterfield [Member]", "label": "Dr Satterfield [Member]" } } }, "localname": "DrSatterfieldMember", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_EarningsBasicPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic earnings per share" } } }, "localname": "EarningsBasicPerShare", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "CODX_ExclusiveLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive License Agreement [Member]", "label": "Exclusive License Agreement [Member]" } } }, "localname": "ExclusiveLicenseAgreementMember", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_IncreaseDueToPrepaymentsFromCustomers": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase due to prepayments from customers.", "label": "Increase due to prepayments from customers" } } }, "localname": "IncreaseDueToPrepaymentsFromCustomers", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "CODX_IssuanceOfCommonStockForOptionAndWarrantExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for option and warrant exercises.", "label": "Common stock issued for option and warrant exercises" } } }, "localname": "IssuanceOfCommonStockForOptionAndWarrantExercises", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "CODX_IssuanceOfCommonStockForOptionAndWarrantExercisesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for option and warrant exercises shares.", "label": "Common stock issued for option and warrant exercises, shares" } } }, "localname": "IssuanceOfCommonStockForOptionAndWarrantExercisesShares", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "CODX_NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash or part noncash inventory moved to property plant and equipment.", "label": "Inventory moved to property, plant and equipment" } } }, "localname": "NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_PaymentsToAcquireInterestInJointVentures": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to acquire interest In joint ventures.", "label": "PaymentsToAcquireInterestInJointVentures", "negatedLabel": "Investment in joint venture" } } }, "localname": "PaymentsToAcquireInterestInJointVentures", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_PerMonthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Month [Member]", "label": "Per Month [Member]" } } }, "localname": "PerMonthMember", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_ProceedsFromExerciseOfOptionsAndWarrants": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from exercise of options and warrants.", "label": "Proceeds from exercise of options and warrants" } } }, "localname": "ProceedsFromExerciseOfOptionsAndWarrants", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_RecognizedShareBasedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Recognized share based compensation.", "label": "Recognized share based compensation" } } }, "localname": "RecognizedShareBasedCompensation", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CODX_RestOfWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rest of World [Member]", "label": "Rest Of World [Member]" } } }, "localname": "RestOfWorldMember", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, non-option, exercise in period, weighted average exercise price.", "label": "Weighted Average Fair Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, non-option, granted in period, weighted average exercise price.", "label": "Weighted Average Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice-2]", "periodStartLabel": "Weighted Average Exercise Price, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangements by share-based payment award, non-options, exercise in period, weighted average exercise price", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to non-options that were terminated.", "label": "Weighted Average Exercise Price, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangements by share-based payment award, non-options, grants in period, weighted average exercise price.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm21": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, non-options, outstanding, weighted average remaining contractual term.", "label": "Weighted-average Remaining Contractual Life (Years) Outstanding, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm21", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, non-option, weighted average exercise price", "label": "Shareholder [Member]", "periodEndLabel": "Shareholder [Member]", "periodStartLabel": "Weighted Average Fair Value, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, non-option, forfeitures, weighted average exercise price.", "label": "Weighted Average Fair Value, Forfeited/Cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercised weighted average grant date fair value.", "label": "Weighted Average Fair Value, Exercisable Ending", "periodEndLabel": "Weighted Average Fair Value, Exercisable Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Fair Value Exercised.", "label": "Securities Purchase Agreements [Member]", "periodEndLabel": "Weighted Average Fair Value Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options [Member]", "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_ThirdPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Parties [Member]", "label": "Third Parties [Member]" } } }, "localname": "ThirdPartiesMember", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TwoCustomersTogetherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Customers Together [Member]", "label": "Two Customers Together [Member]" } } }, "localname": "TwoCustomersTogetherMember", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TwoThousandFifteenLongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2015 Long-term Incentive Plan [Member]", "label": "2015 Long-term Incentive Plan [Member]" } } }, "localname": "TwoThousandFifteenLongTermIncentivePlanMember", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_WeightedAverageNumberOfBasicSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares, basic" } } }, "localname": "WeightedAverageNumberOfBasicSharesOutstanding", "nsuri": "http://codiagnostics.com/20210630", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r423", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r154", "r229", "r235", "r389" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r196", "r203", "r250", "r252", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r387", "r390", "r411", "r412" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r196", "r203", "r250", "r252", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r387", "r390", "r411", "r412" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r154", "r229", "r235", "r389" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r196", "r203", "r241", "r250", "r252", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r387", "r390", "r411", "r412" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r196", "r203", "r241", "r250", "r252", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r387", "r390", "r411", "r412" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r104", "r109", "r251" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r152", "r153", "r229", "r234", "r388", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r152", "r153", "r229", "r234", "r388", "r397", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r104", "r109", "r181", "r251", "r349" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r155", "r342" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36", "r347" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r156", "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r25", "r156", "r157" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses, current" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r11", "r12", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r26", "r284", "r347" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r96", "r97", "r98", "r281", "r282", "r283", "r316" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r254", "r278", "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r31", "r162", "r169" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Securities excluded from computation of diluted earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r90", "r140", "r143", "r149", "r167", "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r312", "r314", "r329", "r345", "r347", "r365", "r376" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r10", "r51", "r90", "r167", "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r312", "r314", "r329", "r345", "r347" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r319" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Fair value of assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r255", "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r95", "r135" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Overview and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/OverviewAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r33", "r81" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r17", "r82" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r74", "r81", "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r74", "r330" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing transactions" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r89", "r90", "r112", "r113", "r114", "r116", "r118", "r127", "r128", "r129", "r167", "r183", "r188", "r189", "r190", "r194", "r195", "r201", "r202", "r204", "r205", "r329", "r429" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r180", "r368", "r380" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r177", "r178", "r179", "r182", "r399" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Aggregate number of common shares reserved" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r96", "r97", "r316" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r347" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 100,000,000 shares authorized; 28,889,890 and 28,558,033 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r133", "r134", "r154", "r327", "r328", "r398" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r133", "r134", "r154", "r327", "r328", "r396", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r133", "r134", "r154", "r327", "r328", "r396", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r130", "r375" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations Risk and Significant Customers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r133", "r134", "r154", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk percentage", "verboseLabel": "Percentage of revenue" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r133", "r134", "r154", "r327", "r328", "r398" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Schedule of Deferred Revenue" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r210", "r211", "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Deferred revenue, ending balance", "periodStartLabel": "Deferred revenue, beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedLabel": "Revenue recognized included in deferred revenue balance at the beginning of the period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r201", "r202", "r204" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r66", "r90", "r167", "r183", "r184", "r185", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r329" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r131", "r154" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r79", "r91", "r296", "r302", "r303", "r304" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r79", "r138" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://codiagnostics.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r229", "r233", "r234", "r235", "r236", "r237", "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r255", "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r36", "r94", "r186", "r188", "r189", "r193", "r194", "r195", "r341" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses (related party), current" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r94", "r186", "r188", "r189", "r193", "r194", "r195", "r341", "r367", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r42", "r94", "r186", "r188", "r189", "r193", "r194", "r195", "r341" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Accrued expenses (related party), noncurrent" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r60", "r101", "r102", "r103", "r104", "r105", "r110", "r112", "r116", "r117", "r118", "r122", "r123", "r317", "r318", "r371", "r384" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per common share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r60", "r101", "r102", "r103", "r104", "r105", "r112", "r116", "r117", "r118", "r122", "r123", "r317", "r318", "r371", "r384" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted", "verboseLabel": "Diluted earnings per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r119", "r120", "r121", "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r290", "r305" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "effective income tax rate, valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r290", "r305" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "effective income tax u.s. federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Unrecognized stock-based compensation recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r55", "r56", "r57", "r96", "r97", "r98", "r100", "r106", "r108", "r126", "r168", "r206", "r208", "r281", "r282", "r283", "r298", "r299", "r316", "r331", "r332", "r333", "r334", "r335", "r336", "r391", "r392", "r393", "r434" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/StatementsOfStockholdersEquity", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "auth_ref": [ "r62", "r63", "r79" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.", "label": "Gain (loss) on equity method investment in joint venture" } } }, "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r34", "r73", "r166", "r329" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity-Method Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r319", "r320", "r321", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Summary of Assets Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r197", "r199", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r320", "r351", "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r319", "r320", "r322", "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r197", "r242", "r243", "r248", "r249", "r320", "r351" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r197", "r199", "r200", "r242", "r243", "r248", "r249", "r320", "r352" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r197", "r199", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r320", "r353" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r197", "r199", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r351", "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r324", "r326" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfEquityInvestments": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.", "label": "Gain (Loss) on Sale of Equity Investments", "negatedLabel": "Loss (gain) from equity method investment" } } }, "localname": "GainLossOnSaleOfEquityInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r132", "r398" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r65", "r90", "r140", "r142", "r145", "r148", "r150", "r167", "r183", "r184", "r185", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r329" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r58", "r140", "r142", "r145", "r148", "r150", "r364", "r369", "r372", "r385" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r92", "r291", "r292", "r295", "r300", "r306", "r308", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r93", "r107", "r108", "r139", "r289", "r301", "r307", "r386" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision", "verboseLabel": "Income tax expenses" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r54", "r287", "r288", "r292", "r293", "r294", "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r78" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r78" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r78" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r78" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r78" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r72", "r75", "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r49", "r347" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r13", "r50", "r86", "r125", "r171", "r172", "r173", "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Rent expenses" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "2021 (remainder)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r90", "r144", "r167", "r183", "r184", "r185", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r313", "r314", "r315", "r329", "r345", "r346" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r90", "r167", "r329", "r347", "r366", "r378" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41", "r90", "r167", "r183", "r184", "r185", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r313", "r314", "r315", "r329", "r345", "r346", "r347" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r14", "r15", "r16", "r20", "r21", "r90", "r167", "r183", "r184", "r185", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r313", "r314", "r315", "r329", "r345", "r346" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r6", "r39" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable investment securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Investment Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r74", "r77", "r80" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r52", "r53", "r57", "r59", "r80", "r90", "r99", "r101", "r102", "r103", "r104", "r107", "r108", "r115", "r140", "r142", "r145", "r148", "r150", "r167", "r183", "r184", "r185", "r188", "r189", "r190", "r191", "r192", "r194", "r195", "r318", "r329", "r370", "r383" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://codiagnostics.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "terseLabel": "Net income (loss), as reported", "totalLabel": "Net income", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperations", "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r140", "r142", "r145", "r148", "r150" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payment for royalties" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r71" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Public offering costs", "negatedLabel": "Payment of offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r69" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r255", "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r201" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Convertible preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Convertible preferred stock , shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r201" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Convertible preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Convertible preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r347" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r7", "r9", "r174", "r175" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r70" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from maturities of marketable investment securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r18", "r19", "r176", "r347", "r374", "r379" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r35", "r176", "r400", "r401" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated useful life of property" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r61", "r170" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentsJointVentures": { "auth_ref": [ "r381" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The book value of investments in real estate joint ventures including direct and indirect investments.", "label": "Investment in joint venture" } } }, "localname": "RealEstateInvestmentsJointVentures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r339", "r340", "r341", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r286", "r362", "r413" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r208", "r284", "r347", "r377", "r394", "r395" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r96", "r97", "r98", "r100", "r106", "r108", "r168", "r281", "r282", "r283", "r298", "r299", "r316", "r391", "r393" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r136", "r137", "r141", "r146", "r147", "r151", "r152", "r154", "r228", "r229", "r363" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r136", "r137", "r141", "r146", "r147", "r151", "r152", "r154", "r228", "r229", "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r87", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r240" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Deferred Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r232", "r240" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r133", "r154" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r64", "r152" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Summary of Revenue by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r267", "r272", "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule of Recognized Stock-based Compensation Expense" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r255", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Outstanding Restricted Stock Units and Related Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r258", "r272", "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r209", "r253" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Number of Restricted Stock Units, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Weighted Average Grant Date Fair Value, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Number of Restricted Stock Units, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Weighted Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Restricted Stock Units, Outstanding Ending", "periodStartLabel": "Number of Restricted Stock Units, Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding Ending", "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Restricted Stock Units, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Weighted Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of Warrants Outstanding, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Number of Warrants Outstanding, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of Warrants Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r259", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance", "periodStartLabel": "Number of Warrants Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Number of common shares availalble for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of Options Exercisable Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Exercisable Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Intrinsic value of options execised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Number of Options Outstanding, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Number of Options Outstanding, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Number of Options Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted Average Fair Value Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r260", "r280" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Number of options", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance", "periodStartLabel": "Number of Options Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending", "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r253", "r256" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercise Price Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r255", "r257" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Option exercise price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average Remaining Contractual Life (years), Exercisable Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Unvested option shares outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Weighted Average Fair Value Forfeited/Cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Fair Value Outstanding, Ending", "periodStartLabel": "Weighted Average Fair Value Outstanding, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average Remaining Contractual Life (years) Outstanding, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Weighted Average Fair Value Expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r85", "r95" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r22", "r23", "r24", "r89", "r90", "r112", "r113", "r114", "r116", "r118", "r127", "r128", "r129", "r167", "r183", "r188", "r189", "r190", "r194", "r195", "r201", "r202", "r204", "r205", "r206", "r329", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r46", "r55", "r56", "r57", "r96", "r97", "r98", "r100", "r106", "r108", "r126", "r168", "r206", "r208", "r281", "r282", "r283", "r298", "r299", "r316", "r331", "r332", "r333", "r334", "r335", "r336", "r391", "r392", "r393", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/StatementsOfStockholdersEquity", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r96", "r97", "r98", "r126", "r363" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r45", "r198", "r206", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of preferred stock to common, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Number of shares issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r23", "r24", "r206", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Public offering, net of offering costs of $1,457,922, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for warrant exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation expense, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r206", "r208", "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Common stock issued for option exercises, shares", "negatedLabel": "Number of Options Outstanding, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails", "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r46", "r206", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of preferred stock to common" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r23", "r24", "r206", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Public offering, net of offering costs of $1,457,922" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r46", "r206", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Common stock issued for option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r28", "r29", "r90", "r164", "r167", "r329", "r347" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r348", "r350" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Income taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r158", "r159", "r160", "r161", "r163", "r165" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Dilutive effect of stock options, warrants and RSUs" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r111", "r118" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Shares used to compute diluted earnings per share", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r110", "r118" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r344": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r414": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r415": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r416": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r417": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r418": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r419": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r421": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r422": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r423": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r424": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r425": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r426": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r427": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r428": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r429": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r431": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r432": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r433": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 57 0001493152-21-019503-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-019503-xbrl.zip M4$L#!!0 ( ,* #%,Q+<)Q0@L .UL 1 8V]D>"TR,#(Q,#8S,"YX M7HX+"" M"/.X3UGOLO+YJ5I_NFXV*^B7G__U3P1_%_^N5M$M)8%_CAK5YK38>CP\8'^$Q%U_E@<<'RPE\4EB%,I%V.#FT?\NQWU/I)3C[\]WO'RCYVA\]7XT[Y.LIFX[9U?7; MYR_7O_]OV)T(=]/BH!@U ?WP4$X:RVL-XF!!WL>P8 MH;;!$%,<1@F,%3M'7UO.*0P#N#&/RYTP)P+'I VF(#T!0Q0 MAP)-4;OF\*"I(.I?5J)++0H$&V$^Z5)&C48['(]050^^4)L(EX;EHC9/G!$1 M2N*WV,_F>BB(!#YCPAWM[[PK'.@1]]0G M1,G(B;.WW,X\!@_J!Q])O,E\PJ";^DKR@/K0YB,K$D4RT9O/#(<^A9;_[CUO M7/* !1C7)T""@P(89MO=F)R\%!/T9D;=#F.4N%&VNJVA3D- I1TF)6UN;-XN MATTJ&_$N2J7O1\X\*M=8]F\#/BX )6UR8_)N'4RT<&2D[S&9Q^1)<>]KGP<^ M9.4WWT*JIGEP"FC<*)VN@U)6RW]0I&>/UV*\"J:C51C<2+Y_#23W0RTD&AM!V7%[*[#'\F(L)!$ M+HY_N)UZ-.]4R[:[3KS!@L'XE0]$//5A]HN\F;OK=NOQO%MC?@0"D)&PNQXV M64=5+V'Z>K$9LI3,)%K6Z/;W2>[Y;,1;#"Y)&T_BB3%[P^W= MM_/>C5B1X=U=CSZ20.?4D"*K:5M@B# OLY)1VNKV];O\ ]G(0480RDK:7<_# MB!Y0969[2+:AP-$9%V%ITN-.P%Q M%4&6P U-KAPM*870FTC<#J-@ZYFLWV=O.3U]G"LZ+?/>L[E"*>OBDC:WKW.U M:+YHVKN]K'K*>M]-X@8A5[F655)[*%QI:!:.Q61N2'+%K3,EW>.R9.K4( K3 M0'["0K\''I%54J@G_AA0%K=!ND2 M 3%N_36+TB(J-SSYE0(K3^,32TR3\STJJ;_U4\6#Q*-!@U 1?SXU+T%I22XW M:ODEA QJ1H/)7ZR.PGQ_CV2)Z^?REH54;J1R*PH.+/:9R,SX:@VUMKH'#J%J M6C*Y\+$!1I=FSWV$@K0>&?FT3)@>XLZK)P$*"5[3U3LO? MJ)$0?:L:.1>PKV3J=:IEHP;#T%G5X-G1]DKV-A(E67/M&0*U]! !^WO^H($+ M,)P+A5CNV +7,131 1IWW#.B'"SZ5S7FJ^I;U:/CZLG1P43Z:4]7Z43JAM4Z M$?.MT8F2PS"*],LR+FYUG[D(_-F>%S5L0X?!H^T^#R4DQ+>TJPAA M=YSUVD0,FO#$9SH/?@@PR\&P$M,V&&H6IZ)7-G+6FL*6;>ARNT^%67. ]&$. M@**6;>CRS<0+0@GXWU%/+\W6>X(8DMG^+R;;!F,:X@DK1417GVPV:T!QTS9T M^@&>B%#8]F?[F[N[#5UMB"M]M('#R:7M6]%]N^>EC2=FA]EU*'1WD]Z7-B_L M?)1PJ[BI$YUH!$:0#E6Q15';@#.BL)ANP)ZZYT%_?/M217[BS)NUR$6PMDT> MN.@5C8H7X]J\[GT+J2!-!L$$DW&3_-71V+6/9;0D^*]D>3Z>_7N)C> M\Q$,0_X0U>)3G9HH,$L?MC(<9.+[I4*VU3E-*4.MI]752Z"&> M5%.)F4L2;RW,SX3V^GH_T(@(W".?0ITQV,V4$229[3VQU:LR_6A(XZV!IH/I M,1DVN2YI?$'.-+12-E&':3FYK0=U/79ZAO1JFI+8V;@^QL*W\Q$\ETO UL"+)AP3Q2/230N^'J%X^,_H[>5V;_,/\;I5OC^>O%AM_-6\\6&WM MSSQ[YCP0Q]F#H-ZLN[^7QNWQ\3H!EEJ\,+1>',RKZ=H>O[HB22X.)6.=;+(' MT_>-Q.^FM6[1Q/BR8>NT>D%(?V_-?Q&G+Q%K4 1T"36K M\[S%=7O45NWT1& MD'/%$DG"QM.2-3NQ15"\, R3FO=[Q_^JBO\B+G^YX:_ZL%]+^1:Y_F796WEN M_$CTFP6XKW<6"NRI$ ?ZI:C>2["QY'%-]6NN6,1W-_)J//EVI# $TS?E"^FV M=O&IW1>$+-K#X*;9AC=;A:_)M_$->=$G@?E]%Z44VV""Z5;!AH0?U,F+6K3; M!R[_#U!+ P04 " #"@ Q38QD9N%4. FIP %0 &-O9'@M,C R,3 V M,S!?8V%L+GAM;.U=ZV_;.!+_?L#]#SHO<-C]X#J/MKO-MK=P7D4.:6TD[>Y^ M6S 2'1.529>2$GO_^AM2E*TG1=F6Q 7%$WB<(8S\QO.#!^BWO^V6OC.$^8! M8?3#X/C5T<#!U&4>H8\?!E_OA^/[BYN;@1.$B'K(9Q1_&% V^.T___R' U_O M_S4<.M<$^]Z9<\GO'KWX R'!FQ_Q]1C_.O=S8;M/ R7P=EH]/S\_(JR)_3,^+?@ MEI(?<7D[WU"OYV)_QY0@!TP%PW.5@'Y,!#]JFZ?3U\Q M_C@Z.3HZ'OWYZ?;>G>,%&A(JS.;B04(EN)31';][]VXD_YHT+;1-T ME(BSX0Q_)9KV*4D"FTW3F4+\=LP:384'PV/3X:GQZ]6@3=( MC"\MR)F/[_#,$=\!O4VOPM?0(V5!2%R)VDBT&%TP<$H05]+..9Y]&$#+%71Q M[G&(=!G1"EC=L29HHXIN$< M0Q/D-Y*LE/* 8HIAA!?013"9399BY(-OU1I/3]62>!(A.LF4E93=R9N(Q?=@=4!%9E ^'@B^'E,O7,4$)!ARG$ M74HWK)/=C/J0=H\6"\378"GR2,D,C$+#L>NRB(:0KJ?,)R[!]4[=B,L!Q;]& MA,LD^PFC(.(Q['72:HD.*-P=?L(TPG7BY)H=4( KQ"G8/YAB?C\'OZ^3I*K] M0<*-DP#8S&10W9 06\@4IU@;^@5;W7ES0]J/?X$,<\B%?A^@M' MH+%KE/[JZ XH(D"Q(*$K)Y,(4=6^ M\\![V #<=2#^@A[\>MD-2 \?E,U$*VW<8H VDTI/U7ZP-I/2B+B;8&0FL#&# MSJ/ )0X1\8//B(O)S%-M'M^/:QOJC8, YHMJ@'OC<#/F)_0.NQ'G())50 MQAKNRK@-)56T.%]_Q.R1H^6E/Z5E"8+$5L'T.E^01S[,9& MUY*W(W 4RO5GL-@=#D).7 !;IJROE,@$H.KHW77:LX=6U/Y#>(-(!CLJI:=O M160(XPRRV-_*>,6*XFHE?FP^TG=DW'Y]U3C=-V/3SF2YJ= &I!U,IIM*W91/ M*R/B.@JAV/E$*%E$BULH?? 4K67=VG@,&+/JIE!O"L<.K'2*N,AW(U\.GEOX M/4.!5R&F'O82/D*51AM.(0D%A=H(/':&8M?D@VZ1 >?N1FY?;%#R'*[ M<,ENJ]P'G*'@06X&1L'P$:'E2" ^PGX8))]('Q@>':L]P1_4QW_% MPY1?C;GK,.YA_F%PG/2#N)OQIN(.K6HQ"L241; 9 O:+A'[&V4)G<&5P3+1VSZT;JA8@&=\#<)6HY-M98;&ZU[1 M*-/+/NM/.5XBXJF)4.T@J6ANAL>;7O'0:GI 8$IJV,GEGW\E"VRHXRJC+HU"ML'TQW&/E7@9@DBB06Q-/O_S)"P]_AIXACS7 QH;6C MF*J S%QY^X"[)>B!^&9SD[*V-E3M4[06I:MQO9YOWW>82])CZF(>D[;#>!2:^V?4A=1O@+2RUDFT"EH^D[7AMC5:^X?6#)#1+3H%?: MN._9L#$\&E7MPR5WTJ%^ %6T[WMN;#YXM K;!U!*L<^,N@WJG73S0\[Q5:I0 M2PQZJ02!IKU%54Q1C?1\OU9G^QRG)$N8.% -F44%335B9JK8"EQ*1:-Q;M4P MJH!BW[JR1S>KU^@E.%7UPV]%WRIKV_/J?9RSI6 U>\FEC?L>()I'#PO+]U6J MVN=3XM0*HR:@%%OV/<"-$:E2TCXXQIY'A.+(GR+BW= +M"3A]MG0DG6+*H*^ M9\+&X-2H;!]&=^(T%]T>QX:Z,EI$LD*!B0EQB:8R,Z'M>Y)LC)RY(>P#,97Z MQ]1KDEGK*?O.5*:Z55=#+Z:P:Z)?W=T!56J^'^6UO(7?NSL=67Y+0.:HY.F^ M1R6='S.]_-3V\<^:>S$RRKTV4V[+TF$S9\O4EA.A'SD+@BEG,UU^R#3J-\G) MI;5K&'OB*#-';O@'"><741"R!>97*]>/Q.,D8H,2_HE#%+JLMP.SOJ-H"5Z% M_+>SC>Q+B!">I!*]2HQ_[!G^ZN 11^3]#GUXC.X6\$TRQ,:FKX'?B42^7JB5F_[1GE\:9T/,H^]!:$D".,G4FH! MJR7L.Q*8HF9H ?N@N\,!!GG$DPF7$,U\)D]GU0)70];W,H$I;$;:VP?:)5YR M[!+U#*2X%5(8%GQOP7A(_LY<'%2V46M"W?=Z@2F$36QA'Y(;+>.'16^A[C#( MT.G&UN2UH@;Y&%E255FY$F"N4K63VE<*?F:4916KC?(:DGZ?F DQQT$8BS0) MY]M'4,L>G"EIW/>@J<6B\"Q-I<;VQ;1X%>P3#N?,VQXA%L>*Q4T$'Q&A8D1- MZ"4)EBS0;4,TY]1WZ&@*[*ZVL@_U;:Q,5BX(C< *VR6S=;%6@^9^6+[L!3-Y\>-YU2WI)5M"%>W[7J'> M&T:](>P#;CN7O4?B7K9XYIMZQ%BS2U1/VO=J]=YP&IO'PI7%Y,&IQI5I+6'? MSXX=(-@:F<:^X2I5%F\9NV;\DD4/X2SRDP>VJP'54_5]=\O>:)H8Q3XHP?>X MN/?R$L??;VCQHBSM[-& V@S:G^V%MHF1+ S!1?&SUSTUP3=/:8;M+R\)VW+C MO ADGX:NST(G!6CXFG MQ%?W0#3,O%5,##&W>(UI!YN]I%I+B2X66@H7ZNQ2?>GY&;J#QK%C$DD?80W%I]GHR*[M(6[N.T)25I>OR#7Q@5_.U?W=OP3VWY]'J M;L44].;DEJ[*&X#83$]KQW"% :X)1=3=+TN5\K E7MT$020>8IW,4K-I25RUHJ2S-*0T&HH%1+$PE0NGO;Y:N7.$7W$=RC$5[,9=C43B:[EZ#OP]V/WXH&AIM-_*P\8VVQ, M756ZAS';BX0V&U,7CFV[QR5]Q%1S_4SFK.G;7MKA MI2Y%;0VNL?FY-=6[OM]F\H3Y$\'/,$[D&[\GLRE,)T& [-FOC/:_B-744,XG9EIVSY>=L&;:KUN;% M[.I=[=EC6VDMCH_R6@A:1Q([6>IV1TX+C2FIY@M,I/YO:CM1E.Z@925_G)8TIG-SN M6?[ZX7)1WQ1=5)([DM[),FA7<,V+>LME?YN7/<5!QN8.EG/B MCCE&6I4+U4!*Y20F/JR=+4='L.Q0.7>.O4@\F9)[38Y6JV*]H-@(M1)&VYC? MO3+"15QQ^Q?QHW![YW22#;3*%1.'?UB5"RB!:W8M\HV5/7CC5M]1+S M=!131W)U$K;=C2[-%,H,Q$(54S.9JL)1[8.)_\18AT_^!U!+ P04 " #" M@ Q39 5[&A47 !#= $ %0 &-O9'@M,C R,3 V,S!?9&5F+GAM;.U=6W/; M.+)^WZKS'WB\55MS'A1;=IS$FYY<, E).*$(+TC:UO[Z M!4!2(D7B0IDD0$6IJ8PB 8WN_AIH7!J-/_[^.O.=9TA"A(,O.\-W>SL.#%SL MH6#R9>?[W6!T=W)QL>.$$0@\X., ?MD)\,[?__>__N+0/W_\]V#@G"/H>Y^= M4^P.+H(Q_MWY!F;PL_,5!I" ")/?G3^!'[-O\#GR(7%.\.S)AQ&D/R0-?W8. MWQT].H.!!MD_8>!A\OWV8D%V&D5/X>?=W9>7EW?7$'W98>VFS;X?5Y9T[A3,P0 %3FPMWLEJ,2E6]X='1T2[_-2M:*OGZ2/RLC8/=C)T%9?JK M%RTJY L?[B8_YHLB">DRR^M."1Q_ MV:$E7VD3^\.]#P=[K(&_%@I%\R=JQR%B9KCC[+ZE\6/@,VW=32&,0A43E87; M8N8&$!A$4TB+ +\69Y4U&V23]3@XHTV$U^/K)S9(4-M2*D]>JR7V3D X/??Q M2RWN2I5:8NXNPN[/*?8].HJ>_2M&T;P.E^+:G;%;RT37(-6@(-=T^'A&\&44 M>,<@1)2'&P)#VB0W0Q7O>K6;U'L\FP$RIYI"DP"-J5*":.2Z. XBZMEOL(]< M!-5&78M*@^R? T2X/[Z"((Q) KN*6VFE!IF[A<\PB*&*G95B#3)P!DA ]1_> M0'(WI7:OXD14OM%^3COD@'EVC\WN8!!J]0M%M089O*"3VAF\!Z]JJZ\HVJCU M^'0<\^AX%Y#!ZP3S'L[715HC!@:51L=Y1Y# M^*^8MG;VK#-"B,IW/O V.P!W/1#?@T=?S;M&U>8'93W6*@NW.$#K<26OU?Y@ MK<>E5N5N!B,]AK4)=#X*G,(((#_\!@A;S#PK_?C;J+8AWB@,Z7HQ[>#>*%KT M^>O@%KHQ(90O/N%-F=*6<%W";0B9CA;'\Z\03PAXFB)W1""H*Y(>F28%<*?0 MBWUX/3Z%8TBH'E,6=#G7K-\*RPQO19]0=U.KUN_ M%12NG]C8/J(SS6>ZQJZM=&GU=AB.([Y5335V"\.(()>"S5W6]P!Q!Y#.H]>7 MZ8TMM"+V#V8-S!FL*92\?BLLTV$<4R_V[U1YY1G%V2O[6+^GKTFX_?E5;7=? MCTP[B^6Z3&M4[6 Q79?KNG1:Z1'G<40G.U-#;P\ R@FDR7:W? ,6]I,(.S1W:"5XO=8M7V M>06^7X]#7J%]O@(JREM7IU";A&,1^M+919M6+/-.OZ4C(!O1+^L\"W_ U M@H$'O8QS1K#6>7.$(E8C#1D8.@,67Q"SH8M^3$NVRDWUF7*!JWW*RN+TC+-% M&Z$S((]]"K&//.;\G)22DY!R?OL>@-A#])?_Z5*$ZH.\@CP';Y7'^:W02MOR M*4ZN"[*]UY-M2=+!8V=)M$/4Y"?>!:$.UQ&*T70X44-"20[("])]6$>Z//&_ M@2<<_NXD;12$347-A/6Q6Y#09W$YF)2'W3 ;+\<@?.2#9AP.)@ \[;)YUB[T MHS#[AL^\!GO#-!+GK^G7#PMVJ5[A!?VXP-8'C]#GC3^DA:O*[MK .]_@U> [ M+;?*\]*X1B3C/O4ZFJX]<76?73J%I>9XYO/6J+N$$_8AXVQ,\$RIT%1Y6"I! M7L.4D1T'$VIA7W:&>TM>?$QM\\M.1.(*D8W =.*#,.MPHU>D8VGE*HV"5SD[ M5X%5Q$ E$C6"LS,HI-G]#2=[8M@J2K;*![EA8<*#*&>L9)S$2#[>WU&Y&%8 MP7Y3H&03[[>.=VNCQJ43 7=@&C@N&YW@JAY0YL-L.!ILM:*=H">EI>2MY15AU5%=-" MWV38.8T\CZL.^#< >1?!"7A"$?!5R$BK/50-%):AI!9 . H:1NR6G5H%R[ 3 M%535Y1^JA@'+,))P+AS+,8IS 79 M2+!8+6H_%)4<6SJQYG9S$88Q]$YC%F]Y PG"'H_"_ 9?^"_2I9!&=?L1TY9" M.+I9B6)BB>O#N%*_KSA6B2$"\KV50"9!T=%4-IM05NTK?"L2B) [M!*YU!FL M!5VN;E^Q6Q5!!-X'*\'CEL=_2V*D_'QAC+-CG>IS;RCG')+V!$'AIA'O& M7-6,AQ&J3<=>W-871X39D6',$EMK"KF$VH;AEQ-*N, WO)/5&P]? M"0[77&E*"-J+? -RV;IU+?('+AC M]WTI)NMN-BG)]M42:D@G- >;=Z>:MP=-NGTUB#KB"2W"\#;7-Q@E5P@OI:-^ MH9CU>)6Y%:H_MU?UQ^Z*(+29G^:"WS4N9GQL+1*^XQL;FOG:"L)_8G=_4,C" MJV,"Z3\R(@X(V&442H:)6R34[F6&>NG;"M(G6+M5CE>S017X'&XRN.B=*L\"7/"%9C;7V4NJ^;0>DY: ML>4+.?(,<05V#TI&RVOS>;)3K-XJTU49Y J,OE]E-*GAI%5:MD9%(KD"IX=E M\^35'5[?*1)H^=JE.K5<@?4/JZSG*/ Q>85&RV.Q(/5<@>6/Y5$WJ^9D]2QP M&5+7,2PY0GW70=U\^JEM#Z^3G:X@5+[F_M$Y7 M+"H2VA5X+;G!LJ?IBFV]#'<%[DM^4N1XNI)!/^E=08Z2 Y4.F9T!\K:\=P4) M2YZWSN"4-N$LVC!Z0_>&8"]V(_:6 9F!5-NJJ[K22D:W@A;):\HLJJ[QJJM: M<[-7 [35S1Y=Q9BY]1N2* ^YGDM-6,J_@6 M0F!(V<((\XSMK$#'-Y\JM8:K61/IM.$[38TKU]JH_%JQM%)_/*:.-,)^81ELC&-E#@99)3,WCG5TKT"K++E]MXZ;ALM* MC]X&I';?0H[#",\@*?&OO),LK_CPR5 >#8VNA6L+(D+ODWV>[Q@&[G0&B"+I MD[KF)OC 2F58=Y^LS'C&=NWAM533&I=8#84*P6I%], Y-@9AS]QD$S!;[3#O M@ _#]-#G&XQ4;K*RN#7.4=2_L*8,0K]H>&F1GC10IEV(GIG/4";R$-1X..H5 M5%(Q1&@=-8N6YO[(_V.23;U$&<#X+D2Y7']F)@(!1$ T&R>JA0-[K_MZ7&!2 MZ+%H>4GQ[C>]):K%.AS;M!?>% Y63A?>C%4[,P+!';K[%[Q@]!Y/(+M.+70? MK(:X0N>.7LO@L3;K0O]N>,54=G/\FLY)3$C. '6\?+[>P]!06K7Z!]@Z@HC M,SR!'OD^?F$7,,\Q-U M^@2C4@Q+3V4N A83B\F<\BM&*5^J1ZB4V;9T2W#!Z#E58DA7'5\Q]B3;N=7E M^XA,A0#=+)?6Q^@6O%R!"!($?!V(\L7[B%"9?Q% AI-$41GIVCZ:W_@LN#7P MV!6X)[9"^1Y"ZE4OT5@2 *E1N4?@:4LC@M)PRJA;&$+*SI2]-@R?H8\Y\^FK MHV(0I=5Z!)^&'"+@#&> *NUCWD#"O@ 3.*QQ*)*KU2/8U&((%]@FKRR_^<'X MPNV TFVWW.V I(7LKH_G@"A_!0@'SJ*=]+)O=EW Z"6!A1X2]FFGO$3@$?D\ M$T F2TY'M, W')""RDJF4^X$#3=CY<'CVC5=G8,57SD I,1JTZZS:EJNZH+CA7Q6IH5383 M<5,'$P&::HW8%W?3-IQ6'J=U ;G5,3B5%\T7PYDJU$.GMJ%7X.KT136D54+9 M/BP?SQ^25;\FH[9&G]7\$G:RC0NE.'2O,M"[+.B"XA8]Q5ZT"E MT<]5BNJ'WVX;[Y[X\I9MHA^._2)XBJ.0"S[4]N?E2A:Y<74G%8!:+97MXWB. MZ_UU -PW^]!A6PCFQ1).Q2S$\& =# _,/H/8%H9YL83=T'0 /)]E+KA?[K]+ M F]$54R%P'>Q^RD76H3NG@VG,^F%C./Y5X@G!#Q-D3LB$$C/8DKI^W)G,5DB ML\>YLZ3H,))VG+I0OL%D0N"$GZ8MY-PXZ>&26&N>1]DE"TGQ[B^[ MJ#6,=1CO:$.@4SBL7-@W!9EUF:-&,T@H>^+WMFFA8IFN5^%:/0!+F&UZR!)< M-+J%870]_H&I84GO%Y7*/;RW6*-BCD5J?;_-HF'6@6M+8^FNTS:!AK8XMAX( M;!-H;!-H5,);G7QB:&A/L=$,&D/9#N+0]!;B!F55;,87JA,JVI9':IM0L5Y^# #?Z@:)I MEBSC(G#]V&.'3F$(Z7_>/7@5 [L&L8=]0R??:^[8KRVBQAF;%8/SV^^M]0Q1 MM2P:VV3='X\N4G2=PC$D!'JIN-)ST?(;82D9=C":$5H^];0X#FWYC9Z%+.PL MVV67/Y$?1]!;?01**EOYZ;"<;)PP?X4H)5WY1E1'\@K$4KP^5'I$3")!_I6A MKK"[?N*]VZ6MHF@N@^J@]+A8'JJ$CI,1,F"%UW$41M16J'+9!B]!+C48_BK7 M=]H>"]!('S+4$K;T.EE!V&53SK*MY DPA[?&C39[.+%"*29W."H?DA]1RPLF M?+Y\/%\6N0%S]M7H!1"O-"17;(K-X:K)HTW]Y]5VT+2JL9NN'2ZEA1RGTD M%[^OSDJD(9:;*YI?!%3LF*ORFF7EO9^"(%D"AM]P\$R5 KUOL>+LM"L6.@]( M:GU:W*GF+-T#[4 )/R":3-F.P3,D8 *_4M+1*5W2+VYDN)7=;NV]+J;_< MH,[U$%X$-Y @[)DP^R('6]-^B^*$JYY?PWRM'-9KLKCM *UJUM(8JO:4]"?W M?B8'^"('6_M^B^)$YFLX)WE7.K!R@*_)XK8#M*I940\QG!2^/26=8S*&R/ 8 M7V)B:^5OU)W(C@UGQ&]=#3&!H97#?!W^MM;?GEI%'>.C%>%_/UBD%Y5=)Q1I M7Q:*E!(R&7AU"UT\"="_TR.0P>,J_NE+$%(A#V1"+EMP- MHYTFS4LVK)@,.&"ZD2\B%-4V=E&AI2[KXE!6F%7-[ 3%S4SS]32.=02P==[> M!#PVSYP;@]#JJ7"Z<:WRE(5B#Y_,N$9Y!\$*AD4(?#+LRT8^ITZG7)5CO_+Y M:KWZQA)+M+9A6D=N$?9&<_17G])HY3,X>%\ZI^'4CLL',E59#6S>[=D>R6R/ M9+9',D;M,%L\RA=3Q5(;NW:J4H9UVUVZN]]VG(%4JK1:Z[8O@M93O,W+GMK@ MM+.\$63#OW_!]U,O/;+?G_[:XT/[;DLWN?+/._P6S@MS)M/C%(5:R M7-#4V[%='/-))!9.!C;QW/[CYD*L+;\(\(]V 5X3Z(5%_VH(YP47[RTU.TO4 M>OCMEHDN?L4R]_/F3>&+\@F=GR%09$_Q%0IT_VQE66NXFK6.YK"-*]7*&:*^ MXJU[7O(*O*)9/)-IOU#$Q%N(58:+)>R)]/O>P"A^116CTF^^R,.A=?HML2?2 M[Z'IO91M+%L'L6R&4VYL8]FLWH/:QK)I0KAYL6Q'?8ME.Y(@<-3L:EYKKG#/ M I.NQQ>!AYZ1%Q'I^]TFDU"N$B@^\]IEWT(H@(HA[;;2O16XW6MX:Z MOM:$4]E^&VWNAY5EU7R*' )*X^O907VD1NS[OS_#H7 ?T([\$K#/5RZARNYM1)*#B<1&4>G7:?=N"GIY"? MB,[O*:XA#1TN3;9B1]Z@!F323B#47%O69!)JP_"$.86:QJHGR878I;?K<4X@>9B[ MH+@%(8.-XX=U!+?T=+DL/Z@6616<6YN0F9AX.3KX;2)U%%?8&Y"MC#-LWQ Z MC3<\>W7].*1#U26=U@Q^*9B\4_)'8@B2,8(^I[4'U:4[-H'-A.++Q"DZ1%3 MJ/!C0@U*7^O5Q1^ZWIMM2O<2<80(&'!:BUNE=W2.! C"XFF'H.AF3SND^K$B M,4S&V/<@?((NHL;FR7R2I'CW4PFY=K$.TS9-&IJ"PM:)P)OAZM3EWT!R186; M2OU.L5#GF02U;!M+V16N80W'6(]YXZHER:8ZD35934) M;##D=32@L?+J_@6CQ20ZN9B;YMRZA""$F3FGD075,0H?2Z\8I10=/'82FDY* MU.%4G8SL(F2A[2 ,=BL911GP)]1_(HITX"+=J))/JS+F*#H@8*\UY6B*PTQ2 M=-E?+#R6?O,?4$L#!!0 ( ,* #%/>\FL:[DD !B#! 5 8V]D>"TR M,#(Q,#8S,%]L86(N>&UL[7W[<^0X@!YT6'1S?'Y^??H*(,TBA( MLA3_Y9LT^^;?_^U__@]$_M^?_]?A(3J+<1)]CTZR\/ \761_0E^"%?X>?<(I MSH,RR_^$?@R2#?U+=A8G.$?'V6J=X!*3'ZH/?X]^_^UW=^CPT*#8'W$:9?D/ MU^=ML M!8=Q2JLMQ-\T6K04D=Z[[[[[[@W[M1'E))_N\J3YQH$245,B?!-_;=ECA=B,$F>OZ'Z;U)\'Y0XHA_ZCG[HW1_HA_ZI_O-% M<(>3;Q"5)/R0VO5=KZQ:Z8UKL%JCM"3[I.WFY@P%=?>$'^U8.(GTHR M@.&H 4F+4'A@]@4V,-1EMZ5G8:_LX$UQ>!\$:_*! M]^_>X*0LFK\F(Y+K)-'F*KENY:8UJK-<)50C1HU(;3PQ]NOODW)H:R!6*" MZ&H.YY(:T&JY9)>A"5V. M:53 ,,T,)\>WK19JU1KR59I0Z-=VI=/?-G'Y3.'%L*OA" MYR92 $,[$Y1#TE6B:"L+S<^M5EEJXMDX.;>^3 *S[[T&0F"((T/&>R@J!],E M'4513&?C07(5Q-%Y>ARL8S+)4+)&H^.204;PNVQ2*H!AE@G*(X:ET&&][$9IA4],0*"[*."3.XC,. MBDW. J)9@QJCYOXCIP*&@&U,#Y MM6JP/.!-D.#B&C_@=(._X%+I]R2R3I>?57![R\XB03"T4J'CI^!,K$L@".'Y MW[.\\;2BK0N9D+M 709P&ZT/);S30PE+.LY-XT_"+'IB+?WV#Q_>LG8^OCSY MVR^WCUD+YC:[Q^42YT(GH95VT?*&D"D%-*+>N6"&;T@*HH!:#=2H0(M[CL(P MVZ0E\8 ACA^"NP2K]QJDXDZW&32@>SL,$EGOK#($R.TKU.)H*P^-4V=!G+-C MM!^?.ZN79SG^;4,&SF=%.&VDZ9)I%J9T26>@!H9_YEBYY:K.TG0K#RNF;HWK M8*4];9/G<7JO='5FJE[(:&",D(T*/7ATU(,=\I&J5N?W#U"K =@YMO_\/S'. M274OGR_(!",Q\X]*94\NTL @B9=4:,)CI@E<.3=1JX."-$)?CGX$ZC+/T_6F M+)AA[\P\I4C#"Q7ET(7\X\7AD4Z*4>4%*Z4#Q-30.["^L&/<>VNJO8="M?=V M5'N_!U1[/Y)J[_>!:A^LJ?8!"M4^V%'MPQY0[<-(JGV L C;'EK^A+/[/%@O MZ=D=R5JL0M;5DJP6;K,R*Q7T3B43=$,2=<7\'Z8Z6N&<(!&?MQ0)N&*'&%A# MB?ZO('@@A,0MG-5"D[D+R3+]-2[*R\5/69Y$\M5Y@9"S17DIP'8MGI/PWLI* M6/PV75&BRP5BDM "D:T/LCOI8J#G,B@Q-J,;FFB5O//,%JE\A-F#,R]7!#I- M?J%8<.J+N"28"%R72]W?P=!& &K($"K"4H[,OEE\N\PV19!&9_&BQ#B]R-+[ M6YROSADMXP=,D2CWCVT*<+FE;&]8=Y?97-L[K49#'I+N_=MWOT=4[; D>JA5 M1(R-P-S2T6.01YH#Q@,9IYO/(GB]'>>N@'<.J5!Q(3*5F?)LL,0YL:N7EVLZ M,(IG/U(I9VY&#K'U);R(]\96X^*O&=$;L+4D-"] @W@R7ROKG ,_I'%97-_\ MH+FT?1 '[_JJ)"P3NQ;%"*IF.53GWGFFFA5T2O> V-=C\%>1ZDZL.W M QF7M!+"Z]*H)P"&-B)40YK4,A!6"J):$-E8,!D.;T 1 2&(@!C$&GJW62/6/<"=F5+%+( MNV22%G:735)A,(S2(>3F3>&X-M072/OG6 6(+GLC(T6JM50JS?W88R3 M_"8H2YPO:-)_.6V$8LZHH@#9TD,@ X,2O'),W+$'$C\PJ?D]_L><Y\]O(EP7(T'Y!^,-8PQY#]^.<'YT5Y1Y$)8#VP2_NV"&%!9E _>C M=P;($/'SC0>6(Z.6 '_PNZLF%L)JVKCW(XA&%B$2G*6O9! 5\M7,)[@( M\YBMM:KLZ(DY;W0!2*[M.S*P*, #DS.A(^O)L5_C^[BH#URWDPZ%&Y/(NW;] M2MC#L4 H#((T)@BEHT57";5:GGATE*:;(+G&ZRQ7T:&/%_-T%.YBG)LY84G*1K7DB@#JDQ$ /%#C$V*4%:<;\7-1SB)%VS1P)UR)N!&"C&B+%)N5*)(R;OGR2G:61$D5;.#T$& M,,7TJ(4 DJ./3$<-(NV3&&=Q$09)A>6,_&VX8ZZ1=4T0*=PA23A!4$21H9.2 MI5)H.,-4O!+F/W&0F]&E(^F'+!Q4,55:,8!$&6+3T83*>R')\2;/>ZCE(XY< MU-FFK 9LNS\KD0-!% TX_G$#)MXCBJ<1Z#0MX_+Y+$[PEXW@3(=8Q!4W9. : M3@Q_!\$%"2CN!"<30U0.58)>6K[9)4A+FD!%:LY0S"T#Q"#[+.C+ &*"$)B$ M#5M9EL_&"R..,PM3W M_DGSWI0T[T&3YOT8TMP^9D!(\\'"U _^2?/!E#0?0)/FPRC2D(;WZFN.R3\O M\]OL470X6RKIA3(\5"%AMF+PZ,)ATY&%*M!XAJKXI D+K"[SJSQ[B--0'C++ MQ+T01@):R)J!+#SJB 'J^-,&Q(V>5U]3!>7:3M*(^?$R?9!B%U/)P"-)'YC6 MN532/BEQE15ED/R_>*VWA[R!:7 )JV.I, M##$Y3ZOQ3R5."['[[OSF;&0?PFD'\N8'$*T[1,-G[JI_=]R:/^5Q2;Y\G*U6 MF[3>Y1&=&Y3(N6IE)ZA"Y& Y$6=CD@1<.R(-?@?!#0DH MZ;,@[]Z_NGN-&BW'S?\EN\V#B R)-\^KNRR19)\22KDB@0)BPP.!" @JR'$- MV? E0[4HJF1]9*?J@168,_C=%0&$L)JF[_T(HM%%B+C.WVMK3R[_]"E<@/@2@HJLCQ27U&JX*V M.JXS6K(49^?I(LM7[/MGY!\"*R5RSG):JF"V22U%0B XHD+&I;6LDLYUA!&5 M=LV+3127.*K G,5ID(9QD+3I$44KXGH59VPQ!-\21R,/@T-F(#DZ56I-+L-6 M<9OJTO52>G4 XR><)/^19H_I#0Z*+,51M98BVBE2R[L],:.!W3\T(Q$&02<3 MA)*C,U3I\%>JA1JU>B7,"Y-^S))-6@8YNTN>BSR31,XMVA;* .*,$*+O#7>?\V,;& ME9:G*Y8EIN]%Q _X)"B#&IO47IFXZTN5*M##VY0B64 44@*4WI]L=6BJF*#A ME+>4,?DQ";7N,\4I\8&4^\0Q'$0^=TPK H@>(ER*##(Y:F2]<.%F%23)QTT1 MI[B0#T0#*;=<$$+L/Y;+.SRJU M32+MEAM*R'V."$4!<46%3\*91@55.DU*73_D>=HF%*^R+,HM%8@ZIHT4[( S MG!PDPLC <6Q)<$C76[YD);K-T \%1N42(W:<-2)_[V2"K\KQ]=)(&-(+$554 MGD9!+J*02MCYJR-2P-S;(YPD"")IX[N/(Z!."_Q2GK; M0:_BBD&FX!L>Z>1!L,D0Y)!3U7/JOWF(UQ-R'!D+ X" MXXX$"(Y(8E2Q% M'A-$3-)+^W\,TE_SS;H,GZ_R+,28GK(J6F^E6W\SU';+&2N3^FPR4@7$,QN\ M$@9NBT"=,@XZ(Y;/Q3QZ:)QF<\O"7V^6 :G RTU9T!&4 ).O@BN5'&\O&!@P MV&10: "BG@%,V88#TT1,]0!5RJBC[6E^5FRS .+HX_,U7N"Y9Q"' S3 M]!B'_-IJH#A]P$7)(JJBU09"LWK+J;C&(28]@,#]@DLUS]0J3D=/ _"]050A M#X9J!B"Y"*Q607FK(L?R:&2(SNB[CDD A#:QIORP,.M8K;D48/OC_@R.6]^QL+D/SP4ZFP M23ENY"'%L=4,S>D2SR]%ACZ M&4,51BUY4T'/;D&QSQ_4%NLTS>,8?4L :1/'E9?/KZ%1[39XPF9CGU#2);D44+NL$HB!H9,<&[]<$&8K M3%?*,;0QKUG&O\8/.-UH6",3=NJ5E(!['DDH"88^2GC2W9:\D@;"'N-0R7>, M9!8<>8Z*M*M2QC%1?Q,&WCRM8\@7TGBV\W^1CB%+B,4K@/%()BCYY_;2 M^\,2YZLI628Y$E"'8_4IA0Y&T6ZV0MC9L0 MX/9@@%32.SF,X.GG9&FK L0% M"28#4D(9ZGB>G(GI9:3@G64V*.UG:>#()_2T-EX9P'AG/,Z!(9<*G3B"2N88 MW:;GD-Y>;WS1L 1L?*VF!3@RT%OK<75^@=YTR5AV*)R&0M)#[UT] MDHN#<31ZC/QK]*U&==NHJX->?0?,5)FVRP8*"CHM>^_;E*,/KP]0)0I M3.8$AY@F#4,?WK&_O@7"V4Y"$.4E34[,M2L4@1SZOZX,&)Y*@(D\79;*6?FN MXJ2,E^__>/#'/WYW\,?OWC*ZD?_\_>__>/#VPX>I^'J 2"EKS-*%)U .RQQ% M$4NJ$"1701R=I\?!.BZY-\>UTDYWI=60>WO28E$PS%;CXZ:CK32B]V0.XQ2% ME0(0,EWC,HA3')T&>4JS:9'Y\V:U83/F$[R@;ZI+ZL%$T>WY9%-#^N>3=5I@ MB&<,5; DT@@B7"L#81]_LE%BO$C0;?X?&=!^MI^A%*PIK12?>&:[3\=&A<=D M]3-[B1JD@\V:11.A#BS:&:+5+J_LQUGF_A3M*L@O.N GSH!)R)Z*M"%@H^";?'W@.N)5TJ!)UX-HY>QZ:R^ N2;/SVRL MY9MUD@S-ABJ@^:?/T6Q"PFRF7,V3K#U;QH9&FIY6J&VB0@,U,,PTQZI>VH86 M '(IT;71GU+#$^M,XCZ%.$26&4=\779!C? XNY3AG53:*[OD@9U$%"ZK-"&= M@%&@8CB+!S;,5+SR2A.Z@7Y:PP*D$MBP+!W//8ALZ]!W>\[SHKRD:D)^&2"P)H729T?H:U M4\H#&U*!2: U$P'"@\LUS@-Z0+FY$::)EA3R+CFBA=UEC%08C!_1(>0>^VWD M)\O=/-69()PD='1,H^HYA*U)LE,M"@6G9X2TP'MGA:328"BEA2&PDJ+ M\2WHZ0$AW34N,*E1^MS0"8GIP!&H3^L*:,,GO@T;08UZF_-J%9S M+\@L5V=P5](+:WBH0MYLQ8 RAP,H66&GU= P*$NA,.=+EF9]2^J>H%F&,-!S MR2IC,[H&&%>#J8DDD"[#&W"5:;#?8XW1#S+MNX]"->9#FN MY%A:YM,G$F%D>12G0?Y\7N(5R_A%M^8SML#=#!?*TR@S?=']":%9JXX_933+ MYV#ULOD-E4S([EBQ34]E&<5!]5)B:NUO/N(4R\\)2*7=]PXI9)[9G"B8.$2- M3YZ0GIXK>(@+..N(7W"I70\:R#@-&43P>F%"5P"6TQ)!&S*#R ";0M7I2YJ[ M-Q^#(@XUZSP:':>3(Q/XO9F02@&,NS%!.:16HX/(&(G"^E X5?X>,M5L*@ MM8PI!9M*$@JQWX"RY21.-J7TII-4VB=C!I!5G*E%P;*FCX_;0*U^!<*?]G0!(27"^X^38WZ)"[")"LV9#9!9PV:L6^JPEWR"694#L#](1WZH I^PF@.ZR JNF M*6/ 0PX4)/;4?=3T7JMU*0 (JS/1@+*R(O:$M!KXL..4]GKEY>(X*)9G2?:H MBS[4*F[3=^K!]Q-YRN7!C/\&(+D#^NT=V6R!J!)B6O!NS'[!)85W1=C< M/:A&T[VW1:C8#6>=^#VDQA'@ K],?!3]?5.=D2CH V*TA>($]XRYS:;Q+_-\ MRFUN_ODJJY_8?_KO@.DH,QK'/RG0?@J5&'!UG*[I=J;JN(A-V&DPJ ??"2*$D&-(JX?&A8Q;^>GA'I>E^32O> M7"0 PJ;M(3MZ&?5R41W)VQ[&D^TB&^@YO>QI:D;ONJ=.R0WSOJN8E^)[FBM1 M-4\V!(VS[$>?#_)L5P>#,<, M0/*KUO2J\5T);( EO23') HXP=7_[82P]5-8^F1YQ@4X/O]G:=C@2*"A-AA. M6D/F5ER6Y+]HEM 4!46!Z]=*.P^V0)EB\)8V?8],U7#\$-PELLL)9JI^>2HW M1LU07@]:@&B!6?#J&1.D$^1:$BP;KW),7P=47Y/1J_EEH=@(-0/[.O#9)\0[ M9%XM!.V&/6\-G6BEY'/R=\$U.GX))X"O9EM' 3[5>+#\N?U* LK#9[P-W,S* M@FA"7;^$4YBC)IY $3X!Y:"E4V%8^4F%P4.^Z5ET%3S;!G^R$KS'@&K3M*&@ M6!W:T1I[Z/+K3F3JLJY$(3.61;&U231#5&5NYTU-Z]A979AW'AL;;#:[494$ M>"YN 5\Z]:G9764)J[2A1:7FQS]V/C\"]6#/;@=ZP-TJM,,M.DO"MJ[7=1'H M[AF]JO>Q7UL?ZO'/Y&HW:X(C:\J" ##;P% #ABM* >.L1T/7'5F+FQ+@L9L, M0_7IEJ/PMTV<8V(]Z8OE\Q6QJ"2C$]V[93E193L@%@4XW6ZR-JRW^62L#6W" M9XV<6^8BH)8D5"GH6>)UK"0_DT>:HPHQ_'&Z3@S![NI=H6 \547$%WJ?#^2A. _5CE_QKRUE+7!5=' MF4/Y::4(Q=>. 2U:Y06>[\TX'-HYGH(:Z.X6X.[%%$Z.VW(*!SC(E9A^%J=! M&DXPA5,6!(#9!H8:,%Q1"IA@831TW11NT90 C]W= (D^!4QPXLM%YPU7@\!* MHN\ =/+77=!:>6YFR#4T-%[TP;@U;--EP70!F7546PA8#'NA H#K". MQ"\7K",UO8N^KBF=\BM5?*Q3J<"+5J9$\E#F1Q98.0)6*HQQBP7.Z8@;4GD@ M7#,/,':.4*"&CKN%C'LQ*9+C-IH4 0X6J;7T?^DJ\ ,))MB16Q()QR'IR_0' M,D;T_]"1O"+]D6; '^YIUP]?GSZ%[.3X-?$+IZ3S2J=1KD$X?:[:2P7WWL-V MB@!6?_9BNR1O M.FBWO,/]"XB?T#;S_X$GQ"6SW-XQ>?\FRSIH\PQD58I4S' MT39C^ASM9@UA;_S!R,J=S!M8?M^I+UBSWGI3!GDYFT<89[]P+4G4_U%0HCM\ M'Z3O1BQUF69DLUXG+/=9 MD#3ITL[319:OF*6Z5':FVDX3D=B9U,M,8J;J?:UJ'%XN=TE'&T5M'ERV0-JL MWY, K"T."&6;C>*K((Y(K"@].CR0\O&LX "BZ$G!6@0,I<2XI$\)TBM]8'C1 MN>J@I@8OZ.5)'0ZH\#6=5@H01R30-)=*P%"E\97T=2GRS^TF?AH)UJZV*<(U MP^'NQ;J>6DU1"<,@=)B*Z 2/ M3$LV+6MK+_,K,BWLF,[NTW[.'G!TFYF><)ZB0&?;FY,8WNYY[E2:]RXPF0G2 MF]EH10N@Z1B; ](':$T+ 7E.NLT.?:NX$SL4\I+&^U9VL[4OX9UA2ECRY-P_ M,S$HN;A;7!=Q6KT=HK.R(^B%'AQ0(45:*7@T&4)34(6*(B:KY,NLU9Z%ORZS M),)Y465P%%?[4,K+VIIV'5B!D\O0UB[)W@4)/;!P@!Z"!$S^ ]/'1#P_%V+T M((C?)S],J6/XL(> -]7K2E"(TQS"P=')AIZLJ38\?Z3<_H(?V2_R,TBO[EG]\=_.[W_WKPW?OWL,E: M]<61;.64 =!58I !7P>:T DKACL%8_?(S5Z62YR/Z.BU'@"^\F:8NE:F!)VE M'%)N@[1S\A[%3!\MLKPY$]V>F0;.QCJFL:=C3Q$ 'P6&&/O.O6 D#W4T)??( M4;+?ZFL+S3T&V;/+(\H!0%R]F::.55@(=%IKD9NRO+J8LE]^=P)V*PL"0&\# M0XW]]%X27 ]]+,.G"?K3K MB=JY(CB=6YZ*K%6WG*1VFJ+@$K=O['CZ5N7L*8E[X*>@\CZ%T<*G MX#[EG?=*;<(U56D 8@Y3DXT#:WE1T/(G[V;&GCX*J(Z\IJ*^07$ N&]LM'G4 M#83]XV/OR7F_1Y[_.$N)VZ!/D]&!DOZ[C$V2(>Y8)H">8&>^Z5B@+1!ZG["R M@@^3&KTJ*VCS,D05-]%GB5D-50@1?[]OA.;?U;G0Q58%R6/VG M['R4Q;DY> ?0 -X,EH/4U3^P<+4^W5KG@^I12G=1UTS7R[%D$W.$)Y55BH"& M3'.T\O/,9&#L:O\+JO31STT)ODXY3YI_S:WO4+6:$4S-X2M0B=?JQX]HR)81 MD/IK:*,:C0,^[U#?GW<%'&*B^($%V$>-WL) M'X,B)GWHBM0AO?)(_WJ+G\J/B3RM[IB"7/)QO*%=GMJ7 H:_HZ$/>7U)9BT/ M,7YDNT1,GPYSW1* AE95 O]C+2!,-5*[C\ M7>W5*LB?6>RU+0<)W#$0GIX%<9J)('PS\#D$/6 M417$=%!'"=Z +S)-YPLU.K[IIO1\2@70A-/YN0[C/N. JJP 9=>\KA[/I@G9 MC[.4=8&?XG)YO"G*;(5SC7\SUG;)/4N3NBPT5 7#1SN\0V;6VE4V_48?/9(" M4%,"/,>H,5GG(\W5 5%6Z3E-=:'MF%CBEI 7""M/@YQ>K:9)FMERN,9ORL5= MLDX'NLLRF2P85Z@!R&U%U.*(R".F ,_5#4W2^3:%O$]:*;V75!@LL72.B6<6 M$#IM8U9V.+D]/G:-$_I4"EM\9WC9";-FB5[CR78MU"4QIZF +GMW*Q$,Q2E;]OLXA!,W==FM!?#BS [_X^+R5J@SR2.>D)_^* MKQXT817)NM0$GP#9QZ:S2WQ$F*FA;ME NEB;V=8XYZM2PTM68;-,K0IQ,)34 M8Y0D'"8JG=53>)Y<8)C.+:M5/!--Z3!5\I"IIG-E6ZZ!V0&JXR&:L_7YMI,N M6+M*JE-SN]9D9D1_C4FM X9GAD#YQ22FAI@>ZBK"*HDH?G%H<6:4]ORN5]LDI] M1E,F#)97^I.8 V(!85/]JN3P'61Z*O19.[::Z;I^$,K8G.&K3UI%,.RS02M] MWY/]HZ,.A)&?@_Q77 :]:]>599+*4"FXY)X>>)=PD<5DH= M_P?%Z[5/UYD%=W)QMQMU:M#]33JQ++1#N1JRFQ96)#0N!-#U&7-Z&I8 C:MVL(?$/6DRPL&Z4G.- M"TRJE:XEG1!@2<9<^6F5ZE0Y!S'2=,M/8U/ZI-2J 6*B*5;>;U::;,CNZ *A MH?BL;IO._9PT?EK&#Y@&+.JI\:B2G+^).LY4+FF=73%@:#P>NRI9,^23V*8S M;IFXEZ.Q1C-NL2R\&;<2YQZ:A2(2K*QN)N5IXDHH7!N>"G3S(MIM7Q>DS7P:1H5 M,!PTPRE*CER[MUPG MZ[8K PQS1P+GYS0A'N0RZY4%A,]M.J.CHL!E4:21P1:Z^JJ FE56$@A)U,EQE*6I+KI). J'Z3;C$ MT2;!EXO.FMGI4XGS-$C:Z.:H+//X;E/BZ#8[RW),(J!CVH/S&!6#^3X'IEO.;Z.B!S<;%7?/:%L&HH4 Z:O" M5&;4[1RET44@]NC0_P\].QQMFE[&7; MU\'0MO3JT27$RF>#5Y/+ &YOY-Z8^I*5N'[3O;C,K^/[I<&UQ_'E>>IAX\R6 M]"6[PB#VFE$6J/I'K0N8^.*4=5..-OLPJ$PW=NSY$#%Z)*B/Q_ZC\?Z"(S*H M/C8&I!-G^!">!V8>)S4-(+A&8]8%1)+NF_@ZE=[H\H!@SQ MQV-7L?YL4](\-I_C-%YM5HB5VF3%A;=%T9.)@.*?'*+B'Q3.,*B&F!85F_%7M3WE6%,>;/">.65(;.B4/S[=J#! \ MX2K1 $,Y(YC2J_0YM*OT1TF2/=(GCL^R_"3;W)6+3<*;J.&=71E.:3C&O!XK M;0J 0](1J+G;5[4>"FI%((QMKW:?D9BU(+'#IRR+9(.O3-C+=7PA8.%E_)XD M&%8IX4EOX*-%+8WNJ3@T%ET'CV3RA/,X2+0DZLMZX9 (KI!"74%X#!*@DQ,H M#Q[1JI$&PA]I.H ?"DR+CC(VFO-8J:BZEPB_OH=T^,X.KO+(;;?502%^* N(Z MN(M05SBG?PCN\3OY432%BM>+:0+PRIMI'7DP[L$ I/)N&LKIU;1UJP2$:(,S M]IUCBS$6G;@G E^R-.\?P%>LKTY8OL=[%[M7B^)"QOC"P72.J2V2/T-^T+FB M01UXMQA@R\!35(INX7CB;^Q;%U,N3D_Z@1?5U70+X-WN5E^9HGVM\Z'M%:K> MI2FN1[+/@5P\9V:UE;E]'4&V6B:7=[I6J8/=6Y>4"8,ALPZAD)@/U66]!0J8 M-A!"$>S!_7V.[ZND*\W=*%5LI%9Q_#2J%OS@G5.I/!AR&8#DUK-[*MW[9K!" M"XEINFA!KP: =,HQ7:<#G7RZD5=!0'ACJ":!WWD:)AMZ:)IZ>?(_T6WP)%W) M&5$2H"2-*E,M,C6*BH&WZ#;6!$G.44^+HY,N4H%;&C5"RYU[:66HX\E!W3T5 M<:T]V2BO!)6.[ZO2''S=I>A6P2G;UCB/L^BF#/)2PS@M8&GRUIIK!^@.W\& M7I9%.]]>$XC9>,C^@:(!W1N.TS0TY1)WR$_<+_U#U?5V[0)A%CTQ7K_]PX>W MC-7'ER=_H[D; QJRT;1!7OM#:&,-=?R/IVP MABI(N16-5!3]/QKD4:C/%C(ZYNH!H, MC#,VUQ=<5FD.:9)#4?/T!'[YG=/F* F-E6&Q&)PHEV-CR$SN^"=,[UWBZ(A$]R0"_[)9W>'\D;XXN MS668O*/)74EXRHE$I&6O7I 4U?F?<)/_ MB291+J;(_R09=9M$4\PY-_FL1$Y=(NAL%%4";4=+H91W\FBA#=E1)02S(\&, M/7Z8[ZQFNZAG2T3A+1#K@ K]\RP]"9=RJT]MU H(J8) TQ@S?\?\"U035I'^? M:H>/0-Q+FLM(;J&'_;A-I%AT4[T=H(_->OS+ZX>#./[T">=A7."K/ YEI]6< M?7U/^ZQ)E<[4DU6??N']V\!TZ=I:K8,:)<2T]L 'W.FK[DY2=5^R] $7Q/I! MQ7VB:RLG08G;P[BJMG,$P+DG<%JQG#-P\G6P_L"E]5J7T'D5!KX[V,&3LAHJ MSM,KUE SN>OA1_9I@!=7T)3C>/\+8&;&LYAE&8"S,G;?<775UPJK*IDC!)\2 M :A>.GW56G7AZ3Z_/_U[8PPK&W8WV M%X2C-\?T%EB2[$^'U,4J@CKR$8U;PP#5E6>JY$FC<4L,^^,$YC'< M-AH'[B*FV.?OUR> PRPC .U3_+Y[Q<]RV,4:#2Q7XK,*; )_2X) U;H45_=WS/.5[&"#]9IO70"D062W-;'* M(,]KOE8@]BK&'%7!$Z_W6B" -2BX-MM^K7ON+"@W1G2OJWJ!X>PV ML<=*;N\J>\ )S>0YQJP6_8UZ/" 5R\]7:L#F(AJ/B.%Z1T.&6]1]UNH\S%T M]XRZJ[)"BMK6^M&7FO0DW:,U8GGWOL:K(*9WMYJ$C)L@N<7YZOU,33@* MR3ZM"N]0U5,ZBA$P8$WYO=@N\Q:'3<;!M@#4*0'19U#1JV<-0K)/<_D=JGK*N?P(&"]F+C_>]@GF\I"]2+C$T2;!EXOQ M!R14S_!.6+[3'C]UM?3Z\52%P^F=$UO$;7G6Y=/)NBRDX5Q&3S*XOP+U[/)DIDQ\I@/B"\NC:.OUM$Y?/YVE1YAOF32[+ M)1S2.3,[#H]^ M2..R?YP(O9ALGN:UYSSQV*307I@3<9NB;$)<7ZGKF>QR%=-$5+6WD/=U^J9Y M-W:[=]3%(5\Y5U>W@AB36^ ME^@X@(4DEN"^@I!D7(V,#4F^$M?49M_Q%I0($+P,]R*M6C<.A/O\5^ B9#;; M1R; T]S-67LT@2"\&,4.W(OR(%8-XM2Y&"'[>OR.376,C4L I\GX*<[8W-]'2WZH;L3J;;)@3C+BLZ^KK;N[!. MJ[1_ =;)IR%U8S^F6]]Z=]*5[_0U<">O =OE&8??A7^5?40U[GYSW>*C,+NL M&Z.M;J:_F$.L\O"D/ACC+AYJ/[CG\Q@;' MTCNW6P^E//"V>X \,0(X0?(L56L>*$_Z>>_]UY_-UE&RYQZ]8Q581,R.4<#I MV;-5\933X'T[N>W7;JOP^H4QYD"RIPYD"[\T7O7=FI MF;8!]PSGEV8,OG=[G-0_2#PWI^]FCWVX07(R^NZ>G"V MPCX&")RN/F=%3[G.;H]B3[K\C*:/>69A_V[S[,-9YI=TS6&,W3.\H$Q@'%8X M4 4$=9! ?%?Y*SKS"XCNODP?,O[G<%.4V>I[=U .WROS@(-;'@1_+!8DJUT9 M+?3@RRR)<(Y^_HRI?]TY[?Q\Y]5'/"0[?&O)+Q3XJ_O35/:4/7H,#D"3!F_& M[_3>TG]"?SOY*&&EXT@\$I\^T7_*THN8*KM<=KB^XZH MS!F>ME=^=_^[M;VQPR[>"J$'*D7[>E852F)+/,E>*I!NW9G:.>G+BN_M4P?6 M5MN4O5;ZL1?357466O3/;%O4ONU]\I4QPT:G["._?'B);!K8)@_E:OI \NJB MTVPB >=^D]N1Y'^%Q275Z:EZUQDW9Z;65!:4YS#O_HXWM1YP?I<5V/Y<@GP? M2K*B-]->U#4.L_LT_H=L$5*TFJ_7<;:[8PJ_W8;1*7COM38HA]S9JE43BM7ZBZX!Q?^Y8;^X:]\H=:N ZPFK4RPRC= M8:<\7:V3[!GC&YP_D A ['I:VUF%%&Q!H?O[<5:47[+R/W&Y]4:29ICQ>RX[ MYNS5UNV:LWT,3.>^:=87.FZ MZ#ZU6!\^RO/X3E1L>&/(%XD7T964% M.^G@0@0OO]>KS![E"E"^+0A5AQJ!> 0DKJALKX*3ZN^D'NH: MEL;*EH4X#8%'&=B+;*U* -,[1L&6K_35$6C,%-E.;5&K>EKU.4])#\.WP5-] MYNDC3O$B%F[E2T3AK?OH@/(+^E0>E<%3=_ZQO&2+H&=IR=X@?,<1T3HJ"AP6="MZ&J5+$FR M1\41W@8^X"[:3*(\R&3VU#R\RWY5Q&$;&"^I<I%'OO]F;@:@D/1_UE7YFY>]\QW*R&RH[U]=% MG.+S$J]D@>2TGW![KV7ZRNE?>9FN?#!]<0:CYNB%]!N(?01*5SP*PWR#H^OL M.4C*&!?'&Q(K2"_#2*6=7EE40^[=412+@J&M&A]W5:N21GDC#H1#]:8]S?O9 M6B(Q6"SJDCTJL%WJB.3 \$8!;DB:)O$-77B&1IR3#;[-KG%"K^5>!7FG!]1N M6^F,C+5=TLO2I"[C#%7!D- .[Y"71!N5&4%)O-D7"_/IO<7 M."CP11S!I*9V*= E>77BXL@E=W( MZ0HX73_G@/66S-M?P7""@\0MC!,!>M26_!'*\?#N"JU\"9.3\K42+EF2'(B M8808EV3INZC6OLF_@'"#N:K3IW5<'?^D*9-EUW_$HFY''#G8_AC#RX'ABP*< M>!S!K2R*X!PJ9-B.THAR/DC4R68ELLZI(X/+<6 MK:_Y4HCW_M22L%I#!U-V7*'I#BAM-;PT2!,.W&9'X6^;.,?G*9DNX*(\3_^: MQ6GY(_EQ^!B\E2*LYK)$+0V>R@P%50$HKDM YRGZ.RT#/=2%^&G0/ LQCHHS M\J+EHDX;01QV\P EWZ"&BL :U XUUZ"U.J(UN,T_U4EE1\^Q/=:%>&E0 MZE*"8GF9T^,$]7^^X*1>M:,&T_Z_KHM&:ELUX@IO2O1"ER6E. M5X7:-.AD,EAUAFU?:%.R:S+NU2SIY3H&?$9$2H[[7U5KV:385- 5["(M*3;Y?9IB#C M\UF\*#%.+[+TGNZ:$N $9/R Z:1 [N#,M6&UZ1CH_ F:=[]'5.V0[AVC5A%1 M3:]=DP5T]?1>TG:\"*P&DN(3)F)&M:3G,6CJ),>@6L00[8ADQWYUJ4[RFZ D(]LBQM*@6B #JTGD +D]P/Q;U)'U6O579 )& M[TA(:KW_,ZP*%V+C-A3(;)%)>2;X1[JC:,)RL2"LFM>@%/&=*8!A_63IWK6O MR]<+F\/,,_Y0P&*2SRK@PGM)S(B"3MJ,N^=>;%G/L%% ,;']IO(9Q6E1YIMJ MYIUMTVQT'LMCJ](1>JQ!H^;9\7NV;$T/,/WD]KXP?.6] MHZV 8=]H"D!U"8AJ(J:*6EU_1!WUSFV6\D^C#2JJ,8U[W,OQIP'2TJ7=4C8V M?I.]3X:"$CTNXW!9N5%,YI\A<;O-N2#BB(>/A?>>)$8;>MF=B:59>EAO)]+# M!#!Y7>AKF?7S]J77:;D]Z>?WC-]SV"Z,1D2/#72BD:(-1PX%XT&W%/? MSCN!%8*7UP7&F#_[,-#Z>/.!8*_FG]OJUTYZIIMP6GP4(,W=6#R&V<;$ALOA MW>9)RC#2E-%.(0#DMP_[9V9[%?=$>Q'-3_*LZC"N-%C3FF\]<0P:@/W"4AX>+;; M' ,!9]>#U*=Z 1_H-3G+:W.*=X?&I7S,SH(0/5/]D-L;7O59(5Q6NV M(4^W;:I8E?X?A(-P69^Y&E[[)<(;TC&[0SJ*V&O8K) YPN,_:) MDN6N9:63DEDQ?HC=YKQD3W6JGK;J"CA^D+V'NR:F&A>7&XI)':!:SFLERVL7 M7+5JZA/]?((7P28IT075=CWVM@GSZIS1ZK?9>"E U:T QR6,W(KZYG,'BJ;& M85:U21U[JEH6U"ZS),)Y<G [!1JJ(J>PH*P2MQ3(WW*R2I;ML4^4T^3E$-BRNWC'"O,59 9Q2AE[ MF=X$";Y<5!'O.3M$Q8YP"T-/G1*@%C7'RH6I1+/ISEF*J#IMP7H^URG!W\A1 MY63#U?\]3X_"D.Y@%->6D M$_B9M9= $72[J? :ME_[(DPW4@73DO7[*!W[KH)GJR%/K ZZ5?6HC?OFMDE1 M78:O=0E<'@?%\BK/'N((1Q^??RBHA>WBR5%8Q@_271ES;4 -.P(TMY2!2T3+ M0$TA=-__%2V'-.]KM%UZVI;EJ7VYEW2,WB"QUP;4OB- JQX0J@M!32D'++MN M>=!N4;"B7N:C4!^\-^HXO++VU!4 RPE7D]RQ3EB@#:B3C@!MZ83;HOP[88FQ M9W$:I.'8]A5HPV]?%6C+]FV+\M^^%"7]7SH:/ 0)9JLCS5%Q^@-[@;/[AXYD M=3&,CS;#9!.Q'<9P2>^S7 ;X.TZD.YTN% #%' MCDUXQ9*T3D?6YPE&^LP;CD[818[*3;(;T^)KVNR4D[!IQA4%:,C;U0)Q,Z.J MQ(,J>^L!ZMZOK:=/J'/7]Z#92-\F=//$C6O\@(EK:(X:T+NY/\7ELGD7Z18_ ME1\34F,B,ICJ FI]:\C\)496P/:,!"VB2G_7%()^IL4@5HZO@_CM$[%761*' MS\IFE,D":C8M1'[IN%8@,2%303_7_Q="V]0KX$9M(Y8%U38:B)+#1D0#8.-H M'$0;:M%K-^1_(F+%"-9MUN7 F ^N=(X-8M2^>B5>_=EN9SXC@FG=3X MYP@C:2LP/X%1IH#/^J7SWRSW;OIG.QU7D.K+DW,$4UP'P$4E\YGVYP10N>K!_5ME_TGH.L@U_#3+Y.L M1A8[H_!_AP"@G@;]6L. GO$63Q_VV(Q.O6ZLMP^6'NY?;"V]=F=2=M^!AWF=3Y^7<(SKJ^K:WA= MR[#O-=P8P@ CBK@SG+RX7O4C,[]Y$L%MS^E_^R4$\V--]M<#*D#L0C&#M&\$ M;]\SX*M^NU0_0UAD\=V7X/;'F#L#J0F,PPJ'@-^#W1DO8=!7]-ZY_X24OBP6 M$ML)A+U:;0'_S"X9R;^]I\O\W#PA$B"X^C7 M-Z??OWLS0)$?!SB:_OKFR_W)\/[\^OK-($F]*/#".$*_OHGB-__Y?__U7P;T M/W_[/R+X(48KH'_(/_S+X\?N/CX.3$X-F?T-1$),O=]>K9F=INDA^>?OV^?GY M^RA^\IYC\BWYWH_G9@W>IUZ:):O6WKV\*_Z35_];B*-OO[#_>_02-*!P1E+58*Z)ZIQ\_ M?GS+_UH6;91\>21A^8T/;TMQ5BW3OV)%^8HD"?XEX>+=Q+Z7<(DCA$=V@R8/^D[*V^RFS-FT9QDF*?L_:6 ME7A['E.CI.+RNC.")K^^H25?Z"?>G[[[Z<,[]H%_VRB4+A?4.!/,;.O-X.TV M'S_S0H;6_0RA--$)(2S?QOZW61P&=&B\_"/#Z=)&2GGMG8EK M9:(MFNI0D1$=/IXP>AY&P9F78"K#F*"$?I*;H4YVL]I=XI[-YQY94J3P-,(3 M"DJ4#GT_SJ*43M?C.,0^1GJCMFJE0_&O/$SX)/L9>4E&)XFL?*?]G';($S:S!VS)AJ+$J%]HJG4H MX#5=J<[1@_>BMWI!T4ZM)Z3C6$#'JW3Y0#RJL6\T_>GJ=2@BI6*.4]Y]Z(!U M'O/>3I?Z!B.&0=5.1[G'!/V1T:]=/IF,$++R.Q]XNQV =ST0/WB/H5YV@ZK= M#\IFH@D+]SA FTFEKM7_8&TFI5'EW0Q&9@(;-[#S4> "I1X.DUN/L,W,DW8> MWZ[5/M0;)@G=+Q8=/!BFJSX_BNZ0GQ%"Y>(+WD(H8PW;-MR'DL5H<;;\A.(I M\18S[ \)\FQ5,FNF2P7\&0JR$(TF%VB"",6Q$,%4V!EU9O1^!LY2?/U/$[E"2 M$NQ3LOF4]27"? (HUM'M==KR"[VH_959 YL,6BJEKM^+R'08C^DL]FTN^;K7N \9-[6:A;DM'BZ94BBPJ9ZTW]!<;5=!+BJ( !65#3!>K M&Z<4IZQ&<1-X.CAAUX89$Y[^F).A8EWB[X_<")/\/ABNH)B>5 QGK8@AGJ<0@ JU@4+T B4^P8OJX;,$ MV(V2AOB^!\57H-N.82[[SAV:8B8O$V5UG:<>%R15#('_ #E2*+4%8F 819D7 MWJ%%3#3 ;Y8TQ/L'2+Q%N@'!_+\974DB$BY-D&X4-@3[1TBP)1H"XHX184-X4<9,^I51,4]G\@CQB#7BEL"CG(-E2C MXHX!/\\(V1!&.:K(2YM"#K(!U2FY8\POHQ2G2Q;/<9O-']<'IYM8-TN98@RR MZ90I!8)M>=(0I2Q.185OO:0IQB![395R(#B?4WV(%UY' 7KY'[14 =TH:HHT MR!Y3J1X(U&."F=O,/?;U@T:SK"G8(#M+M8(@:#]X+]6X^)PY]I'E>1PHAW1-15,Z0/:;%JJ#D#(, @I74OSC M!D?H5$6%L+CQ'1$< 0HU'8']O1WL[\UA!]F':M5T!/8/=K!_,(<=9"^J51,2 M]G/ZXX@\Q,^2&VAI85/(0?:B&A4A >J-&J;0 VY1UUG2%&_ [:I8.4BN'_PPO=2E)U6A.KN&E#%,D";"##:EV-'"42L#\P+.H.*.1W(I) MBIK""[+]4ZJW8ZCO>=@H<[#_3%>(!*^SIVSB+"IG"C+(9D^NV(X1'A/$F$9T MV%'&0O9Y>45CDKY,D0\06?T$M4Q9 MGVF2N]ZG&%A MVW3Q<_K^\8%%S$A&F48I4ZQ!MGPRI7:,[6W\0#P6D7J_G#_&H3P\1%C0%&&0 M#9Y"M1V#O"&'&-Y:$5-@079V0G6 QH3+%W_F15,D]UX0ES0%&&2GIU(.;.R= M&HV]4\NQ%V3')U,*"-O<-YSVJ-%CB*<;:E MZ"5S+L<5_4$,NZ2H*> P(9(J]78-=19@EM6"BW2%(R_RZ99JG913@KJVEBD! M,#&4ADJ#'.]_16'X/U'\'-TC+XDC%.1+?=4)O[2**0N =X@:=4$H^"T.,XH2 MX8Z@1-(')$5-(0>\.Y2H!^-[F3LUK^:>/!>["G%9#5/@ 2\1UEB,F, MG]"%EWJ%A"K\935,\0>\4%0K"^8_3\[IQ#.-U7?FM8*F: .ZP@I5 P'Y?NZ% MX5F6X @ERK&E5M 49$"?5Z%J("!?SA&9TD'M$XF?TUD1VZD"6U+!%'1 SU:E MJC#@OZSCR//X-R7R@M+&V0D 89) JZ!D'>B% M@K/E'D8_]$V]*#*H;LH/:$8A8Q@$-/WM;4.O&_J+?M.=BI^M MVTA[^GYP,E@=B_.\I_0C48("]E,2ASA@R@Z*E@9Y4X/OOD1>?L+^']OG2)UX MR2-G+4M.IIZWR(T1A6E2_H9;YKEH+*Q6@&[V:V19IND_V%."3U[(QNAA>NX1LJ23)G]V1$Z/876P3+%&3,1M5'** MQ<\>^892]IY/X:6 42)?DA>UE)7 4LRV8,Q >T=X*@Z(Z&;!1]2RJ,2W*-42 MI:X%EIRV!5,F^CM"U77$\BW&9$DEE%.S60HL=6T+*D3Z.0+]F*"%AX/BI1)M M]Y 4!\MJVX(,I<;;LB)X86)T\???RV>M'KP7+JH<9U9<6AHLBZT-S$H-G++] M#74,E\6 N6S;S $B#2OH4]ESHFYRK:42DHH" MMG1\\#)A^VHV^27Y$SO_'>,H_8W^E!$D MY+5-Z!!RABK^Z:CK<"0O#Y4UN2XY"9T=8J3V>KN\\DO)P M>95;=QREYH[08S,!;3/S]'9&84V+T92S]WNQVSCR6ZS71=7@,CAW0+$P+F&!7S""<4^4I6E97@ M,EEWP[(!(H[TP'%I<5Q'C3>?L#!I)( M=T>H&08!O]WQPK&'@^OHW%O@5)@DMCS8E%6 R\O=#5$:)!SAZPZE'H[H+L0C M$8O*HIN2;)[Q5>T%FK",N*HK?GU=N"S@W;!HCH\CA#8UE!,H*@N7:+P;PN3Z M[_VR4H=,>Y9#W,TEE,\)_KWJ^C MLUD/.J*O,QYED#C,'\\E:,7M] M9WOHY(S'?BHTJ@P=![@%E1;@N$>G^12HK 0=.]@-?8Y/?@U)=3.?M )T=&&7 M=#DYYUFF,)+IUF:VZ^VLO$O2S*8ZD&W].D/\:#):(%)[X6UC2_^#V99^W>0@ MG@S6C;J21(HXO45CP)MY#8V-P_36<#DSR"9T+"KT4(VJ&\6@M^IV+ EU M= 3_3R1.DC&))ZI[J8U"T-MM.^P%^NW]M44Q^433TM-1/]@KJD!OP.WXU.KN M2+^Z1V'(!MXHR',#K256G*@KZD#OK?6XQ\:Z.$74)Q11S4(JZ#"8XP@SK=B[ M$UJVM!6A]].VE!DBX0AO=Q1,*@1+E'9!9]8PYBD?M*QIJD%OJFTY,T+!$<8N M$$63;C@9EO3G$'%0J;7-6=KB/V5/]A75S6I#[Z]M^;/!Q!$:&RI:K#K@\P39 M$B35]G!6D?D"["86OKA3AZ%:&#H[4,N58U/?O>?R-H[B3?4*<]7O# RJ@F<5 MLB/:& Q'!E3^V!E*TEQ6_H:(ZM1.4!@\[Y YY/44D%+5'2$G=WC[C-)9'*RS M5;$,5NQRZ9.'(S:0C*(+G"SB1.67;=\2>+:AMK2V!4+A8Q2AB./+-G+3CSTD9V] MQ_S HQS1=/ XG.VJ-0'"DKPEE MM23*@41.9I ;T.0X/1P[IFM:,9ARV; LTYU MS&4[0Y$-\'9++?J1QSA!#BRV)'H7&%HXV%HW!)X8"\*>=+AV;%'@7K[LL;2K M,'Z6./G^V,;)E[4YX(VZXN1;<=]>*6P5J2NH!;QY9A*-2?R$ _88ZQ=*R76T MNJH;^BE^RN/0]1=9+=IR)W)72F=S)]X2,4?6%/V>E_1VAMX>=KN3%-A40__, MBM=86"9&/XY\S-_'6TO\$'?67_OY&K1W&TB<9CMB;0PYA_;TBVB>->^]+ M5IZMH. \GK-#?@WGLO+0WM$[9%D-F2.\KJ_X[[T0C2:Y0T#EM2\YQ095H1VK M=\BV,9#V^[F/^28J0E.V]7'@A*!\KL#ZPE-;$=JK>Z>3@!&(CHP37-^$LG 5 MDXLX>TPG65B^GB3G6UT+V@5\AV2;P.<(TU1Y@NBL=8'R?U;4+?)X&D4L&[^0RNPA]99FVB^SFYC#:+:#OBHVY*C8U<.T@$L IKJ;KY,;F,/]9HN^+%W M;0QB= [2$-BJ-Z*?4R;]UU0#]Y3OP00$N!PD_XVEK9T="*N#N]CW8 \*G [2 M+HIGGRKJ%N\16JX=9(V ._#WLX908W8 '@?RE5.A*SL;;;P"VV;!J6[/!9_\ MOM:@)D@ZLMLPOYGIXH[9 6_[+N\L+9';>]=PB/8Z3M/L*$XF[1H SQ28 O&XM9: M'\Q*E.KH(Q3PT#5V.\-S':49P>ER-,FS'K&Y\1[Y['?*>:5%4^!1#-T93UL< M>WI MV',ZRCU_XYQE/Y&_Y@1(9VLOGEU\"B'[2FT4_A@NKXY<%TL"QP(ANBL ML]LC=ZAKR2+_7[ER^(^#A!+&Y8K%%&$VY4I:6QS,RJ9;FREBFCO9WK==<)#= YW%6; *\N)F!S M ]GU":"]@=@CM_>K-J8O^Q\[N7BBNU+N<$%!PCXU9O8'.MAM_J)26IMW O>G:B6)#V:. "!O[\W M-_+>SH8=-W*&42=F?AFYL*Z]SQ:+D,/MA27SA@*Z^55XIM8+&$8^]<60)N#@E<$UQ9VBI.$QIF6F6-26G MO[/8+\(/Z5*+"3M>+&Q;=]X"MYZ>^[*UI5 UN6YWQV@L?5%1<)$1JE_NJ?6;%V;H%CWSORB7\4;5 MG9GWC+JM*1PNC:E-F7/+;<]AH[XSDV)+$B6 N,TBMSS-<\4&5:&SN7;2 5U\ MNEAI:^UXVZ@+G56UFTZW1\QQ2^-_*^)MR@ F9;XG0@C%:]BDHNQ#H,KY9&%#[9H!SJAJ9ZTEHJY15AN M6UW15K8&GH&T)_8VT7)[>,VG!^$K"I^(\DVBU@V"9QWM9DK58W8 60/5.%*\8V0C)]["\D8?+?Q^6.( M1J\: J9FVD&@G775SXA[K9_H5UU'71& M_Z5L9$#'N0%OAG74C88@G>WR1/=L\4J'%-_L96-%'=I8E=-9)D@N4^ 27 M9WD"YAZH,9R%RB2%;=H"[I5Z*FM=L3U>KG30^VP^]\B2CB5X&N$)GJSO@E0<;M0&-"N M94)2K7,9X>!*G[I#3RC*D+@7G=9[45D:- R B\#2Y])M*N?A*TYGYUF2QG-$ M]!W(N '88 >ED ;=RKP%X!YF26@C,L(.J(X/9$'Z;!D%,D:$GW*).^_[>N$3)HL::$ON/*:X &7]:D,NB:BBK ?5%'2CWP4J>[*[,:S? MH(L[SH?&OHW7YO?O@XWJ@&:W%I#[&*UDND,A.[7EIUV<$ZYT>2:F[V3;M@O9 M%:NRBUTFALSK:IHO_<^6ZS*%'L-GCP0&';CS#P%W^VZ,J38X],2&*T.*Z''@ MC6'DA_HPDM<8Y%5<2,%HD[U/6]&-S"\JK#WC]P48#H/LUL5(FVU%=3=A]J%@ZJ\YF MU0CX;M2,R,8VU!HG5_HC\U#':3ZC1\$Y3_8]19'T7N/TIWJ7K+3 [R WVP!. MO2)1S2ISK5TST,EFM*(:=%G;=H![;2NB!5EK[*%SI1??9X\)^B.C;5X^R:]% M?FY>29;5!D4]T#3\FSJ8Y-V7U8!]3F!3*I.+1GD5:%<<#2F-QP(TNKO384QN M]I4W_*<-5QSS&_[!=^5/H-YQAW397[QQ4G^=BLFX-)GRS*KOVU6_%2J.A J( MWBS/)9;3IZH#G5G*FC0] (XP1?!*-1,[I"/J*&Q'*<:T@RK0V>4 MLN;/"A9'J,R=:S^C=,8>\V-O'LS7(X7B,DM=#3H[E#5U1C X0MGJ!0GC24Y> M SH#E#51.N4/(/1*^B*(,=_F+4!GD;+FWQ8<1_ILX;!")X.8;A 8NL9D&E2% M3BEES:(Q'&[1)_,WLN72N!WHG%)MB;4$RAF6$T2%8!NG"ZI'&/.!Y?*%75UK M%[5&E:%31[7@TQ@21T@4.QVL4O!<1SY5 #\A-H%HE[FM&H-.-64?%] >,D=( M7]V$6RR)937 DTVU6!.KM3^ -3&=3)@1Y@\1W^'DVSG5 :?L)]5UEJ(2>'(I M^S,]/0:.=,>ZAZAQK]16!$_M9'^R8(:%(\S=HN>*AB2.Z(\^JIR%&%-IWQ)X MOB9K;MNBYRD%;WQ?2/4;A)Y82EJ,DQ3@A^SE+WW?!43A*?1.9LU")UBSI:?4#PEWF*&_2%! MGHG;2)\?!??$W"8N< =T.+)0$X+#1CJZ8;_!WB,.<;KDPX"1WU^+QJ"OU[>S ME"WP1NG MJ'BO)!F1.SR=F84TM&\2VM^S;P-J![%[IB*.ZN]X^-ERE.GMC@!DE+$>3%P+ M*54M?!N)5Y2!I4ZL?E]?A.D-2A*$1@O$;I^CZ0VB)KHZ)OGLI2Q:P;COMVKL M &)-MP#1E3YN%C]WP1ZN#Y-;-KR0W. MC.VR&3$@5VVUI^B6M(2D%<+HO]7)HK_Z_8ZEP1J^8!$M].^5/^\I 9M*5/;_ M($A_1O-'X=O=I9AE 6"T-U$3(UJ*NE[T[!K2SSC"\VRN K56!&SG5@>M :E0 MEW[VW6;8>B]:;#>+@(7QZ;$5Z>+(F4;#H?9L^4 _*AF295ZXU4I[.E";J%8Y M?7.*,R;A13SW<&3!6;62&YP9V**.K:I2O4P,]F05CA4-4:5#6ZF;KB)TC(V! M&=;I,L/"W:'Q#$7^C.[/OUF/C[6:;G2X#@?)FGZ5A8Q;%)9B6@^7C9IN4&AJ MI%H&Z^JY,7K>>R%*"B^W6Y3JQDQ)<>=&2HD9U@]<5,H[,D@V4[SH.)+7 (\Z M;,F3#@/0;=0_8[)V^I4>M(C*N3' M3EQ$6E3V?[MFH1;;T[%WQ!*.OW0\HKB M\,$P6$S56S6 [X/-;AET,X4(B!<82T,XV?V M@/!53(TP>TPG6=A40$^B73/0+G0M2&V#DRL<-^2D"\T6_;):"]J'K8MNV43! M$<)6N=^HA'*"-DM!^XO9$R+2TC4"KG"$$[HV_13'@>(L2%8>.NO@%J0(-7>- MGCOO^;.7(H*]T(2=S>+0*0&W($>DMR/<2/,6?DD0G3-O\$3A5V-4&3H)H#UO M%I@XPJ(R'9J%-T:G%^OE$+.@>@/=LF*#CG MH+J9]F.8KO*!U#. %)ZD*T4V?%0;#Y%5?%3S+Y1Y;X*!EU;3X<318/6= ?_0 MRFGUF!6GOZPXE?!]C$197VB!VS@BFTE@U&ZM'7["C7/E[=/I;(.!*XZR7:C4 M&#K[L9X;UYQQ.^]U/9C;3>]NONU-[FQ929=V1?C;2?Y2[5EA5/F5F8<*BGX< MCMMS+I)4YXIA5-DQSO6V+6-3I:0;/AG"C(DK,]9=_YO5AKX%L#!8 R)EZ#BR MHZ]8[>K'_\*(L-WM\H;M;8T'965]Q_IH_^.R$@U'G(F%]MH4O,T@K6C&,5,P M,GR3CB[7V+&Q^SI:9&G"=3PU'K)%E5PJMKN;&(W2X'L%I#5XZI)5(:G#SK:[K!HHE]FE'7_Y&OD=/[/460+P;6@YXG M.T>@Y17%]X\@M3Z 22#NT;0NDRH205$$OW!$I".)E]C$@;*H ]!.3!'/QL\);([M3$Z_&#I M%C.T<9PT]"'P,4[:F,%CG'2/K\\=<*#TH2;:Z698;.38<2YSQ#''CKLY=M9+ M*.LL.P95W1L5M8EVC %Q9'#4G&%=1WZ8!>P$.DE8_N#@P7MI?1XI;@S^81"C M ZY&#$)KW(Z1"=M$)O3Y@D<;0[ ,3^B"<9A;FE4VD(M"@P(@Y?7,SXWKF:(9 M=C]3-K1^.?1X*[/#'MR0;)4-7MF%5=7V^OE.(TA:=^4%(C@.[E./I&X,X')= M"QCOD!]/(_SG>IRPM =!.]"#?(\6(D7-WF0^YB83L;FH*-OMN2U=GA#V_L,% MW2[&8X(6Q4LQ')P+K1W4TNF+31T:AW?QWC^^WMX)Z<>.RQ3KY-! M_3*J]U'@%5KMM=+Z8Z;*%=M?5"LVWC!_%JEH6OB2KPNKN$-YRO<6I70XHG9[ M$R>*X\I:L?UZ=E>H8^L^F=+!>:L]LF3._(K8$WDH&-)-&=W0MF+$:XA^S#X)YU)V() WAU;-PB] M:K+LN5L"YS+]HXE,#TO:50U!KZZZH%L/5$_.)Z7P?(@I-9 ,O)*RT*G ; 98 MI;J.]*3&2C.W#/-%UZH"=!XPRYZA4?P0#H ENPC-,XL?Z]L)Q8;!D><4#V7K M,(Q2'# [I(#>L] 1'EUR^<)NIE"0[ZCGBRPM[CL:2LQ99DZYTATUOU];E4XQ M=28 9W5P,%IPV(L'GU7G!!_>JWEJT&%YUOWGX)W'>CA-?:^&#F0FZL.\:EM M9RY?$/%Q@L8$^ZIGAG@3_><',#% M9#AR?J55+K'2KJ<%1I="0)^ PMAH]S3NBP%OH[CU:F&7@D ?&._!8-MFW;#/ MQGSYLL"Y7_8.)G_AQZ!?Q7#2*!6T[(OAZ>8/@8I :P%K2:"? W%S0="24)?L M>8N=YV_09P?& D _;^+DP8$E?2X9[1;3S%5,)@BG['6)_F=_X<>@'S]W;+ 0J LW^UI* /P3OYO3?DE&7#+J+@^=---RX36@ADZF1[^'-&BC+ MKIA[&OO?KI,D0\%%QM+EYATV=T_E?UPMZO,^JUH7M&C+U+SV[/:J-:J0\8^N M+ E*4* 7!)9R@"=@<7,YT(K-GKS@=W>KK!HNF2@@DIA:Z)Y<8('AV(G#0#,0 MULG!VF&?1HN0Z]/7=94EA.IHM7OGUVACX:_K7LP"P$.S^U?CVFAC_7MXQ;8S M#(\=PN$,L427]?9D&)?/"!T3F[_OK":V$,>T0K^O6;@M>73F(V]I1A$][ M+)]QWPMQP:=,K?)U7=]).3FE^GKW=H1/56I\H&(=>=.O-M2^"]?,U-^Q' M:/N=.3FI]'?CU3'1TO;N_HONQ3%-->A\.WWVC\;K508 [OLMPN4?&=UO7$=4 MU8S#-TIGB#S,O*A^)M+;[8*]", IS;I;IW6U]&C+XFO/?6..&T26ATZE@M=V7OKW[NXO]YP MR1,H0 [M=0F@T[;MH7&+27P-P8D=0>;DM& M(G2>N+WO.<=IH<1E%2$/.3,( MA(#..K>')BZE\K48,4MMXN0 ;R18;W$R>VC= M A0/S:?5D0-B-V\'++I-;X$\^]QM(*,Q@7UIO[+7""E@)IZR[U6>LD5#1Q=8 M]UU@VW8HVE_RGM/L63O()F+U]>.C:=OQ!GT1J@K[V@J"+5*(K"*4=B0 ](U_ M3_%=.Z7/93MN$\ZS!J+-DG6K&#NK3T/?RCL4F]B",FBK=7>AP3%3YC+M\9O0 ME^W[LJJHD=1G3LA6GL3K'KG52V9&,UK'0D!?B0.L"7JA$1?'*HW,3L=!;?^"[TY?&^S.0"LAR>S;=_DJ2K":FO)TGV)%LB M&(S]FVB;'6#CEJZN8+L+J$XSYK23"?JNUJ%M?I9 M7Y4UW[5Y?]MW1[J:KGIZ=V1/LA,"H>CZ?EZGSBZW]&UD.;!WQ "1//2YW3$G M )LL]'MR#[5C]%SP(3PZ MC8\9YT>0-=-^7!] 6S,=]^NK78 W6$;;HOG M'T3YACLBI)TT!_:2&2B6TB4RL)?T'?+C:83_+%*)G32PN7QA/R*E^_0'E?OT M^@N#RB<&U6\,BH\J]-DO:D:A!85> M:?9H)F$5$::ACFIE)? #YQTR;8">,SS3+1%3-+^_83+'$=\.*5=PFFINS,B] MK]S5(%0"TD#GY4WA=$LT27%'QUOKT*E;(C453D>) -[#6BD%[G"E-J@:_ M4$-'!K]AR%NG\[%P?"@.1Q7[6,/ZA_HX@1U^SIS!B\_;BQ/P6V:O*7Y:B[UQ MXOY#X\2=MW;6/%HOC]0'JQ:/A^O'P_7CX?KQ7.4[TSVRSU M.EC>U-F1DW73,W$W3[-%QB9!O:,=E<0EZ.$Y?IC%6>)%P16>I A%-W$T9=X= MUY%/]:#K*N71%&O$L@WHLV?U$5,+A=S:=!WO""WO"*%/D(YWA*_^CE#FK[F^ MLDJ4(["H('1"KUW6=E$ M38QH*6HOEV5&D'[V7O \FZM K14!+@"6YTF,K MTL61*??H8]&WC\4/1Q^+HX\%B(]%?ZE4''6R,)I9'MB=^6AR'07X"0>9%\J7 MJ9*BCO2%'I>L$L4KRQ-PUK[B=,;O==G1Q0PO'N++*&5/NLC&-Y%:ND;@E\%* M:U4QIE.MIQN1&2;4PDB*D?K03500;N/>!D#!S8=4>4<6>W1XF,=1[@#L+7#J MA7Q82.XHSN0)!5.J>8 M?Y+ADX=#-I]0?7ERAQY\1+1?A+X>[#?INC>XK-]':OOS;"P-J\R["Q_=-T^#X^Z+RKU58C M1G\4.6*(JP0@B#S1:4V,YDH5KE_"MVW5O[/ J]LX_0=*U]U0<0/9WR>A@Y-[ M,\;>:3IT<\P/'*YB4OR*E1/E7NT;;XD^^V>Y2D8=,6=^:<"N!5!PD1&Z MO"_/=4@0(:I3N.73ONN\BVGI5;(>I*^/]U1']$#]X+2LQ"_G^LA_SG M+0QX$ZZ%^:^T6TNLC^%75H+LNRO!BE029RA"$VRB2;T"\,6H 2VU3J91'7*W MW-4Z8S)!/NLP*U7OO!2Q%-XXRNBH,EH@DGL&*-8(%FU WUO:VX ]0H[,N6+! MV2(A\G&(NOZ486IO,XI,+'.=95WUHZP-'MJ2_Y ME%OB,PQ@&P/1D]M)%G' MV:..D62'$TEV0>Z]-$5D@E$8*$=%84FPD;";4#*%]MN.?%*\SYA:YJ#+BH,= M2G6%O!H'P(EG%?U^3V=&C^!8/O%(BKZBB4>" & &GE*0+U&R0#ZFMA6HIAA% M-4+@5V_J!%J#DYB[1RY1QGZ/LE0@DH3 M5K[H_K/J1?>\S4'1Z("W.BB;=>,-=Y:H :>E,>2N*E,4^90_&X\TRV8@N_T- M2A*$"E><:,I)N<'>(P[I'J@DYPZQY4; 0A"NJ/Q>^ _D*0Z)MVD3?&)O80"U MSK\]I(Y,"4:*T*'NEHXU#\\H?$)\Z:E8 +1O$7Z1L"/#4."Y9V;!+/KA.=[> M&E8-P:\<=F<$-?3VD7OZ984S2XNFH+W9=LY_%<$]LX#MB8=/][!+OEW;"ZAT M-_)5_$M]+U!I<>!%[+W)2INNN2L>=P+,4-F;3.P,/M*H:5+W0%?V8H@<&:R' M!'FCR0WM;2J7GG690UAE-W5VA(SJ(:#R)*U1\!#6O1+M'>&&=^7+EP7.(Y(N MO!0I8KO%I0]C=2K'P26JJ(+,BKQ0^\JYI/AA+"T52%BM(XN_L/]CR4CH;_X_ M4$L#!!0 ( ,* #%-/Q_(V=0@ !5& * 97@S,2TQ+FAT;>U<;7/: MN!;^GIG\!VUF=J>=,0&2YMZYP#+#B],PDPU9XNZT'X4M@VYLR[5L*/OK]QS) M-@Z0AK1D ZWS(<18+\^1=!X]Y\AQZ\KZX[I]?-2Z,CM]^"3XT[(&UK79;E7U M)]RMIK=;W6'_$[FS/EV;OY^X(H@;I%X+8V)QGTERP^9D)'P:&/H+@]RQB+LG M4!&JWF;U?!I->- @M9/V;\%8ALU6]7:ER+9--TG>6)/$[$M$>1*+$(%.[TWG=[@YOWO)[43=7W;Z?>SZV>; M->=./,6BM5^;9"PBAT456W@>#24 ROXZ47MORQH]OX,9SH--O6S P&M/TIV\ M9?6_&7#M].R"![L<]OII/N16?QWAADG7C6RG,7:XV#6T*9TQ$K$99W/FP"KG MDOR9T C(P%N0$0M%%!,1D$L1^5"Q\B<1+NF)2I_322 O@U=# +[M%FT&GZ- M]F6J7]"E]GI^U['^J+-R=B >UZ62.1H>>)2_(/>!F'O,F3!#.UZDW0>>%AB5\YP BZ-=36R%TA 5L'MF)#\4": /@ ,.3^93; M4R(3_+6L/V<12QM!*WPN/48='DR =.,I6"E#9B/*% 4T'@)(X8#!L,J AL:+ MXH#\%(NXI)9]G)7S'X):&'%Y 'Z+/+#T4P-XQ2$";D>%^SQP8:NG,8=V>&![ MB0/^"%Q0\$<#R(2C/ C!E9&*D*(\+^<:C2-U<[G2/W":P[%U TLD'A0 @A% M *I/J4#95$Z)ZXFYS-@G8A,NXXA";Q2_U. !JE'@#YDA4I S=BEY9%]7[<_# M(^\.A$>L*0]\D M#-AF['$YQ>)8S 7+QA;U7]^H6CK_0EQ\1&H)D'.R&H,0J$I+D! M 3W2D4:QUIO[H#<7>D.+5[D*2F"$U=B\R*LJ&F^7F80RD_!M5+X'*.F!4%N? M20"1J205LSS-0 ;&5#9-0%UM6P6CJC$#(M'=I9&22")H &3*C$L4/WD Q@+5 M&*87E\%:481%S*.*GJ#P0W8Q4H&&-SGH* DA<<=&BNT8\D=3B..5G =U2E9 M&&!+B<0@2U%Z2K,8FRF=)R0#5#&(-*P94O26Q*,H^,! A609L4$-'006 UCX M:\RP(,@QJ,^)CU)[!6/([%H4] M8<8=9&PJ14!1%%,);(\9-*1Q&CD9FP+)ZP4/<&99(@UB0. MVPP/0?J6GKG7L/;&.TL:?V58]H'0N#FC7H)R=7D2P%R7V3&? 2?)#=F_/!NQ MA1#7E\N$X .-BH(<*H)^ECKM.!9)_ 2,;>(%FI=FF%UUGS[>(&-,WF+>5NU& M3(\)@&IJ.-!#Z4K[#&MOW*GDW5>&Y1P([_8UD66\NT*->-R/(+&!3H');M2.D5O M [^JXW(\20^2'-Q;#6U*99YY00VLF)\Y:8H&1+0:F53"+XC'[QE\J+/SE4K& M=P_6:9DG+O/$SQWVBP-AG>\X7%)/J3D9:QE+R80RKL@72_6$'O^$WV5H\L3 M6HHUQT<3A\Z'_@OK\G' P1!%@$MCJ8/QM>894O??G9K5&K2KLJJM>?C/@ZWJH%UN<_L,:V^V.KUP-+Y\]90K9W]A M[X/ M_LK K;P7X#^XE3ZU+0&JI6 J"J15 97V\:CR65%(Z\8O"6&#FS\<>8^YJD:^ MB M-+Q=]M@"RR6]582RR82D,9A5'4X_8=ZZ/%W/=E?>N5/&U+OH]+_@ZF'\ M4$L#!!0 ( ,* #%/)+K#\80@ ,A% * 97@S,2TR+FAT;>U<;6_B MN!;^7JG_P;?2KF8D*-!.[VH+6XFW3I%8Z%+F:N:C21SP;8B9.(%A?_T^QTX@ M!3IM=^@N;>F'TB1^>8[M\_@YQRF5J_[O[8O#@\I5L]K )Z.?2K_5;S%Y'&EUFU\83?]+^WF;T>>"J)S5BI.(M:78Z%91\Q83XUYD+,W8^/I3\_?ZA94U;+/X5%@99J%\W/5ZU:JW]X<%HZ/JD4:A@@ M:O[B&> [(HA$N$W\Z4AO"7$^4A.#.KDT< M'G0O6?^JR>I7K>8ENVQUJIUZJ]IFW4L4:?:V.D__IM77GWHWGZH=++]^E]TT MZV0\.RV>L,3^FVJO5NTT;UCW<[OYA57K?7IR4BQN=ZG^FT-0[30.#WJ?VDU6 M.N7YTH?4].;G^E6U\[&9&EWZ]?3#&_?/-<3_CW4DO?DV(;=RAP>U4/* U4(U M0WE'A-0'BT8\.G]1IFP>_7ZUAK56;[;;-]?5>JOS\;>CXI&YOJXV&NGUD\V: M23<:4='B3V4V4*$KPKRC?)]/- "E?QV9W;C2[SV]@RG-@\/]=,#@LD?)WE[I M-_XVX.+QR9D,MCGLI>/%D/<;/X+PN5>ZA3;B4\%",95B)ERL,YN S7SA3L4.>MXH74W5Z'90$6@S2#B,F \ MF+,XB,)8,!WQ2(RQ4Y,?9Q![="IL8RPM384',9_M I(@,Y99<]C^SJJGT[//+AA?!(?R12[TW] M[>=0?XU562=,D<3#M)LKSY.X-)[88CP4QN?APW+@"_)-)L V U_J$16G8F/( M&9(T=.U*[?A*QZA'0B=4OG7^2:@*VME#>P>%= 0:Q1-3\YHQX,!2L"@W1 MBWW89S(G9^_$>U._=.;:*WLI*:L16.:A3AAIC PA66X@0/=T9%&L]>;=ZA!$58YYL7><%$XQ?[3,(^D_#<5/YL*/D+H;:&T&@Z54DF9GF8@7(4 M4SD\AKIZ;!6*J@8"1&*[2R(E%8=H #)E*C6)GT4 )@+3&*47E\%:5H2%PN>& MGE#X+KOD$H%&#R5T% !IY4N71P;M0$M7\E"2%=)&=486!M12K"G(,I2>T"S% M9D;G*2V *H)(HYH33MX2^YP$'PPT2)81&VK8(# ;P.*O@:""D&.H+]PWL<=O MT5UW%-9>$.[BK&P3UN#EDOFC==X:IS]>(=Y'[2F,);]34>P)4^D28W.M DZB MF&NP/670B,9YZ*9L"I*7?"!]&T.9.(@LB6.;D1-(W[UGO@I8 M>QK?Q5G9)BSGA=!X<\K]F.3J\B1 >)YP(CD%)^D-V;]%-N(10MQ>+A."=S0J M"7)4A'[6-NTX4''T (S'Q M\45I0=M5[^'B##2AY2WE;LQL).R8 5;9PT,/> ME5X#K#WO[N*L;!.6^T)XMV&)+.7=%6JDX^8DQVJ>;.3?)XAF2FTHQXE#XKY, M"F&]50MGK'2$A_0^&AK46(#LJWTEA;V[!XT'.H>272F=H'? K^:XG$[2@W@! M[KV%-N)ZD7DA#6R87[A)B@8BVHQ,(N'GS)>W A_F['RE4NZ'!^MXGR?>YXF? M.NQGWV>=#9-N&_FGV?$'#I?,6VINREJYI60B&9?EBZ5Z(H]_P.]2-(O$P%J* M=8&/QZZ,5*@78;BY@7;'8QE%0GQ'J0X4 GUZ[DJ -(V\ ZM $VH2GOBD9"_Z MSZC/K[&$(88 X\ Q!^/O]V=(>VYXFV=(.\-@53_A#$H 2A 4G?'2D;$C!1@E MB3D7QS@SP6\I?K1I-Q-!FM2A>5$O?>/E$3R5$5/VL(6'"R;=H$NXB]I:+&3) MO9R6)!Q1!<0$+\G92%9C!'0\!C? =&-1(@PWOB6TCU)?!JR=<:)]E+K;ASP[ MLU"J0?*>LA=";>7 ?<*H1+"G>:\XH=F<#>-D,%7^5% L%_!A\HYTF A+,9[X M:B[P=#925DWR.R0.TOU.M)N&R?LH[I4JM0EWZ2QN\9]_I>.S2?3X5;^PXZSX MTU;S-%CBR>MG\1 SS4HG.792/"E]UX&W9TRK)W9YLRJ21>063K[9;.[ ML'9FV=1'4G@6WN5"@G0S6;-K^]X&[BZ?T_WJ\M6.I/CKDRL _9]\'H8+WSUG MU]"#933P-4:43A7+K#LQ2;5SUN;85O/Y=*(;K?^EJ%:^#."_M(<^M!_!L*50 MR@JC5>&4]'&OXEE11NO;SI(/-GCYW4'WA6=J+-9PINGE^*5SG\Y[I8"Q2(,"YL[%V/Q8\R,N.M!JQ@(< M%M(4)O0:9E%(N%*\H<"<)LROX42<.BWGA219,-Z!9JWWEE^F<5=K3.^%_-O4 M7=@DZX*@-T(E 5O@9<(62U'K:4-[XFPG57T2LF#5^5[:/#9E?]$"!6;J]\SS MD=6WG&KEI%UO:8T^-DBF[QT"_++1+P78I5S09,<-'Y@SQQI: ]VQ[$FU8@_! M&9DP&%GF$,QS=D->I+[IV6Q^ID^048X-K=_@K#ZOPZ . M>J M?3XV+T ?.'*DW6RV7[; /[-4,']U2*+P I M7JVX$>?4%2SB<,W$$L22PN>, M)+C_P0IF-(X2 9$/@T@U&%GP"%&XF-/B;AV.9/3;P+O*HNX@"F/"5V^3_.H8 M,.$P2D)<2OV,2R=YYAB11!Y0[E$/?L\XA9.F@OO=;BG5"DG!9P$.;(#,J9LE M3#"LBG /S!MW2?B"(I@P9&DJ0>.OC/2(H+"D"8U\Q*: <2U%'T9U,!>R$X,E MHSXFP(2"?:-@^SYS:2(KD]/7X)4\Q>4*VT(3V6T%XBQ),\(%B*A4%2DJZY9) M45$ @1,OB@5"WPXO@R3?U^O,27)).$U5^R:@*]#=O+>2[PJ.$Z'(>>$*OO+H M&CNQH)V#(M3C]X"C]\=XTICC\7RJ#ZS)IX^U9BV_GNJ&45X_NZQKYHFE#&V^ MZ<)EE'@T4=TH"$B<(J#ROUKNPS1G]OP%ODD.N"0H&R:BN+9V=9IC_##@9KU] MROC/W@O'.!SH1ZWC'>%^8:#.DA;@MI0N"U W7=230,K61LH2>I6QA(9XLJ;R MGK]5D"."8IE Z_3(.][HQ*WP;41O+1:M#R?ONE(.MUN$?V;[0_1#8O8KUB>P MOM)J3[$>M0]-(1E'#QB27//0R[-+IXA165 (;82>,U\V+8#<=7SUQ^G> MR#U+[]5O[9_?BHGG,;Y0+R,AHA SUT]C4?3F676<-M_L(VT4U=S]F*@UK-Z^'G][>M+]9%B/4NZ_P%H0I\"W8<\K<_87UMXP)_\F MJH#WX.LH!:;H7)B'UB>W,=.$H;N)T=X\"/W_^18$_8NJPI#1P.O E"QH%Q-< M992[5;7<9,/Z2_/TN^=2%C8K6/:=DCW'=1Z MC7^T/OU9;6_B.!#^CL1_F$/:JI42WKK=NX4L4H!PS8DC+*2G M[4CC?--[EO]VABYL M?'9!TENIDY ML)FPQ5+B-"-GXNXZU0,2L7#5^9[;W#9E?],"10[8^G)N]VVW M6CEMU]L%;N7^$/#_S%+)@M4^ RC3?2C('N62)GM.^<":N?;('IBN[4RJ%6<$ M[KD%@W/;&L'(GIB3@6V.P1FAB34[[)(<)+[IQ6Q^84ZPIEP'6K_ 17U>AT$= MYM9 10RMT[/F*PS+G%%861^%_G4FN@,1Q82OCI*\=0+H<"22"*?2/^/4 M2>XY1B3"!\I]ZL-O&:=PVM1PO=LMK5HA*00LQ(X-D#GULH1)AE$1[H-UZRT) M7U $$T4L315H?"M+GT@*2YI0$2 V#?H)(QP_Q0VF8;!D-( 1XX1[C(3@! 'S M:*+"4F/7R+5\_-4*GEA5[!KV$ZFI<=$*OG)Q@VE8T,ZKJJ;'-X!K M]L=XS%CC\7QJ#NS)KY]JS5K>GIK#8=E^"0L$R9%7%MK.\,=_F? S7K[C/$#IMT=ODB4QZV3 M/4$\JZ?Q;+(S9/B.&N^V^=2#+% .P58,UO@4D.K7=Q8?'.C[BN:T[T& MTU]UOHEZO?HEZ'Y(O*\%=$A%R/RG!/#(%ME$]?[GO89EV+U&VBBBV;D_,QIV M[^TL^Q%@'9QP\ZHI"R@OG;>R>?VP#EXV^?\_Z[NZ!W\"*;TR31A>C/'JME]= M-SU/9%SB"5&:_WAZ!4'_I.L8. W]#DS)@G;1P75&N:<&=L&)<_G6@3'!8U77 MRX4>VG_X<4!K952KO*Z+YRNGOH/90\]Z31PV-GRP>/[/*[ M20]ID(_8U/".ZVW^RK4OU]UH8"[*M.PDLZ&R663L?Y;&P:J@;*RU:T,]FRP> M5JIGFO\ 4$L#!!0 ( ,* #%,QFDIQ!>< !8%"@ , 9F]R;3$P+7$N M:'1M['UK4^+,MO!WJ_P/V>[S[)JI"F-N7*+S^!8".HP**#CJ?*%"TD T))B+ M K_^[%S\%E9^_>DJ^O]L]/3S\_/'Y_T#T7MG)(L MRYX.T#,GUD-G \_G*((@3Y_O;NM\%_2XE"AK.B?S8/R2),IOB\='OXX?;:F2 M./4H^L:9A#Z=&QK^*DQ><#^<.;5^G'I4]WPT;3VJ.X^*FL)09'89'-83XQ<& MBYXE$#Y\N%V\KCN_?SDT5-=Y62MK:@]3H..-,K13^W.&V,<0',H-N9$_X WZ#&XZJ@O7#8S"G\ MU7G0T-6%#[*G\-?Q@UJJPW']\<-M3FN9#]H_F-.G"-*U./B+JDA \WS'_,7C M)4%74_JP#S1OL.#/I^AG]":!WIRLF5<,65>'W@BR?YQ"DJ;J\Z#!+SV@*E2+ MS^-GD2AS'5G1=)'7?O!*SWR!R-#$B2G6@!/@OQCZOY^ZJ$O@XN>I]2_\M0=T M#D,#I<"[(7[\>U)09!W(>JH!5W6"\=9?_Y[H8*"?6M)_BMX[M8?]^9]4"KL2 M@22<876@GV,5K@?.L($P.,?*1?-#DZ#RS%@JY?=MNMA$ MZVW.K;/IK'.-P9B<]1;\SR:OIXM- )D;+@+^?TF&:!P6('Y43BK+ AC<@&&3 M@ HPPU(,F5YG7-8U;KX'9 '^5[^2N$ZSS4D:6&$-UMO$DVH9JT1.'X\0DL1AIBF#R7P[TD; M*H4SC"3Z.M80>Q#0"OC$'I0>)^/6%SB<117;IOH1Q _G/4'4^A(W/,-D10;F MC^+@#.D1H"(%9?XE"@*0376%_H0/5B"OJ2)O::*!_H LR96J]!RE2)"Z8GW. MI*#&PV2X-#@5$,\\Q?/D8B*?/T^GIMAF5LNH_GL"#?%92X&VA)--N77#,R76 M)Q?F[P&",)EH@="?7*#'=S"C2R6<7-Q3HB@1R1TT M*ND3S)!%ZUDHU-!>:V>R*$'["4<_N7" 5E K@,,*F!P 8%<"S0RLW?0%I&4#!YK->CP M D@_H:XK_-L?3C+ >MAB]P;2(BQ11. @E6&,V@,-;F#+Y"6005N<87E;64#7 MFTDA*- G+YQ13/"2N2: Y H @^>SHDW30 &E"3H,3*H QI5%8/U;EFUU/(8< M:#5NR+4DL"'0%!."R"@\ (*&8*AS$H!:YH[3#17Z'-7V':>^P<@* EP'//IN M3NWX!IT.0]HGH)%GD&V'3P>@ 2WM3BU;8)F@-O M <:!WBCU!6?P!J<, 8%>NU[C1*$"O*7+#VC9X%G5#VBK&3$;H@I%\KT5;+G M8#/=0>1B<5JWJB*7R_ZC+'] /E34X9WR 82& J6H#U1]6),X68?27WHWQ'YO MSBM;@_2YX%6K*3-=18(QEH8 U(?+['K3?JT)_:4/N#81*K!IU^ .]%I G8<\ M>'FR(N6JH:,L+TI6AP(X2[D MZ8,"NM(4P&A"+6_W+%"(M.O,G^K]M%;6FD M5%[4@+",9:Q/]!:K9$)PS\)>X@,TGZ(,(S).E>'HVJ*5A20R\RNSF&,OU,OL MG$?1))?0$X.!4P_YC.:&P;6J:$M-;@!K9:C=$]L._+%_O@C@X)EK&X#S@B"B(3D).7=EN<#U19V3%@$? M@@OAS_G9ED^R(5A77\[/UH#OWK"L8SZ9,5LA;WGC5>8B[/PL6*)/8Q)6O!"( M\Q,4]>+@_ 2T5G;'G!K80GWR*[MK?MT?)4/A6E_&.)@5I(G@>7$[\%7\[,=G^PK\[,MX.3.,S\5\&G^XF,G8!NW+DV%Y$D'O"Q_ M1B--!;__L=1H[(I*-+-K_JOJ701'N*L*+A$?UI)\\AT3O#U9RG>[H ZS@G/*J(K1;62A7E9>.)4E9-U)VNXD*>FR_@V7V)PM-G)^GP: MB%QP18*;+QCOWL9^"LQ/Q 4LY#! MAU3^O>3M^&1_E:'; 4YMMS^P^FB;:P]#4_7FG2B+/:.W !I4'3-7Q.]=?ORH M@;8AW8IM"&&-?O%_$,X9.:]I0->N.%$U?8:BJ/&2HAGJTE-*8SR/W[L#''K) M+-Y_0#D%9*NMYUYI?2BE08O,^NM=+:J.C2: MAF!%]KS2130E0\H6S/FZ>12Q=4S +X>31^QC-/E/3A7L$IYK%-II9=GRGS<] MM9"C0BGT7+DX;:W5/0&QT]6!D(ZM[6[UVRS> M_!$=EA[S[^88H***@=*@+ZKF.]MS>$A;M=MRN,<2PV'S3*A$;JTFLV]9B!()V=C72V1:,K4IQ!W /H<2)*7Z+^$&@I!B/D)VUA_JCMV/.3M6-[E^_^\4.4HM;J8'M M$4='SCA"A6EA:0Z+)FZ6G]1<)JTL%2B7F)MOFQO(\3)W$.2PLR=LMR>SO]5O MN?C@;")+I6/$Z"[UL/F"LY%D]ATYA.QLQ7&0'!^$-SB'D1 =0I8F8\3\OD[D M+U\N'4G6'Q=@A,KX=."*+BA5OVK]03)\=L\1$(L"TB#TQ@1]&T1 *#2@7M@[ M,K=!;)"7)(5''0N]26_W(5N[XF0=[S0=?&W =JLB UE5\+6I6ZQJ\>DWNVYL MT2J"+UC=;A4+XJ'EJ]BFS'F;_K("7&8/OM<5N.$0P-7*,Z"1!#&W6WR+^NI- M$L9(54()OP(MC&)Q.!/C*>3HNTE+7@2[N7,.9!YHUA.H)?R99O;ZAXO S ;^ M9UT5K8=7A$&*LGML_QAHT"A;/Z.&Z?^>:&*OC_KYG4ZFFA[HL M(&3;$T<&G+(].S/0OBMH]X7,B8""#DI^N'ZP?Q(@,(.^)/*B'DT?9%%O+#;,W]H7" ME5A&"01%-F^0F.&"F75_,;HO/[KP-7A@*0Z^&#\L. KX-1C!>_&'R@%;]]@] M%*:(C8\02%:1=C%4**'A,H9*G(R$<39@G,1+B9B7$G>&2MR6,,X&C).X+.4(DON'=?,.(L MM.'E0H?"0;'QB79080\@W Y8.L;Z Z%*6+C(P1RDC/T M.K)U[@0\%!:*N),1=\9)O)2(>2EQ9ZC$S=F[FQ-3%HI9>4[$L;SAU;"'(J>Q M\3RG6SB$7@J7.(X1<1SW3/?$[XN8W[=G?DCO$F M/US(V0.Z:D!:7MQ[4NUT#IJ%R_ M"YZ[X1]Q#H(+ZRW3E@DJ:?V4223L$BR[>?=-2-AD?UJD8U:?NSA MM@.[YN(!:'JU_:1 E!TTHYCU!'.+W;<^B8M7DC#+OIDE1OY)PBS[9I88>2H) ML^R;66+DL\R[M2L*OYU?)X184%QYH.RVB7N\3DHP$E7>:Q79KN2$?2ONN+B$ M2V1Q)8Z72VTBBY%F_TCIA\3C3NQB/&0QL8M?(Z!)9#&1Q8.6Q1C%BXN2"XFG M&DJ2(HJ"$"E-D42.OJ0RL9,1DLK$5GZ-&#*1RD0JOXA4QBB:3*0RDXT@-HKFT@5/T!-XN1XRY?#,F@E%:X' MIINR^%__KCEJ5R=55[E19I_7:A^)5\P+,,=M@#XY59CH%),5YE>9V'4?&B1A MCL-2!A,JD^A,6$+E/5*9#/ODWTHJ'TX3TZ#I[M>QCU+CU&ARUR'T3(X*=^VS M3_.NN,O+74UL54S=53+\^X&G#[>C1(HJ\KI];C$JS]WJ>2,$X4 M&">RIFJ^2BAAG"@Q3O0*65;Z.$F 'K&\3C1-UK+KX1,&B@X#1;;L?+'I2A@H M8@P4-Q.6Y!@3D[66R4H8)C%1:X7E"<,DX?A:/DW",(D/LY8/8[J!"+,0^>;1 MG,,Y2++ !5ZRXGUKF[CY,PGS1(5Y8NC;),P3%>:)H9^3,$]4F"=Z/H]5$49F M+<".-\U2T^JUQR^&=,EA.HU,H-*JJE;US(!LV*VBT/0OH7K M4D4X3^S SF7)&_'[,P8[NGN<@.+#[HV]MD:2O8#@D&3(HH6AQWIQ#BT]ZW;/ M"U%3&(K,GL%GG,&Y52@+9S"9BKSH8WG@/#5%LQCRH"'FD3O M5HP>4#E=\1"R-7 P"Z/7J*Y)BT!6>J*\:MK5>)F=UVM@Y_F?8<3XSY:B0T/F_D8";3@B<7+Q4^MS\KKSG%S\[[]DACC_>8K>OOAYVC=! M_OF?5 J[0GKZ#'LP))"J<1V I5(7/^&BG#D^14'OHDF(?TZF?F@I*L2!!?JE MQ/%O& /AT!1)%,XQ!%E*$T< OMG7SS'[86=AUO/DC[3SQ@1"A$_[?UW@G4[! M%W5LS^(Y?%#/,:2%4YPD=N0S#/540OY.H,P2I47D?-"@=?%8*3=*Q>.C>B/? M*-5_GK8B31A_:ZJ7"H\/Y4:Y5#\^RE>*6.FY\"M?N2YAA>K=7;E>+U6.KLCX\5&Q@%%$FF&COK0O)%Q7U8<["+CY/K*Z V'09 FZ"00@ MIE)%A3>0)X]BEB:/''$"_J?9-#]E8$@W&OW^7=0+][^R1!>.!VVJK,BF=R/R MF.U4/H#V[#Z$KDR<^A-,YI#S#"<\<\]WKA]P1Y*M>I# ZL]/M0?\Y4&UJAB M4),WH+;&2!JK/F!D^IOP':M>88U?)6RBY"?Z/5]HH)])EF:B1?J#X-^U%W&E MJ,='>A=@[PXO859\C %9 (&->2L9)1F)*-F/E^R$F?>A'5AY@O((I4F(@P M,^O>J)RLB69'Y"76[6J4?2(_/E_S=V]!6KYFT6*MN^,8';M\9#OE(O MFU8L,7#1YN'-#9P^YB;'PK4AGV+-\?]ANN+Z*^;+/@C:%91>3]30ILWQT94H M :RB_/#R2"YM=58R=P[0DU SF#MI7FI,4]X>U3J9[E[F HC89N=$FQUDBLZ1 M3"[Q,:(>_,\R4FZ*D1Y 1]20VM!1'WAO9AI*3U0]]])XD3J!,=/TO&A3,E4L MYZ\KU7JC7*CCQT?E2N''X3+7M]* X_7C([1X3&EC$W1@G(;5^X!'^X8")LI8 M6=>P0M<,7+['?-7>(J5S+:CV>"!)\'M>E#O_GD"&07_W.4%P_EY[H5.;(>;^ MD*ZN/\H'4'5T\8B# 8@W9[_JIR[,[*\X6&S-;IE8FRQKP4U3_P2*>P]-0$YI M@K+,*RIT0<)Q>/.M?UHS=T89Z,:Q.)^B<8,L'L+N3U:DI> M&]R@;!>8\*8L+/,'6[4'1BZ\O"J/FR=M9P5Q 0 G%TPF164(EF8S/@41_H\: MMHKV/UZ09M[43Q8LBHHI,$93L5=#%35!Y,TP36G_;*G8J0VOZ-9MYAMJAY/% MD?GW]T D+$RQV@^.:ZH(?9:A!0U$N"QPJH"59<% _1GJ71R*XQJS18PMBOVF M.;0 >%O=G&&&#(VB),I@/IDZG7W("X(*-,W^YQ:^07J;G3>1-@:=?O6E'USD MZ#'YR07%$.3Q4?T'=J5 )2M*$E94Q0^PP/[@V*+]GD534-[K^_51)UYNZ&>U M186X/CAVW1!U@!5]KX?T6D\!?JRJ#>53]E[-H/1RW_U-%0V%#GHUDZGA6CA) MQVZY-X"A;WTOB?!:DFE?JVH-Q@O0=BX(4XJJ]MYJW9%/76%W88HW@$OCD[DE M%[R67%/@W-)?L;\X+GNM9I7,Y>5#00FB7F/Q["<7T/WL%D:^S%'Q\I M;:RO0D**?4["P #P!KH0$7IQT #"$:#O@8W$/D2R XS61.S16QC\QR%@[14 M7@7<8GD; >KS^7W$-D:9 .3-/1_DO1Q!?E\@8?,U75D;YEL%!D2UKB(OW27( MOVK#]A]1?G[9?+-S O?LG# 0I',IDJ 7AX$'HR F^=O__3='D=ESJ"MT(($^ M0@@D!9@)-@5HGM^SDT=M#'!\%^-1_B*@+(%'WBR&Z=<5-*&8 M@&FB+M&-*?#T_W_:O&.QU$^FY&_$NVBEQ<]/,D76?NQ JHKQ?SBTX& MI0IW4=MAV-8-/\PP(FZK0+TR>'/+MC7$^"Z 7A"<[@VZ$<#ZG(:U10F&BYPDP1]1%;<&_WTW1!1#PM"Q!>P'X)CC,))&V[M6H;4=3#K\ MCZ)*]!VJKCX^$J!LR!WS@;X*>&"F#T@*,X^&:-@W. H4,TPSH)NC=154)N;4 M_NI=3I^%^).;A@T!9KUL0_X=-[.8WRAK92THK/#WUBM Y6KP!?-9^!8"PQX( MU;%K)A0FE)RF8RR!"=Q0^S&7TBY.I;0+AHJZD%BE[\@XZ)QN:-X*J<*2AD>S)&$AL^HJFNQ)'IL2@=@@8 M0Z3M.D]#LG;*ZZD&]@VA/GN.433UPWY"[XH:!)_KHWI/S(?T^Y3\XZ-9T;<@ M'X,]EFR@?9^7V\),K> 8,P@QMAAYR^T+T"N_7G5!'7&!R:WW_$OE=BRXAR.W M<8?_2^H=*-T<)D%X ,;Q/-0[*HSV\QR- ICQ^@^'.8UH,Z"TZD M.E;L^(A7>G MPQ\01H )H"W*YJ$@#2D8M$%!$>>+0#!_)L^=QQ8_@/2&_= < M!)@-@/WL\9$H6VJ0I%HIRLOA^1%W-HA=;?M6&:PQ *%F)=U0+D%LZ MBCKT]C<_?O='C?3?UO!]\^*GN<25.;G)FKP]N5?-UQ1T)Q>5::,]Q=]A)CZC MJT4"W;.WG X+FCG/(WR %[&H"=>EH8DRT!:D,M1[K3SJ*AGF%QEJDP$/@$+J M+Y"HPLC $*I;&QW 2I!M.^.=^(ZJ?.K=W0G_UF9M.I_B+.;:7$;!6H6W[K@O MOG:)F\N[AQX;9ONM)7"M;,%U8#LS!Y*F:!\?P?> 3=$9B4&UB58: YO.8HAM MK\2IF2Z%<9"LF+5QA@;,IR"X5D8[7FH5MKNF+-HW.$_$$6Q03Y3ZP)), M>S(E??GQ73'H8,BTQ,E&3U!T ? BC%=/,/N#]N])N7)U@J$N_^80SO4.5 [/ MY5@\QQ*.\#GPC:7/NC0!*1W>A!"B'(*(8WU.Q3XXR0#8_Q$_"()$/HKU,(XI M$]!COR6Q>_@#EM" [SR8JV=>>>O!^):$Y,Z#"#*V0Y*^#'"C%.$9O2%XRH6#*2B+C.U+^,3L(^;/EV<,0'6[=NR-Q$&<\MZ=/(W]Y6SH^JEYA MA6JE4:HT(G'/3%P+3\(XOPG'A :XHRJ&+*!Q%?4,4SNM;Q3!X!2=PZET^KM[ MBP@^@I;][PFUP5I66I.MW10.ZZHH9ODOUX1AQLE%+?_0P,K85;F2KQ3*^5L, MAC;5A[L\:KU]]O.4"^OD2P@'3.;WA;9KXC9/]Z>NJ(- C]FYCU,2/[)I48[P M7EGHW+F3(TUC;,\A._+\MTSO1(^:91WT+/C('W'AP&G]2)U<7(UW?\:W,6O8 M-T/F# 'J N%[S'0D'4/U&!L-$R]H8VF!XZ4!X\5MT[J/1D?B90'=!BY@\).9 M>S(KC2\Y":I$@-6[ .A:HO\2_1=+:!/]%V_ZA:S_F(7ZS^4(*FVLV@=6X[Z8 M:4(FT80QXLU$$R::<%^:,.U3$Q8XK8M=2+-1!,FFG!?FC#C M4Q.:=6==11* JMG-=['2NV&VEH^39LPDFC%&O)IHQD0S[DLS9E')N0Z?UQ5L M@8KTVDF)ESK,)NHP1@R:J,-XJ\/)]C$5Q^WCCE5?<\?)7,=4=LXM#%A1U'C# MO%[;;%B4ESEIJ(FFXSC1D4B)6J<5T3,/0#.D>.<;R23,3K1GHCUWKSWIN&I/ MZN3B'AVH%J&[B/I=(D4(OY"E13-0 >J\BW%T+$[3GT#.O8@:F_Q4HX4 MF2C'1#DFRG'GRI&)JW*TRG-T59&L*_YJJL(# >G"1/,EFB^>T!ZN,Y)P-QFL,I5L,DMQ&:4^:BAB^4=!9EH MQT0[QA3:1#LF.Q"KM6/VY*((VIRY]?K81Q=D 5E45)=63#1@H@'C"6VB 9-M MAM4:,'=R<2?* /J%;0#=0=>6:Z+Y$LT73V@3S;=#S9>.J^9C3RZJ9G/QLFRU M!!85.=%YB1Q,E%:= 56V+<3F8DJBY1=8FJ.PSZA:WD MR).+.AR7TV,8Q2YH7[6_B\RV[8"\?M=\ZARK]LWS+V=H7/NFK7/L#[H] _[\ MU9KJKVPG[T:F@\9SK#'LP_GS*M<2^7.LPO6 A>J*@A!(3?67=]XR[[E(&O9_ MH8;]K?':6A,U&=MFZY.KB.SFU_:24-GC\5'YAW<7["BL/;EMRI.$U)B$5O!% M_EAPRCRA8%1DL% ]/C)/PI+GF/MF"BAQA1]1(%30:H8>\VBA6BF6*O52\?@( M?JQ7;\O%?*-4Q"[SMU#KE+#ZKU(I&O<_;(\#5X?L UC0JOLLEKDNSLUW-)%K MDB39'-$LU;CZ&+9XFH>.C=&#< _-1\XF*@M++>JB,=U\%_OV.,;S!D<,_/E3 M$(ACTN+,OXU41Q28PM%2'X_JI M5%[3H'SD6^A*6%YOBI?-43OW^J:P[.^G8?=D.2MOD:&9 =H"PUFT-XD\A,6* M0;P9PK=0K1HP2M!X$S0]1]""H:J0M29T)4A(V:?G.^WJ[>I79T!M0-E%Z=UY MB.W9,2ZAZA94)5U413U#\[* _D$5QQ^Y.6JP-\)O>3#LW)'AR+&CDRQ7 AG2L3W,H/2"!V.@UJ>H0)I''\!D);/X MLH>A_EF@KJ$J*)%$FE:')31#,4SF8S>):D@T.T MMV1G7))M]>) +O*D6M;6GS/R7/C5[I;_L,,["@2HO;V$>'Y-$R@Q4?X FFYZ MWYJKOC=8S);H\I8E MQNW[\#QD>5U[@-XT5!QP@16@>PO39;:7?="+R@?81)@V-([SZW,@QM0QR#@F M WV_#+(,CV$(%$GAV70:9]-43"5J;81M*5(0822=P7/T:E.UB4Q=NF2J#-6] MK"OJ$*YH1H9$(5\1JV)Z .A0#=+)Q1B(_9+9C8LPY(#!28K LP034S%8B9\M MV3Z+LVP:)W-LZ):DIH(^)PJE01_E%KU-B/&G> ,*0RZGBOLT(3:H&+!@W;,K MYHFX4&P&3M LGB:V]2JBCZ@MA8;.L#A!K0X>-Q&90A,ZD!KD\%2J"-H KD%H M< ,S!>4M,_=WU%^1>GZ@ZN&:C'E!69@.=@#'=&Y@9:Q\Y5Z7Q\NK$\-^&6N] MD9:R7J%:?#Y;0*=0XB0">OVK/90%J6V_"/JRU-E2+Z29+$Y1JUV-C/[U6Z_>?AO?&R2<)Z;1-++3"Q#47G)(S?:59[ M1<#AQEX8LLL2. WEETYO:SBBBZ$MY2>3P^D,U' AQ6#4E#>J]"'7#VL2)^MY M64!YT3[*P%DQ&5F>2,R?/U?*Y4.=_VPS.T\2.F":&7[@P!B!?,8R_(7CFY(L MA;,$&5/961M?6XH2R[!XA@XGJKMRR=$#X*22AHI'RN,DMO9;$67]#_R$ZMQG MI.E3:AE%CFXIM9"VPK?R7">+P$09>T7KP#ZLA1RJD^1PZ&I*AB/75#:#PW$2 MGW8GY-HV2XJS5!8GJ=7[-*'ZN$BGV,ZMJ50>GM*WM,05&TPG-!/M[(6A.,P4GLVQ.)-9;?0],;JY M2W0!;+IQ6L>-W0"^X;.Z-5110N:U<67+FPO*-BK5@GB_;K[ MI&Q2PK5^P9XT 2B*&(T6--[T93WJ$6K<$.T)SZ7$;Z^?FZ.J_JM6O/]--EI2 M)"H1^A:P&V)\SFALO)<^C;10MEN1=\CL?+-UIRC:-DG,YG":#&?SB)B6%-4 MPKQ"M(2EWR?ZQ$1DGG3PVGUA^M71)F'Y=DDN&]+Q=BONY(7W7H'BC# MF 6>%0L$0>(,$]=2N/70MK8P+4(;A><8M'D=3NJXY!*LH@$:R@.0T*&H&J>N MDBRJT2D5*^\UV=AK3<.LD&'?5&L)T#JI^O![1(1N,7+#E3J6@&)'Q%3DUD1: M8#*'2JNVQ]KJ@NX&-P#+/3ZR_/PQ+')_U$9X":!%DE66>:4'4*T#V-;5"X@? M// 5BK,'?;U<7&7&+XZVW=*DLW@Z$XZ(N/=AG"J'!_ !9&.!E.3(QW2NPS&\ MOHF4A+WW,JX:4JTU''H&WYMDH6RR9&BS6X4W$L;3UN:@T2>"97&BEN5XB4U%D?B[53%TV1ZWG7V^46N:DNY B/X_- M!@6*D0[47I)W#L2_C9+BUWD=SQL&XK(XT?-$?RTR5E5$?/G[W=!R+S M>31Y#.=^I-\LP%V(NU".=K,,GB%WGCN;ZNZ3T@"?$@>IKB@( #X"N8D2!RU5 M(DATTZ,SLJN=YE+4IH+@97IY FN*H70:'\IM ]?W:5&S.E G1;!8Q# M@%Y'3FNM9*6^3Z'RKF>! PW5>[7Q"8Z9D-*Q5BW4-ZZ MQ56OB70(TB5_C&%S="]]:")+WQ"CG>R-;:96OJ0R"<,W3^-IBH81^NKH/%$= M:]%E^ZP)XR]K$J"F<&]>%)1>3[0JV%&;*KA . F0>=$Y/6+Y(J/[7+KTNU*_ M>M3Y %T/7U6<+A"M;FMN(+%O%44'&/L="SE\)#/KAX\;-9X]QP11ZTO<\ R% M3L",(%9.N,,XFEP5)D4,$1YWMNR^$KF>5!X'G"$DION;6-M%)IJ=[I'VT;=R M^KDY&JF-AUY)8X AA-SQ4_?3T*F L M7%7-UM""N: :4.M=3@5-?MS?N"_ Q>BBCD!9.FV?4[$/L]'@Q2P Y&8 6%V$ M-P)@51\1'R $X"&5*U?3MKAFCJR%".!ZKL)B (D?A.=9W+DO;&5I_C,AP3DV MRP/IA3Q@39DW]*ZBBB,@K,]\&(YIYB 8-QYEG@NI]2!8B_L60+ &E6=A")S] M-F$]7T!MPW(.4&D4R"X(9I>SW!S:YUDOOX+P94TS-F&[,IM0O6\QNS(991X$UO_:UU2W*]:^"NFS:]]L]NFUK\W9UNHC)&HNK$0( MJB5H"D+X@T=3$%#Y4D7K*2MOU65)D!EUNM@9XR!WM[&I"R#,9Q;>>Q!6*,:& MOJ49&NP4L:?M6'8F^Z'("Z,&^J] 9&O455D*Z12K=P"!8%H8,5#>X*\=+K@G M61(?S.:*_$SG92\63;>\>?KJ"?<8"FP*763C@)PWK7T' 6X:^W#Z+]>8;A5+ MK>WA+YEP3]9]78B",*2DY=F'Y=UGEU%XA6OO05T_OOS<-'X<>8^YUO!>%ZPL M*FRT"[^5RN&Y'(OGV/79"/E-LP0E?/*-3ZVPB&_H=?C&YUPA\4WXOOS:?!,$ M2)!OTND<3GAV'?2E?K;UT'$,CM)'UTE_ &G/#=EGO=%0NMCF%DAI-/8' D#0 MECNR%DN&4L3N-H=YZ/BC@3FIQHE"62YP?5'GI)D 9)"_K3W=7EW2MT'NNOHL M:1Y#B*'6WBE1QG@+R/TRP0+,A5(U0>$$0^%D.JX"LPZNMJUD8"&>LC#8#?]B MG >@LJWEV*'27^H5T20S7JIG>'RK3SQ M#J>2@T1^: MLT(M*,SVV5AS$8ICW>YU%6&3SKSQ)E5<>O:>FM>?PL_'1S_[ZY?9]CBU(\HI M7>F?8<3X3P>4R3>6PB V+.<]F63P^KL"=1J#/( 45C<&?V:W.IZ+J -P?,3Q MO-*#KZ,+J#%9T>$+N@*9ES,$$46A4!0$=)K7_&1:=S,X;8LR)_.BZ5/"+WK6 M5>?[1<>KH>EB>Q@L4>$Z_I-*85\8$D9/*2 Y_EI[\R-Q8A3T\%G77AS,':.-89].']> MA2J8/\=:Y*XF8>?K8M"]?C(].')*QT?P8[UZ6R[F&Z4B M5F_ ?^Y*E48=JUYAU5KI(=\HPP<. QO?'AW#_WT_"PI8Y/QI>2=4IXETDR3I MYFAT+[[6NJ_IS*]7: .,'H1Q:#X"+9GC[F IK##VC0INWVC\B+GQ7.T#E4.. MOH:YL'NR/B;]&:&3V0-N4P?GSC'O],&*KE9+3VQY''I;)SL%5X%H]N\)-2$$ MPV:;9GT.2IXTQY4ZHW(G5Z_3[=H#EYFUS4L\K!6G\ARI0=/XS +-C;A[W!!C MW! V;D9_7Y[JU[^)%S84W!"QP UE<0LYS3?$&_/ZE"7[GZ^O7YAO2A:WD--\ MTWB4+U];#:U2CC3?^#ZZ&P55%H)V:G15 + [^'!7PTK0[@CCDJ:H,E\(6*B+ M@S!Q$"LFH[Z<*HNN=HK+_;^VZ!28=TM,@.#Q@&1@H M?Y9OZCB!QC^^-F_&8)QD5E< M+D63MR =+@&(,0&(+0G X##HP:GLZA;Z"0&F)0#]OZX$\W%3MV\"K.XA6% TO=JVD='L:;;A>BXH5\,N\<(HFY2G MK*ISF_$?$ PHG_9%KB690GG(A@U/0_^!3B>]1 .G46"V+XVS670Y24*C,.0H M*/.8QK/9#,Y2(35[_JHFDU56FCLRD-L]@3 M65,4#O;_CIJC=DNFGLB'0:W;BE+1I\UB)O18WP3_T+G21:F0+3"#Y](TGLTE MZCU@$@5F@,D<3F08G,V$5#K^=4D49'A*XAD"NDJYA$C!RU$PYI=D<9(F\6QZ MI]?LN>\,LPLRY(YS%=+DOK#+YJBHL8+X*HX>JT%>K3],! MM0"=*!@#OL#4.XUGH%GT MGBHFT@"G\EVXSB+X )+21X<)/-5[]?>#KFH"62[LK"NQEZ9W(#95O3"!>;_L MLA2/X6IY!L]D6!RN(J:2MC[J M/Q62AE%!-7YW,CG@M*OV?P7"Z#4U1)9<[00G>QS!T"VX^"6- M4\F]J[N4MZ!,*PE=Y"R9;"ON4.2",>Q,&F=:NXMLC=P*PMW+ ^5>^>H%ZY5)VFTL MX70:=9))I(XPRUT\:LGE5! M99E7>N!6T314G6M=>8_L-;+3*"2O*$_-T>5;[HHA_SX33)!50M-&FE[/2%MP M8VU(&,=4*_+7,=$3L@5MI#5(4^"E6V 0SI(XF4F*=D,BVA8&>R'1&#Q+0"\Y M&U+Y84*TK:SW(K)1%$Y2&>@>AQ3))63;PI(OE#4:QC(9G*9"RGAY&W7WA7$5 M15:FUV][,U,EO]=W1)?OBL6.)(83?'M4_^I= (&V3/8W.Y[^'L6ZT@2:N$#C M+0YIESB446,4H.F6*)@\.-YI>OQ;;HY>_C3>;KC+4OFEN_-J,0XU>"NH- B5QLGQ11U?06X9 M9)EPRKS<5]=9ETW< ;VK"&7Y ZX053L\ #CD" C7G"@C9ZTJ%T6MKVC6?9 3 M5:U6_G+U5R8]Y"-U-8QS2AA"CWV3(/S?,4A0Z_X7K&>N%2IX9['P(_:JB/## M!_S+4 ^^J\>Z- _9Z* +3MDD?;$/(@984X!NJ4UVIN>(^&TWHKA%L@-"^^]) M:LZYH6',[,/^^";H]_C3&N+CE8F/.8E!X@!V*\E9'_ MY.1?A?KM8R>\ZL+-Z@V6YD@.E9<7DB_LV@,6)ZFDI#!4:@5G\]D,GJ63\H-U M;?[:PA6\<2?1CF& E$L48DC'O4@:9W([W;G(3J5JG=T:I_>H*!MPGLEM,I?F M!6?67K MU\V1)++4@UYY?V? +M(*"W/!IM&W[G!S7 =+7+?J:C0J++#J@66)G#*1XND MJ*8#=TN#,(H0TCA!H/\F-/ M!R'4%)!XCF1PEHCK:?(]2$(()0(LC#QRY+:; M$]X6-3-G42$6;/?A$L@ M>"$*'",G_% /V1+([K3"+'UUZH"/FCF4'O-#U'[ M D?I%A E[!8<) .U;_90:HFF;DQ,:8!/B8-45Q0$ !^!@D")@Y8J$123GLQM M7Y,8 (%3\41:5%D\L%:8. G=O*P/Q1H/>OEF\FQTF7SU10L5H'O7GX]M%-_J MTP/^^2/;VZ2ATP;%:O/VBK(H#&&=J=59A!QJ0Y8PW\,$Q6A)P-=='VN.XB__ MX";)KJ(T%O6"QBD?/?\\<;VY]!XXJ?8;S"6T6E.L@@_ZR"R>R4';N$%F+Z'6 M[NO'_0:'&]%J]:&P$J?*<%BM!M1ZEU/!):>)O*MV/( P\<*9 X-1.T1LKP>1 MKZ')SJ)89)Q $Q=H5I^.\.1NL\IP]&)PW!,K/M]?4[NJ+CRY,.??$)5S6G#] M(A(O; 3J[Y4K5],JKF9.I)U<$#]VW])REQC;U.U:AK'T06-L<^=G&^E%4>,E13-48.ZC3ITH;A5(]CIW Z/F M@*MH+AP@,-[ :",HDG^X(0LO>R3>P84#G&6F@) MT:UQE":5P[,L@Q/,ZE8GT:QOV1ZAP?@\8X1F\72.PJG8GM,.A$,#<8AE!XG MX]87.%8'JM@^1U=[=D0YI2O],XP8_^GLXDZ^L4^+0(R?]GK^;!ZB6>^-%U $X/N)X7NG!UX>HZ[>LZ/ %78%LQ1F"B)(0D&$%5--H M?C*KYSCT=5N4.9D7.0E."[] A[&UF*/#DZ9P&?])I; K$4C"&5:#,GX.GW\W M@,R#,XPYQ_YPD@$_45@JY>@=0?SP7XDXL\0,\FI^FA('UR-)MM-CEDZ@OR%P MO//W]!S0D9*XO@9A<3Z=8Y^BH'?1ZHE_SC&$B90FCH#C/"&_;X&C!@G@6:'I MK3PLQ$]-!Y]UXO5"N NXM99TK.\/Z)L7<;'4X&)[5UIZ8<2,4(=KBTVAKU]TKDJ]M M"'ZV+@K5XZ/__3='D>0Y5BSGKRO5>J-:!+U$ZTT4Z')- M@DB/V:Q0K11+E7JI>'P$/]:KM^5BOE$J8O4&_.>N5&G4L>H55LC7?V%7M]6G M^F%@X]NC8^*_[V=! 8N#AX+6:GTBGJL&3T(X]!\ M!!HMQ['!4EAA[ 45W%[0^!$-4]I8@=.ZV)6D?&J8"[LGZV/2G[TY&2=O[ D$ M4>M+W/ ,NG$R?-0[^;+B.,#27073OGV:(0\:3A(6'G3S#,;@*A#-_CVA)H1@ M6*:)@DD"_J=I?X__OP59LWP$F?* T OJ4'3K"HOM4][S(VX M4]R4$$:(,6X("S3KS3_1.1FU\'FHI"KS9*([(#>Y*:?_'EWRC=O61 MI;SP:EC]+[6&\@#@ GE1 E/+;BAK*W""A"JA:3"Y]?N6@W* M/*O.>C!Y(M'P>QZI=0-%8*+LJ=.3FK@-E3JS_LWEU$37/ZOM3./I\[/TNNO> MHCZO*-_/QF"<+C2.YM9J;.X5WD3F2)?,.4=>@%!0>JA_B(>4/=S_^<4*Q=[M M:V=_EP?#D%97^+=4B[.V R? .M<%[Y=CO!$9^L4;.,,0.!W;$LPUL!:,4LVTMC;=PT2[AFG0&KW,2J+:M/N*3#N(H1?,B 4.@8M\Z$.CO5O2ZZ%J-_?+,2JQ&KI/^OF1O1;?BS1"Y\S[V\PCX M[M^C; -51=&'=V^^*3-'$)_W_9S>W\ M**#/CF T0:_H".:![[E^7]LFQ&I.1\YR&'6E9FPN9O?X=, M[?[]S\?;[BW,)2= 0K?T:+ALRW 6>GC$0.6W=9ED;# 7W#WNT'6CM^XMO?H, M&E1U*H!^:1%8_[KR5P6N+^J49?-42,W>&_\UCM:;Y,;VS=*7A6ZG-P! M&LI)<9H&=,U,0T@BUQ*E)"NU#2=<+>4$A],? _$#U3Z 7F GO;CE7:V5GZ[ M'=[TP^NKL$C+.O"A=*8-X)X]33\X#%OC9C,9/,=NTM0E]'N3P\)><%H7.NH4 MGLMMTL)BJ;.^7-!J*NASHC"Y7VI&R+0[OEXUGLF;RY!ZE?J3-QM,QZD)W5E? MFUVF\1BVH&6R!,YD-XF*HR=H/C 77#R,IZDLS@8O9-FE0H;B?5E75.@OS$L8 M3_\B\W^-/[W;36Z!]6_&4'=Z"XSA?CW;I?C976()SV49G,E%-SY86Y)6H3&X M]"Z!PY@^AVZVPL+>-CUUO147B1,,Y$\JL/.?"Q->GDZQ:DPMNL8-G>AL MDO^2LW^'GY=TIONWN_/(K.Q*Z6)]"[K(R=Y"/.[,_*59 J=S6^P,A);KI9@] MY7J+OC(2-J%0H8)%Q-M),FA:"HI_GO_^;7T,:X--\A,!&:*%!<[C#(8M(U9] MC;6DN3!K:4'R!@W1(W2QRP9D#MU,XEDR#:5S_9LCHGGO2QS)&6 I1!IZ/7[* M1P*\CX;>J-A_=9HCD5-OB,%0%ZI!5GM/*R]Z/>6%BL'-@M&^ MO2JL-<2^V=6CWY<>"3A4WO=/YM +IA@\PS(X2:S>3OYR^FO5Y=;;$3'X8(-F M:);Y6]S])$O_BX)UV62 M#7+[T&/KPE#Y+G1&S"/D?1L^T]L&#G![CD_]8S%LTT'G2)S=J QIW_L:6^(P MN!T.(HU3;. 5?U?3=5 \ ()Y8S&J:H2+N^-T0Q7U8;5]QZEOP.S54 <\^L[V M*RUW$LG=YV>/HVZJMS5I9U4<#L26,NY9P(J61/;& +NJ;S%M#/S>JX#6PW7X MU? 4E<:SV]?+;>*^!'!_]5@"1!E[1;!B'Q:P\?>]O26M4"T^SVOO!03;W>XDR>!I M'[6+20 5%!4#L\!91#IBM04.)F3RD>GQ")FL3(]S,;&E>\;YG@Y%R3?%S[K6 MWDG)3["IGV615GRY?J.L@0?==W=)*X63Z1Q.^VA0G:BP0*D9R"6N"ZP22[)X MUD=P$8QJ(U>KMBNK2^W";!!QGQ9O^?HM_<(%Z$YME )J.Z F*:"M7>W"@FBT MK&D&1#*HM@OF);SF<>9Q]%GZ^] <7=VR[?O7WM_[UB:E"0%$GQJ4,11W.M<$ M(Q!##HG21.@A413B8T_JA[RYQ^),ED"7QX=2C'/E"BE="RT-@,J+&EQHM8_F MTO*R\,2I*F<=1'-QN]+XDR^\Y]JEATUR+6OD.*=8'-CP(397+ C-?.>G#>-^ M6,8*$7RB,>PT"L,P>(Z-6^N.[5$8F.2Q)(TS6U]_LOJ";2>FK+9-=>+HF(*B MZ=/I&U/>TD3_#T7]O=;ED&I/?8=)-MRF"+;;0$6.!X^ WI/_[-M695;8JHU< M[CEKE@0=WML77FP>=GT,D\[BK(]K=X*)*JB-HHI):0R2\TFJI'#]J'[^OAUP MX37'"B(_LBSXB"]/;Q1'>Q W*L;^RRFE4 D8G(9"%QRF\;2/+C0!EO"YG1"$ M!O1?M(?\ >-'\UBJIJLBKP,!_0#=KNDO7$_6H/%7A/G22%XR$*RE 6^><7_@ M=%""G@+*G%B:SM1P5[7K!LGEU>X@I%O_YG%C=WHUP43;4*8V0_&#^0%,5K;? MT'.W1 E]7S>+4VS65\(V6C%)A,@1G,;)XIDT(D@X33@*0:F6,8**HM97-$ZZ MAM+?AV^@B]4A?D39 ()=O B#PZ98;XZ>B-OJR_VHG)BA&2P*^&LZO.4HL!&CK;CT$3F49G/#11\23;INKSH3LVUG,;W@N\'$!$@?2=$,U=J\=3;W87PZACN*^^?1@F9U1M:IV*MQHE !YJF-YJ@F M/-_D>M=9N;"3KK'DPLX"%FP8:E>T(7KG-)27^O&Y59)ES(V-E3OZ 7!%H&"G M-P7;FWWRT\?V)PT57!S4D6]O1A]/[:H<7D/6Q6PSU9 B7-99=3QZ!CNAG^?! M&8K&LSZJ8:/,L+E@&?9R)HI YJ^BR,BF3(K\9,$CSUT<&Z$I&UEC6R.& A^7 M17*/9QZ7F$M(^)1I,EW5N;+@VI6":Y$UBS.2HK@-V8J=% O9W%15:YRJNUC+ M;/YVIWP H:$L/2G9''%R_W?YD?GS5&WO06/:H&(]!"NZ'I>33N(NK77!^#X MB./1]4:B,VM^\#Y]WW@=L6"QHX;7PS>.SI]Y]4"KL2 M@22<836N \[AT^\&D'EPAJ7/L3^<9,!/%)9*.=I)$#_\YZ5G%I-!B1^?E[E/ MS['BMG3[6EQ-' $+&6B:A395K MB?PY5H%ZU\)J14$(3+M?.G7>0K],=)>CMWZ>0CQ[H5P%W%NJ!:".A6/W38JY M&>AP,#RKU3TQXT8H0K3%I]&6PY\M%3O=FS:-D:4*5/'_;%T4JL='__MOCB+) ML EFB]B<("KDD0F3'5"M5*L52IEXK'1_!C MO7I;+N8;I2)6;\!_[DJ51AVK7L&_JH6;7]7;8NFA;B(J>XZ5[A_+C9?#P,ZW M1\?$?]_/@@*VW?[4O!,DTC"R(TFF.1IFWH82]=*ZN46GH(P>A'%H/@)-F>/8 M8"FL,/:""FXO:/R(V4##+!CN*A*T(-K_N+ZB08ZQ+K5S(?MD?<3Z,THGXTC8 MGD 0-1@B#L]0T@$^ZAVSKMC]] K^7+:/=6]>>89\'@F3!>4#:\XQ 1MB WW] M[PDU:\:7.&,K$CD+Y2K/&OU=_WQ[OU=V#'YOA5!6^1%_?M7)&"Z.?KX8-KW-\6>\?2V8\Q; MG+)SM+OWLI9N,QV2RY[9M5*OHBP[1[MR+NQ /E*>)[8?+\K MV\1;&WL@&')!4J*<8#= [/*\T3,D,]WC> <)?H/#;T-!53)3J3,KVYH8X"0G M<# "E,3ML4=NPKD)Y\83N5\N$Y0D:@X(OQ%(QXP34S31Y-%9 +^I]DT/]&T MNSNKVX^U #>/^O_^U7\IW*5OVJ60;GJP]X'I[#\K5GK)2:B=%<:9.]9%P)N) M3HPF<0R5K2Y LST\M6KT90PT/13YS\K>:/XDP*$-FRNYZ6 :ZZJA:SHG(PY! M9/ BG9^-S#5V,EN5QT]U.,IT:L()IHLZ6H>-1-C!Z1(EC_F\Y<&%B/I=9B7E;?:J6EO+0GH=,FET)L^>VS])MU^?> M1['XI+PP>B=4$5YZ0&UNR$S@)SKD2H/##?!\LD?T+Z^)!^:2G"QFV%6)Q$';CH3,(*\6$%[WJ& M+;JPI4D"W<6=\$#D>6!3(F(;-X&G"J]5>^$1>W6=JW(\9"$4#M?&V>A6: MQ[(JX-/\16N._HZ$I\O1:TW@)VWU?)5"KQEZ7]2,EB3RXZ;B."8#CR[CZ)O_ M<[5V#N(0]0JO-*9'O5?&0^&">YA(3: Y#&A6MT9>H!ZM:,ZE'V]&%8-)CSY8 MXS5Z^M$1NT2D$ST9(>E+H(D+-*LO[5[F1E;U+DH!9BI#HYK._7ENI,-5D077 MU6>8:,*$O'?G?JCQ_5&)/DST892D+($F+M"LOBMYJ=]H*\1.][/P6.D;3W=4 M1!1BXB@FBC&"XI9 $Q=H?#1G7N(HFK_9-STZ5S\*S='+(*,QGT2G\FN3_I/^ M;QGU<=AF7H=:%Y"Z?=_&.]-:X4 M\(M\/^HPB$(4AEI=B!($X7;-/;Z7/W_C\TH<^$'_HA:7&]CGK00EY]6M M.R3B>L>NV4G;>^?6\FK;90NN%-7"2UX6GJQ\FH,@K3FZS&2$/^47HD?2H:;X M%F-AA6>&&MV'NR]B8BG5XJQFU[T^D#7.=@K1YX-)844C+_A5L)U P$FKA L_K:NZ61 M >+E2\3L!1>O7ZN*!G5PB[HBE&SVD_P4=W.G\*IN(PM$,Y)!WB03?.D[$[R$ M&#O8NB&[:J5]\R"Q&>XD2&T82+:!R7WI+1N&2K9L0A?4T@X%=?V-FRQ9; _Y M)Z(ZDG8HGEMLV"Q&TEZW;1@2S[([3$Q%A<]WGW7<.P/,']RE$KK'B.[A;.'@ M:9+"V>Q!JP#??D4ZV<3Y*F*UC<#0.!QIWYLY/JK?3$Q9D8X&(41IQW'44P<\ M?!+=E-TY<)\=%\9X/K?NB9%KP[[=B+N):-]G'2;1O3+"=0',8T*QN9E$! M>EF&K QN49Y1;/;[1)\(\4C-9OV2(928:(*Y3GOB[7M7K6Z\'&38M]YLVT3, M"[HY![F8N%#$;U(CP_A+:NR.B"M-8D+E1.XB2Q'?KI_S1-7=V@NW%FL5S; YGL[Y;L28L=3 L%7^>\;Y5)6]7DC#C2I(, M/=?:=^U/(2&[?3:I^:'^W*DS3(>#2 MNX'XIMT^MXJ=/KOR?H6P*NRRA]D485%GZM#02&Q_R4D<\;Q*S#(!B=GZA7/, MD('H;F<;(S)XX0K@QI)PR]VH')[)I/'L81]:#DS*@V@Z'UKYFDG+@^X_$&DZ MAE*.EB;P',GB)'70]6B1IFNPP2B5QAF"Q3.'76,<18)N' IF8+"3Q:$'O.\* M-[\]F1>TVI/^/(+&35GM;^JNY(/IWA1HT7A=!3?ISGV95,;JM]GS< M^1A']>=[^4FKO?!%-;L345T_\+RY9Y\^E0?C\@8<;JL]9IR-S:0@XL()8DDR MA]/T04>P43EEL$?:SY\\('W?M9F0?*\D#R4TIM@TGF5]7[T71Q;P[4=I.G(YCZQCZ;]?GL9A!K$=FOZP].? M3/'N08Q>TQ'V:P>O;!*\1BEXW5Y0UP]AE5]<6JC6V=+M+GL"[;3IR&X"6"*- MYY+N$]$\)A]Z&$L<])[MP1$^E&"6I;+0*SWHZR)\^Q5),/MEA&H;<:'IO8>T MF87G+T=/?:;SMY+[JWP*R2',:0\^MM7IR1&4H)1\FO 9/":',*-(Y43NHD81 MWW)'1DWN$B*N3T2?[7X3(NZ!B(M*'R-Y6&Y!B!MLR2N+9W-IG"+IO9^EBQ\W MQ>_\94 !7F1XQOO\97:#\Y>EYJC^JY*O&!V#(C/A;%_.HH'RP=?3IS-_&S+ M:,+S<.8VLVPJ/>;8F* 8+0D$)#X+]D'GCYV5=K''F?W;_M67KF]^\<+* VAK M8BC W]Z)2@CGV&N*&*Y7#.E39DEE\6I3!IG MF?TSBSO=$LJVN1^:'%Z-A^_!OF0%C)\LZU>H.TZ8*\%.@IT$.PEV%N_\I,VT M'3&^PY4P[W!=V7ES^-CZ>%"DE_8SM;_.FT7 FT&%W7R39"/)#;XSJ'5/4@2\ M/:,UTG^?WF6U])>.8G] DDV1U'0[N:4+VBYMFL8S1-*X:D=174BDG<]B^CY_ M\H5"5T/K;.(_L'[7%*?2?$8B)Z@GT4%P6IQD*9ZF#/A<7<843U!DW1$O? MR:6$C@'3,9S^*QD\D\OB6>*@3ZT%1==OH1!VVST##<+_[TEJCK0,SF:R>"ZT MKM#?#X2J01)U\PNXLW061H5[;T]:]-G@I0(^S5^TYDCHOV<_LY>W/7Z3>LB M6I+6C)8D\C ^AAXUA!3'9*"C:-GY M),T\WX^?^L<<:^(5%R+;G &;Y\29 M:(G(4RN@EZW;&#T]Q5'Y?L2V\^ A7YX4Z\R 9$&PBMV6 >!9K4N,;TLAUFV1 MJT$" 4]F9-+9Y3Y;I)U]UF^_C0D3[R 'KHB2/#M*K!)MYO# ME*)MY(.D<"*W0\VX7]AMPDBS.L >]QQP1_VF7M)X/-0_[!L48DSB4()-A M<2IWT!3W[0;Y[/B5!)AQDIXM[I,E=EG!Z1U8YH.X"J0MO8&[F]YEL;_'ZRQ7 M=;N/)&,OJ&W ^;1_DH*($]W#B5II"L^1 M!UU/[=NI2L+6+R-46XD+M?=M4LIG-&M%.1J$L-IV13QUP,,G=1'50_^Z+O\F M!J^W?1I$9 _5 1G5J?6=V,S>5- 5Y-GU(G_;I>\=U-44VD&LVRG1::I4&3V6 M&==>CB\Z;.U3^SFELC'RUO:L CO(/'_,9282)XFPKF+&CJZQP71Y0A-9XB<2*#+J[8\;6/ MLU%FPE<[YJO#8!SOAM&,G>IFQJGNU5>%HH;1K]KSUDUM[^&T7>ZM,9R!$' M69D<6/<^OSX5L_W%F7'$\RJ!*P0D<.OO\?4SBO(VK(#2B E3S *XQS+D;;DL MSJ21[3OH=DE1ZM89XNZ:2$*%B MY67AR>K447(:=31'[+WTZY;J9MX!N[\SKXL:BR@FW!ATAF+78XG>@BJ6+[:+ MX')@#"X']_7?]$A5E&3%V%G^RAQE_^@Z_F>1D["Y.QNY(=-TC0/X= M$7Z^H831N0R%L_1!Q]"^?8ILW(HC$UE:4Y8VEQ(:9S([E!+O M"+<41'.GXH![?_Y='[32W4@ZAA+,9EL09XJ 5@&^G(@EGOXQ0;24NY-YW;B\7'^ M2=T=M;R526DGO8.ZAG M77^"5F=<75"X730RJ#9ZD,GO/?NR9AJ;VP M5&#MJP)-P2QJF OMG*FHR[!SC#2 +BNR'V@(95P"?VH/0X&;>^P+$Z4,7V.=;CU(XHIW2E?X81 MXS\=<"??("CAWQZ ^IGG9(*??N1!G<'VS@">9@L>1C-0M6VZB#H QT<RHL,7= 7R-&= TVP>490%="S1_&0&L1SZNBW*, X2.0E.:X=96LS1 M\;,U)FMKEA?A:OZ32F%7(I"$,ZS&=:!VJH-W \!8\ S+G&/FB0\HNU@JY2A5 M0?SPGVZ>66G&5&>FV,)E29*M(TQ]@_Z&P/'.W]-S\(HD<7T-PN)\.L<^14'O M(B00_YQC+L6!L(*F41=E5"$=/!61=XV-A?^IZ>"S+KPY&#O'&L,^G#^OGSTO__F*)(\QXKE_'6E6F^4"W4<*U<* M/SR430R76*DV2O7CHT85>ZSD'XOE1JF(%:J58JE2MS[5J[?E8AY]?56NY"N% ME2J-^"$@P7T/)2ZY)$-F)-].Z^/;H6-/O![!0;ZFT7-V*T8,/ M\5[[FZ1UA8FN6)\M%QMH/-='.DXUP,F,NWYI:#",T[0B?$@5G0Y!EYPF0C^] MI@(-+L,\4=F ,UU*T+>'2^J/T\%6$@E=N>,C$G,4SX0_3>Q09'/T*\?77J\YIL!T3BZJT#)]B'! U%#1 M1 S:TW2C9DSR_;/PMOB)AF4)@,HN?CX^@O1R^#Q"1+*_%%$8 1^BLC]H[TS% M5R)=04D51:XC*W 87L./C\HR_P/'..Q1Y[I0?:I]1;6ZPGS3N\ 48HHX+UB1 MFOD7%&E%'?]0+-M??L]R4(FVH,K#^BKH"#.MK,48_[8#LZ M2I0UZ%*;FLM,YUW!QR"Z4O>H5 T^ &=6(5X@[,A]:-FJ5>M!H* J@BM25!-J M"VU04_W \N;:X)?2$+>&$!24+T1GHR1# !A\UYY[&JBVHNA67E%%6A"AJC5T MH0:!X> &VQ U"$X):GQ/VIFJ' V!#"*""KX,.04:%O0S;@+."8C1S,>/C[XA M=A U$P/(6J#E2!!ZWE!1BQ<$FFIPDO;=Y!M1 &A-T%! OXM3APC?/>X-F%-Z M\A+"6D_4),"9)2437K)1*?S JGV [#_"#J01M*26B49#ZEUH:J'5DO6NA@'( MP<)4Y2&)2&M.X4 D0FQ"[\LTP1^.Z<*<84WSB4Q6"Y@=Z'C=Y@;TT!! #P&8 MY27'1T4X'MI*=#@O-SIJ794A&[,%D=PS"YXC) M#01$@N_!KZP+':FTO>*XJ\/#4.H%H*(]WN,C1&DF_ESY/@,FLMBCPTL<'@">G@HZ-0TH]>W?1YD MU;@V"F%-U>_H \NUF9B$A0;'?&EN:_0'5C>@.1A//'9^H'8!X@?:=K&!L8(Z M29$[*0E:71,Z@")%"7103&S:M Z,P'4%N@PH7PHG 1 4A&#[N+G.#<97F6!6 MPUBS/[J%!LT*M-/D"R+$MFI%M'I7<<-RH-KT="KG?1%""KP.H8<&B^=D/3^6CAH, M5!";+$I[I]U5T[X&:(ZXZV>^]C'Z.\R3L4UU4PM3W51S]*P]B(0,RL3UZ\E% MW>CUD*,.]94+0=@$0YB#HH-/>0?/LP5.Z^9E ?V#BJP^. DI$!.APP4LR[B[ M[?MZ'W+L&T^WJF2';;W%D&-_BA,:<8CFH$)S3 [I8!TCOD;M,%=^"". GF FC__2)J+<&+RXR,G*)_._T,0,!$A!TWIB39KL9@$B08P7@6"J']" M!ZX[G,J"0:KIQCCAA!9J']/!P( ' *4 VO!_38?S^ @^;Z",C21"?U2;APCE M3E FY/^S]ZW-:2M+N]]=Y?^@-[5755(E>R/N)/NDRM?$B6,[MG/]0@DD0+&0 MB"2,X=>?[IX974#B9H$%BSIGO=NQ09KIZ>E[/^T86'4$1A3\'H%_R-R37#0 MN:W*3;"0:=K034-_U-U(L-#PGVF[S/F$W^[ON2'=P[8F.8;[@*R12)"--Z68 M\!/7/5Z"K=ZP^D+7#J9BQC13.:29DK]4'_U]>+0>*G^+MU>5 M[5!'U?KH/Q&O@5+N&-Y[;]71P^"TF"T$KHA:! M1Z(&$I&XIA\W0"TP>UW,EP>O,J+$N#-ZH*,RHC61C-9T%+ \#P'25VV";A9Z MP>WHH&Y1'4[*_U"B>\0.T9WQ_W\67,JW9=QQ\LCCPP=H-"H%'X ^J'" &T C8:+*P*BY M[=L+A_M[1_ "[L='<]@^#=RY=BQB[6@2A!9/VIL"*YIX*_ZZH0]MU-,#W7P4 MF0R99=B1N_BV6,!$!&H2QH9&VM M5;1Z>_W>437]R-*N4;'Q.)U[Z\?<8TWW2LATG^O[]9%=O+?5:].\.R]MAQ5_ M5!]=F:?'P_N.XCZ57KT76]_?"S:_,]PSN MB6%:XQ/-6XKC(AH%_HC37A$D, M1IEM4*R"\C/2:TNG4)-JFO8 #:0W9,KRBIT&5DU0-1%8W5.'7?:_'E#-C1 >S(^ M>?I1[$NR\?^P/?LG2@6[L%4-3%=.)P2].I3@DMJ/&(=B]6?($^$U8LW"(U;H M8E0K\NHPBPPZNB7(CZ5%1UXT4@<4L#TU=*JAE0W 3_E/5*C4RC=E4#)?=*]C:T%F)#Z=%#:=IGZO/NK_^EKIG!9._ZC%[?!%S^JC M3Z5O.>_7;^]S/__J/=O_ 2- .*FT2R5E<1?7?6=_3Z08 M5-09]D^;-F\_9!\)2O)#)9*8*AH+^$>*+^.C_V/IG$/IA\X;.5C*(%JD )K M[COA_(5?#8F_9U66O#E"Y]AAH=0!7U:/YONZX%493>IE ->+N5N\L+0Q%!XY MO$;7):PH,Z/KX:H)W+Z1[MC, 8]Y8SR]Q"@B=*V!(F_XPL::G!+2)=&&IB!Q MM!/^2PI_E%H6EO!.+W +CT).^DI]U+TY&CH/OYU?Q2T1^:?U4>7^JJ#9?P?? M3T#D^UM_<0F_*V%+V(5_1/M[()]X[I9'&<$= &$)6(HTD%0@O6W7PA=<9S$,N1QU(HBYA M?FJ%7[):8A7D8CDGU\K3R17917Q\:8[;6)AV&^/\\?1N8WH1"[E6*\E*-1&# M>.[;>#[?;9Q*E]7=QM0(5JI5Y6HU$05\_ML8:VM-W,;IY%K1;4R1NPJULES( M)6(1Q]W&<)[/3\%1BYVK.X\,]]/1M3[Z4Z#J#[KV(P&ZV UP($"#RQ*%,/NN M7P>&NS;HB_M[K#!<]'QI6*B&P4:;L&'4'C,.7L+1V#B?XL9!Q\P;WIC8MF5I M9P([9KJ/$8X8S_N(^JAX?7YS.CJ]4_M;4KA\5A\UGZH_>M:%5]/:K]X+4K"^ M#)\0.P\DJ\<:/; 0<)*CA_P1<@>HN04<@GZWS^ A-+WG@/Q4_5X0M8M()B/Z MQ2$8(Z$_&Y@_!Q&GD; 2I0BNYZB(-'Y@@KO" UW[>YB%9X&A$SI)=$82ZI5I*9BY"-!<9/_J4WC_WSX-W!^?>C_.+_[,O_]7\TOV M0*[CZ^N1MT=4/9+NK=9W!N# NKHUM]P/Z/#J?0LA7!#VQ)W01"*K>ZOW5/"K M>6L2UOE8Y"[CE6%111X[Q/YPC"=B @J8''NEX'I2O0A5T#O\0:%&)6S8UZB% M"?D]0CL'::&'NL&18_W+Y'.XID; 21^P)H$8L(.@*T#<*RDBU&764]%%'B AC\RG MH["%E6'7 H69FAV\X,@\")#'&+MI."#V$/];7UP(KVPU E^"+L#"F.:A2ZZ(5FS=@/8VLXB[R[."A,MGC8OUXMT(A M./8>1G31XV*%#P'HC>V6!N6W;;C[(R8J B -)(.? 4E<(/:5[N^QJ."F1N.&_28:]?#% M6? 0LG80 9 ;*BT;JYXHA>H8%#IA4(DN. TN]@2^E5X;;X#%0%!&.ABY_=^E MGDD6GL+8!X)J-_5P&YN'H9IW\!1XC)#*_E-@.93EC7T:K$(\#D4ZZ%,R+JFL MN $D9[G'Y6]-;J[=#Y^P6KNW[!5/L%J[M^P5V_ MX+@Y\V\1.YMME/BJ+C HP#-J&X^\!BM0>*C&T'NU'>ZB,M0\JND:@):7$ V8 MH&%0[S?HHN(C'3!C0MHL8L\@-C 60[@$$TC%4Y"]FT\_RI3(\W W!KY]PB^N'X75.^%'- MG^=9[$'UT6?GYXD[;%GG$71PR/2[+R[ MK!YH<%1"=(* ZC*XZT)\\E'Z@8^AU<&!(L]EW MQF9\^(+7=YG [Q3QPSA1*9V._68RO.:(X 1W5 3F>8+GPQ)BPBW=R>*E9;&K M(\;[D:6=LG$TR&UG+$,2V\21CPC@F=^NCTYS^?/2A]\MQRALA]0]JX_N*J,_ MP[N[HR]G#0RK,2JPE&V($#OIF]6#C1Z9%AQ97)J0@F0B47B(8Q)"DRAHH)'Q M-&4B151T^D^=6G$2Y&,L*CCY^UVO&G/R7G;\'/]HJ'2;%[G57? M-74IKQ*$4#&2&$ZCNK=8D57Q0'FZ#IZ5(TC6;91U]_#;]^O7L\&=KJ M2])T4K _NP18KE;+TG^'+EY+\?Q$@>9\R]' MCAVDGLO_''Y7C_K?C1<[R)Q_.7)I'6.EE)/SQ<126R;CGB%N&"V5""VCI:,O M0$0E92(JLH)DK"26X(YQ^J9KP!<#]<=&PV-L/<1+#R=,YORUF$E[86'8$TB, M94"S06F7>%I]U!_\R=^;-]??/VV)07I>'Y6JCVVE<].\U,Q7[^\\N_EP0/V= M+%@G"+,S2+-ZL)&X*L*PMAW58CVK_EE*ZD %KSN<<$0(*[B9_@=E]C^2W>/) M4/;/ 0U."0:71+Y#@M"57O-AJK=WWUQ_FBK5\^!?]6[/M(B; MGO_<+I7\N0+/MF'#8@D?UP!''R._D]EHC"&$-]@,\6K0GTS]O40/AN >!6RG MLAPB#-^=G^3V)L#=V606\6E7V!LS"F E4?^*L9J_?<,U/%VDMGE'=&0A$[T& M?*8,?B!Q&Y%S"RV(TH<'=\V.C1E^]O<#3 U3S*9K:[K)HS4(OX2OQ] *:,.6 M3C/E(N$A;,K&!^/[)R,ZG&SX''\>H#\++P#;"L=M. &Q BW4'QY4$] J^LXN M5KY\AS7VN]^K3].CXDJDZR?^*_61U?O5_=6YN[GKM;9#\>5!\3TIWDG[BW)A M_\'V7=SZ_MX]CHYZ<66WTW,S]%P$23$\]2NNTYE:L/T@LY#,K?#@M/'''$K? MP.-T6!R;?4/V8],HL\1'_5)1@TJG^*Q$YN?"7W4V: V%'JA) MV\'A2FP>F$[0B W=&^ ,Q@!_,1@Q2V$+?$CP*[_8%F';+945Q^(G^,@U\;[( M%%"_M)SFG(1>+B)9HL:6957UI,JP_3W;,CF&!_R-;PO>3ACW_G Y.:*=08]Y M>K-C$3 ERCX:#>(@N+F#A_:@TR.!7[#\F!7@NL!(*A7D]GLV4UXX!94#B!!- MB#Y].#6":]]TSM^.^_N=A@Q0]9L/[L;K\40W$0N7$O(!GO\!._\#//\#.G_, M_[MXM; J+:@]C+MX_%Y&*M=YBP1"J>*?7=?/7EDZ'U.@2H]BG6%0U6CKM1N> M7XP6:QA=%>,0S)2EQ#\HT#\TDM-HVF6]X;<#QM&@N M@(?WMVUL[3S 3=L%#S6%4Y^/8-H#QXRKD?$*3R9_L<]'B&7>1:":0X3QP+2J M[6'@ 3B)% 2./D)N 8N\BX]K8^)L9.L5P0G,7D&&WO!ISBQ ML"KV D9TE#J@:"Q-U6094OJ88+OQ74P4WX[=/Z:60HHQK 39?H>A-H^8"^?C M^D:&@S./)_FR'TJ?Q-S-0#L&VV!YWW[C#T=6]K4&5MJ"?R*-*0Z:WOZC8YAZ MY/K[DZK@RVSJ5?@0$*J2>[EA8@0Z,*@?#M"EXH:I@AK42-]&R>UR->?J,& M^W!"D\SPIRE1RRG?JH_,.[NL_S8[)]^VI"6]4!^Y?[2SF^+QWVNE_.I]9/>( MQ8]3WU"@A*>1BAJNG1>7Q5V,12NU(";HER4Q;X2\#Y6::=T>6EMH*Z%^Y?TL M*/J4W#\HC8D$\:]@./L47/?%IWL8] M]7G'X.IUX+P?QAYZASU O!+P2O?$HWB7^!_;\6\9^R*CW,$!4-'_RSVGH6@G M_UO]<:(9G>;)=\5/_T66Q*8X]GQ"S5/23E*!1"8J\5BS2OCD'XB?'VWL+2#6@X!>MOP\7;))YX*A(N5S(N&XI; MRG_1-E;")9)F34*NF C--3_3;[HPF*-G?OZNP]JNZS#5KL/:KNMPUW48[[YN MM:>YAH$0',H=E!Q59TU/7(?'%,[X9GU4_5[NGIM.3\MUMB,T4JV/3NR!>W'Y MW?[6:+QZ#\X(CH)@$/>7MNN^03-#(FKL B$9W,6QZAK-_3V3WJ#9@<%3.K:)DP#%F(6!CK5* MF"IF,.&PDC[!#6-!$7[>E>R^AS!1]"JM3[A- O#!L+>U;VK3=G%JF'V:Z)' M2(MSD.MDM6 %WAF:L"[BQ)X]59%!] MG\:&6]*@R_#K!^+-&M+;>.15$.)?H4(./W]G#OT_(_Z,_UYJ7VRQH9*8#=+8 M"<:=17" 0 ]^M:.8+U3P,>3$974JA](I(VPP<47GE9 B[FJXP;@O]B*>\Z'B M#-#FP1_"+$15CJ"QJ4\SM.JQ3_(N3$82=RZ:T-?@$P<^>3?]7KZ4#04+.O++ MFFXB#IY/9D'YIMD]-GMK&*DG4'T49.P1 M,K G/50G@MEY K3$(B:$K.R[H!\C4Y[]@@2!X!FJOW.(8\VAV(XKEBSO[P5Y M-GSV$ 2Y_UH9G'C3I-^/%Q.(9UOA3? YT6YL)0,OT]-8!?H+2/;DUI$=3,_$ M+HYP=) EP='A.]I2V[$'7D?B(])\'C_[<.*W>DQ4Q^FF7S3JJ0_(^H\J!:T% MIS=T2V\9GL_Y9(1A:HI0[ R.D<>,0K\ZD!57P3I9I+SR6GWS.O_F]?$;\92[ MP* X8NROU H%&6\8Z$A\/H/-Q;V8A+M*Y<$H"^"WV*5 K3+!!?=OBW]93$*> M#>\7]D@523Z#D\W+D]IQS_('VZ'!&?QV, 9KA.8>/;WG&(]8L,5.($-5@+O+ M$S,$;'_O7&\X?:Q8R^>4,KL;J!"$!#ZZ^R9=V8?TUX-<7I8NT>-QI=?W=@]L M0##!X$(Q;O.+_,8 &DWF(R44V(FVI\B(1U:?#NH#;'7DQ@<=5(+%\C54>=? M66+X8"HIPYXOIEVH]5T[(M6P,0GPY0/NYX6Z MG+C*)>I@?DJHN=C547<;.Q?P?^A@2-$VA,[FT/*>W^/F4$N9W3KH![#:=.+( M ^/GCH^/5/5%>0"\>DFS=9?T.EL2A[L.B2[J>!!BB:TNV028>&'2G$P&/;[M M58.;M@L45Y0YG4-4*:!( ROX N'[^G30!ZP$4;IDPU>Y'"ODRV]\8P$?Q!\2 M& U1&<<8,0R;&VK)%+SI=Z,TV2OYO%?2Z5SC!@:H$2Q1O(P/A75C35>1629P M0)Y:/I1"2\=&&U-M\J_K3X;+!Z!<6!@FAP5.'I9AH'ZR=/L8$CVW:[:%8 M'%TU7G%K6-B@B?4><%Y!WZ1O7H2WSR3-\O)9FB:>P19\GGSV)8FOS,+R5)J4 MISPL%Y%%(JJS=CD;2@'9D<0$TPLEM#K7F&M3-284LZ/N&$.U%(RS6\L&# M>BH6JA@]AB#!+/"0[;"_1V&S33_<[6/1F#AAR$P+8J7A1N893"H@3U$A=VT+ M_%K.(ZV^I7$CQ)]-@58FED.'FS1[?1[Q[;LL9,5?'@,"$KOJMQDYH D]G=^: M>$RZ6[O$P]_?4]Y*7_LVVFE"J#ABX(C*[&?V>XXQ0'-+FH'XQ!QMX'UG1=;L MF& Q)LB_E:X;",A#Y0[LP#FB$)<,-+K7#C[#?^V+*M"RCMVP'9775G!F @6D M[IABP[;&F:+P5OHV[<@Q?+8!Q_Y28VZ4W*[B/-6*;%AY:H]>& M$0HV$9 5C&HZE2-.NFXDF]Q^%_;MHS0*F)\%7LUBR9&.,8G![_,8=T$1"-.@ MV,E5I!BYP1.KH>=W#-U!_.%A5IS YU[': 3P6*F/+H]+^MWG[W^:IP'RGV:X M/5,=O@5+R-)?O;^C(QE2W2^[&B(^2.<1"AO">?AW1:++$IUX[I-O(3TT/XGG MTUBO2$E,45+L3%X)70**)JQS E5%BH]52>.73#!L^';\8R6K)Z*S_(?BXI J M_^^54AS7N5-,IYB73JK,5^\C_#^^\-A5QCQZ4MEFC'+Y] GWFKP$27F3#M$V M:<_Y?^&>"_^F/=\CA,2:A0%(95ANV['[EH:2V7;>2DZ[\3J?*\KY0E7.ETIO M0@)C"A4GW88OY)5S)QXAC"G%'#0>O!5[C2=UC,?!GAM_L.'/4=W./!^,>^!N M-9NQFF?Q^(^.X>DQC"VN&S/ST*KQC9-B$6R3DWAS>7SE_"OY?Q+$2/1CRC]Q MU^<__D-]%)!J&(V,&7LQ.7*._!'%^_ _=SP,I8_/'1;.&(Y!=/B?#J>:?>-Q M OPC]'#_QX_".B=)GO3\"XKNT4<4_MCHB)+S2 Z(.1ROQNF7&R,@YZJ(-7X M@N? >#KH&)JFPV> H'GCJ>&8N4HN_^K]@6\$QYYD_!'%L^VJ#K^RQ8>?3__P MIV*[)-(O"NQRY%ZW8N! M3HJ5-T**9>KPMT?<9%*4,!--I "BH3D63Z,@O/C*+OP4%WXJI>]I3@1;_PTA M)'Y1_TT1I.B6_Q4!I.B6_Q7Q([[E7?@H T&)W6HV934K"1\%H:) + 2AI!.:7W^*A4 M'_7.2\:55AU\_KV)<&[B&&=O._VB4SXA!+]^8B/8?M/[87@= 9R?U'E\'I(L M\SZB/OI6^]"ZN3HO>:7F!AX3:T(N3FM"SOW-/SFU\L?*HX$8?$27%VTZ7B.O MIL^;=\V.KO5-_;H58K&S)T]W+-4,AEYP&%A=N[?/;4>'G9X@/(9CZ.[Q\(-N MMQVUUS&:1XZN)M5.A[/%*WQK??3;:6CNQ\O<[Y\;UX9/==9^D;/$:YQYUZ'7 M\K\O/7O3%/R?%M0** 0R1DD>TH+HX+ M)HDTRFHCQ.455!A2__47F\91G47&464U3KX"*MP93ZNDP3)9M)?CLA74L:97 MT[XIV\W]N[:[.]TL)M7"N8=)O_H;..L@ZNX0"\M]B7S##)?J0@RY/J+9\&"# MJD\LOL)K@8K1078T*NY.('L%IH?*HVST]R,RW%57C(A3/^;.[ROM3\:)X4=M M^+K2"=0LL-QM.I_5C(-D_E?)[*K9"GE()52K5>1*=15Y MB55T'HT9O+E637_ M;'MFY^N2_7-I%5)TW*U;&JDI/+I;)<4F8;!!O.JFD8$0L;H\E, M.MV4R#!W3AJJ*Q2D-;F4+\CEPFPS8\.YL_@2)NX6D^;M"V:G(I9HBYY05 M<>>J0YMQ7?GC"\VS>S!7%T1^R3M#WY,TN]\P]76YA,DV\LCN_/G]O57\X);4 MQ6Y \CY>UM)-00Y7Y$*I*BO%W,*'%XG3SU7!B<;LR.G.;"Z>KEB?]U( MEIJP2%-@J:(,1)+SE>(VLU1M!4;G$KHY(VP46]?U[ I9D$W5O%S+U;:9DZU>P@)O]83\T="#272]8KW9OG48C-/O:48($3GQ=A5?N7^;4[[/_* MM0/'*%;>O)K">-,5Q#2:+UW2X;?LQ%-*_'4F!>94,A=7Y[Z:.D>0I5)]F6YH[9.U\JUD-FF'R>(IAL2?-"-0M, M7EF*R5,IBF@U>E\CD:\(33BCI2>N" MG2ZI15(KO\FVP63WR]>G5[\^7?^J9>::S5_PDRVSJ9H)_Z"VI$9)K8@GVWKE M]_5E[?/@NGIWK66&X>'SZ_$3-I7A/_=K@U--SW__UM;6:&X>?6[XUU/PN 9"^DN^C1P5P>71X._EW\^M3?N M8IUT5*NMN_M[;'*G-#[.5.-<&J3^55/%PZ M@P-(^8Q2=TL!>4[ H"U]^?UM9!]=EFJ)@#P<3UE_S;O[$X/,]#0JCB M>XXY5[&YLPF##U;?&%J:(0E\"5 W[F+]M9'Y]5?[\U/MZO1SX->*%CD5U&O?]9//K4&*_B2YDJTWRD\=LMGF+:"JU!3PA%EKA#JKZR)D(#9QVM?O M[9M@!U0^*M8_1XGT_,1818?3R?7IS[=S;65]S%]2Y&IU1SL]OIIQ%.I/&!/YI_^JI73X_-3]6IA@K8-;'62JKJ.=>W(!)3WZ7 M"[)26%'SR'8$G19#QO[2__7]ZOS7[Q]/#YOF%(NCVVQ7E6!SN3\OZ4\]O0GZ M"=65[N!ED0SX)_^9A)[=@/=2O%92+2VP^,ANFS#T0$2*'[6^0[B\\+&AKCH\ M#A!VXO;W\*H>;CI%8_F"!;7T)S**W__O_PX.I'-#-[6WTHW:!B%XQR87@(^- MT-V$\ ]20SHX$ I",Q[G-Q/&-EQ&G;-8D& ^UY_C)+IP_J(@9HH"AN.($X$) M9B\#;1R+-(0))TCV3L)WJ,S"W/9]I!X7"/%4B9,4*0T(V:(P]=TX-[HSEU'=9*"_KEPJ"_Q._71]UNG-'C(#7Y^W+C0 MOC\XHB0&1\3,C5 ^6TWMV'LTJLU7[R5!" DH(1$IMFB&1+Q5M\KA$>-\=:RZ M1O/(TDX-D^8W3$M*'<4.AECHB?71G]Q/]>9;P;-^M3>->V.'/J!-:C4-$[Z( MUJ:%IZ9ZMD,&*S-3+;MK6/2[O@M6*-B[H$2;?5/U,#CIXF (^*S&Z"7I@N'! M$)9;=4G"NQ=>P3 MF3/E-*FR>IK%644\.'2KA["_5YMOBYR5)P-;01^3<=AE>.7YW(RD5. MXYTT]QB#L5.,;^$=>WB*&/""RXJU4CT.-^?DBYJKWI8K7:6X0!QU]GHG.2(> M+G_L2<]%SU\'(95Z'%A,L?8G-S#MZY;;60 MKV\[CIR3D(5Z3)'GZ,>H,#(+']V3QT4&QV2,(UE0=Y'Y,9LWA&VZ]5%IH'[)J]6J3Z_'($[?(7QJK_XFAQ>:@ KPUHL6)KTVH3% MO9%94JYG.^!U)Y9,)C[OF:4+7]7!9ANCUM?&U?WM MMYM:N[V$)S9-/(N%2"I;"4L,NS++'Z^:ME.J_A>B4*I.#S7D^XJ8O>O5^WQ5 MKF#;2W%VZ?]+<>I*J;FLTY% S8IYD_F3OBOFE\&4G$+ MZ+FLR9W(G67PBY7"<^]ZO!X(E^/%;IT7DTQL_4C#RA=L?JH;]9ZFI1B5F[L[ MCM9F/.J2WFKI34(-!)4&+I;=0P*!YABHCJ-B?QC6Q=S>?@M&K%BIQ79LN$C1P MQD'FJ[>5.12N2;7:ELZ<7(SCC1MY:W("FJ;_)9. MO-V,0TW7@E#D8K4F%^9 N'YVGW!@5]1FV177K23B+&U/S)&5G3O)QU85U#+; MW1XL=DK]\BQ:KJI/>0$&?V:3\(+'N X_N"97BHJ<+\_&I=N0D6&;=9HI^^$U M62FA'[ZBR5V[TUQS'* F5PL%N38'ZOSN/%=S.].,0]3D7*TH%RLK.LU4\RH9 M#L?O5K,IJXDW;)4@<2+ZJR@V*#H#ZR.]>*[>?3XNU,Z6*56;EB!A+5[)MN>" MU)LH5U@L4AJ[_15:?=_N3F^$-,H=S@$9DS*SK8UZ^&01+QS 8XZ]E$/CFDK:): '<&$HM_?#^=*9SO[8334)5X$M%(A@?:,@CNNC M2NO)OE;/[8>&LGI@D'\Y#M^FK__<=O;W$%PE@HHR!?1?EGJV!QQNJ*8Y9*D* M+(YPP6%U#,_0"5PUBC12RX4Q38_@N^)K=_ZWSA@ F488MY0'(;#"25"(ON(TI)O/"V[BR8RYI_*T5ES>D.F??8W\T3[*^ MWM\+*^S<=@+SK@%L\M1PFZ;M]AW]NB7P^'0-^4RW7#J,(ZS[;-,L0_=X&'SF MA@'V'PU41[O7XR$JPQ" *;^I/O)^G]?."X91&_[9-&A ']BR+( MI7%DRUI] M5*QT!U^O/M0\Q7CU_@[+<0^('E*8:%L/;[EINV"S\>BX]OAO1.V.*K)%.XM M>Y@&;NQYWP,!>N&Z?02\YWX&39WUGX+K0)CQZ+#9^X%]W['[+NC20'4G6.\LC,\[2R$GZ6-13\.( M="36!4?Y ;>X%@Z]2N!+1B5SG$RSV'15M,@6-^?E2JTJEZO)_K;J18-B6VIC M;]HN(O;%-6O/VFZ[8I4 Y_&7G:C+:7L$M^)QU@#>?"S6^;(/KX_*1<=]:#[> MWOPI;)IO$PM[[O:[\$YCA-JQQP;T\)V'9^],#\IO*4#Y27UD?;#42M4J_M'; M(O\<5+H>;)T+.8]3PPT7PI7+O6]IC $/:FYM9#+R:7%0 ;G;218U;C[PFK8 M:JQI2*@,TAB)S-:['/QN?>H<_[T-0A,SM,^FL-XT>J3.D.'*O/QA<7:Y?8;X M,3_.CXW9]&\DT/_*MAYU%Z@^1GT*)IVJGH[ZF]1W(DNV+C]E?FOF>E0XW9QX>FRQ*YQR@@C^OORVX ML2! M\730,31-A\_ 1O/&4\,Q<]5\]=7[ S]0L,Z.PH#BYXM0/+$0();D4_5VW'&$ MTPBS='6*QU#(O?PQ5%;&^+/UU<)'$=)1:1Y#_J6.877]M:OP*N/$\=E3SW#2 M%\=*BEQ)2Z3OS)#)G1]/RL/UK^IM86Z9S+>?"A<67UX8I"J38^B^4L&EP\>U_YY@:8-IIB^1TXS< M\>7VP9.:+I&-^]*7LO/TTQRUYY7(,:1(@R6+&3#5%CJ"6=(YY@Q6*IU7=2XO M9KM-\1W3"&]$CVG5PGM5I_-B-DV&!/E2EG5BIDQ6U9=-L$!GN^<\).9'GE-_KQV[UH M_=0>OI^5%O!1QOER#KJDD^9)E2)KP['('\9V\2[)R*DA)S^?FZL![-GZ4B(A M<7L6S]2W'ZW/QU\?_WQ2&W-Z?6DS-&$OO0!)IM5EIY N4F:GBS:'C1<^ZJ6_ MOV:G>@SP=*QV)E*'.FLS:\),C4B45=;6) B,$_/SM:N>77IGS>FVUC,!7-=3 M09,2XK]2E@OEQ<5K/MRE3GI MF5J%Q3V&#'%OHGY/LZ@L6_7TV4\.W\X_ONM>/+)O:]0F6%L MM#)3V MOS(3MYJORKG"[,'E&1:S<49";C6\N)2!FSNI_.I\OE,_MN;.L95I)N^WIU+C_,.9\3O?>H[-&\?N@S:8AV=[(+P, MD&.&A6.3'BDR!>X2'PXNZ2*5-C^8AX2(5&JOY]A/H.4\W1Q*_YD&J)V2]1DD MN>]Q4Q=B3RQHU[-*5CE6Z@?@50R%8YIK%:.O8JOV-! ? ]I(,#X6%JQN/\59UC>RNCT[H8(-5L M3"DEAZ!2A/GB J.(KHPI87^@?)PCE5"0+,S\T.M>10@G2/9.0KWP5CIRU(;1 M?"-ROC:5,F*!(:4;,$(=G_9)NNCS9./UU8>WO?5*MONH,^9@A+Z040/H; M+0.T#?Y2N%12CRI89HP;2K_JBSM!!64I^S,>G9?KL\P4?"D'L+WG6I8)I6 S MD**YT2$T/ W!F' Y)MJ^(C7I2QY-W76\@X-;I"7[+/W[BPJ>3[\;/BPFV_E@ MAD/I%*Q=. *\$DP*-NG.1^3C_MX G+' *@=OO^F0/%!-R0T\ VG2,8#;-G&Z MLYM*)@)!2TO#7JZ7"\8A)2QU.;$X.U"3BI3+^>YS;L)]+DV3=(?2-8HZ<,U4 M&D\457D=U8VX6=-#,*%,YZW_I3G/;ME(2O3L@M3@4SCA 0T9YBQO23QE.ZS2(Y= I<<& M8,+Q 7_3K*[Q>WBZBI+:Z/"$9\8_PQKT&W^! !X70SH6#'FFO\>5!CP3ACY4 MJW(A7YEFEO:CY'(I%#95>YYU>Z8]U/4[=L7C)9M/ R*,2RF'\-]/0$]?V=XO MW0MDY'.9("*ZOUDA 95D+LP<4[VJK:Z4%Z:(>Z5:EI58B,T00\Q!.!$>96'. M\%?X#)PIW\&X+?[81*X#*S!&EXRSG[(.]F/)L7/;X;_"SU%E2'H9PH=?'Y2C MX_;@QX_"8HPJ*$0_,YWZ:O[Q@ OS%DV(U/H.EJZ,S])8+_UQ6'MMHL*!!V6JG1=NVFH7I(^!4_; M\:*.&$]6WZ.MLQ2I2CQY>Z&-F5B4$V0-T-Q.R>"QE9.Z*'^ M"@D;+*A=A*TBQ;E%:QK*4ZK^\^J]'XUZ\8D\$S"SRZ19^NGZ_$,A)O,>^WBBY^25- \XRQ>Z#9%:35G;GKU&J=83:JM>AD4Z%0Z0Q8\ MC.5 H=/D['GUR,;P]X(JXP4N0+2>JO;<&_ 24V/8/(JT;V J4R!GL@M;NZ\Z MDG&KGVVW/31U\S;W][[:;RR@2=CZIEVT6:C6:R+=BU\DWP*KY>5<=38^ZQ1@ M[$Q-V5CP'#9'B$VF*>$RS9UOV9P_'->NR/;RM+&+9AV.Q68:C3"5UL3[S MOZKDY**R=6"6IE++L%0+ MBZ99Z;[J1@43@5X8C@8?=CQ#IXX+T2OO2F"9/!J:/@8>AZT<:*Z 83,)93>^ M'MY'0OTK_,\8)L.%3#2LJ&-P=-BM0LTK"$L778-H,2$4N_V]Z6L03Q=-*"[O M>8A"\N%B&)% %&L&:SZ&I^EJLR.>)1DMO^4F3*DME5PK;21#Q07GK.F.RQQ. MT"*ZD#K7SBV:&FY2RU@YOF5LL6?61Q\[]OGE52[O?2QOFG=$DF"B::K?A7?2 MO1 C"UL*FNORBJ2X;U9!6*/\S M,>GZ97O24DGV7MD\3S*91YD<;AW?>3/RAJY[>M&ROQ>K,7E:(2"CXI MUZDQ8# K;2TT2)T'HP/2JK.GL6>("T]3&.87G,#2G86_%.U\IUY4.\[,G4;\0UTU]6J9KSKV)L87W,8;(/.T M6LU9YYB?4D"[KKZZLP4TLCM;'4WM]HIJY5D',5,3IWD24RI.UW42XR-FGV<7 MI-')./4T%FT_G/CX5.U]ON@,?IP;V>R3?&Z&SB_U6WV&;L-Z'PLOD\5+8,3K\E,I__G3 M[^-F/K7NPBQDYY[#?PMGYS:, \<#("O/X"7PWM<_/UK?;&MTKI17P'LOD9U+ MB^OFRLYEF.OF=GV>=TC) L*OA0J50MWK3C=/O5]/E_$,:3WE/EX;NFD_U28L M8[^A+;;,*E)A->8LT_^^??L3&//M3?Y7[8M2/5V&W^>TI(MY;*.JSFE+;T43 M<[$^NG>52[WX]=<'?>/*]+>H[4AMMQV]C8T\!EP-PW*-9M!S$VXK]1MOQEV& M>1J>4T&/F!0A%V+)89Q[[DZG"/[2V.BZ]11Y(?2D6DFL(_CSZ%'R00<.,Y/?!HL;Z6W[.7; MHL5+M[.3B_5RZ4]-LZ_I[__W?P<'TCFH0NVM= -:[QU\]V]?MYHZO*+PCD6& M0'M(!P?"3-",Q_FCP6,;+J/EL5B7Q>Q&"26'G1)4Q^S"88L\[Y3X"!Q'G"I, MR&P('19ZW:L(X03)WDG82/Y6.G+4AM%\)UW!369DO;*1@$HA_*W_BJ_AGP+] M*W3O__X+A(ZCN:.KP,DZW$5X>(_.+,QEVT/B<FT?V]"]8TC%V]' ]AU_J>J5TDM;X[ 6@=&UVX2$][XG1% M-CU^[,F\]9O 4E8\;E&:=]HB6$7SCEMDKPH/78PAY[@]'HFJXP/813FE;F*6 MH6*!#?;[<]L1UR<>A,5UO(.#>[26KUL78/#!88"+'1U5?(_'=\-.CYO9"X.W M3 6,Y3/8C>#."_Z8:9HO1((YX9;Y$.28;2< OJ0Q-TDN%9.1AL20^M;D)8C< MIJ"I?']O>E=YBK;ZQ)+8.6Z)Z;X=TCJD6P_(366RVS_6,W:LVZUBUS^(>:YY MR\H"\Y:3QBIW3CJGW^^[YO%#<]-"N2("1QA"6.;O% MB\8HY,AN&/$.'&0SP$'*Z>,AW'<<79>^,.OR+&)=9A458@54N ,+>X4TF+O( M;*-Q9N:I7=LB))$X#(WMWN[N=#./^<+2E.L"-:B%_)TC,,B;:,7'NSO<]F)9 M71[ *BZ((NS#ZJ*!Q[8J$(3+G8_=[YW"T8?C-_,]NN_<9S)-[">8IY!2Y5)X] MRR%#W'/Z/-&S*(#Y%.Y1+XVO@_.SP9_C("!.8-XSXQXOSFS)..@K9#:EE)3+$;,?/$U6"V7+/9[:OCY]^-"XN'PVS\N+CJ=6<%N^H99B)_@Z#;(98QV._N0'ULG/]O5W?6HG]_H-L31FC4QA MTFJA)N?SRXP?7@U 0"X=4VM>^36#+2XJW6;W]Y>/7[^6TVCP+[T8>DM*"B+U M<2IEKW#6*=OFGZ-E#9)L&"$KOJ5Y\*I+_7YZE(!N&'WIBJ']GY5-8?/G\H?FR>F<_$AUJ_.SUE8RG$"_-+X5FL M'NXF559\5BIM<1=]*BMJ9]]'=X^*^^FADU%63#9Y5LJ*U;*<*]:VG17/UQO, MF,J*G:)W]>5S^SAW;RYK866+MBL6<7"A6MIE5GND.1RVYT9=AV2H4^[^.BXVLLLJ$,9:" MH24K^>)2IE;FX/QMW%Z5[Y^-5$)';D+;"^ ZQ\?VFWT5[ M88%%J]^K3Z>&BY -?2>I5S87CKU.^UI]5#2&2B]W9W]6BYMV#O]KO+^R/7U_ MKR(1/(7R;@P&HIH_KX_:S>O"0T&[ZOTU7[UGM)" &(B3DF:+8@8YML(8>F)=XJUS$3G2'CSNGRHO*P42W*N$E@7H.\X><.56V?B*_YN;^%;B%=J6'UX['5/ M=TB1NW6M5^_?@)B*)_K-2:'R];/RIZJK/M']AX>.7,)5S2+]_*M*]30(W(2? MQT$^=""X;3 NJH>)R(/_'.(P'X:,,Q6Z)+U;DI_CEL1.<(BA8#4-TR":40W&D:5=@DMC^I_39QWPYZLSK]O_:IQ]*?L'K,<= MM?[MSG6_YZ.2&O3!&3DM;7$?,$-\^%FXS(8F!XP&65#$_OPB\0 MW@D14!P= 8+Q=X%X968(?F*JH(7_:]E2@XFFL$0%8X9$*@)'H?AU\)M\56'1 MW-!1JQJ6I$JM/G EHKFQH+6*."PXKTWJV:Z!OT)YX_9-3WQC7G%SLB!_GG00 MM/?".M7A6CBZ!A\Z'[IZKSI"R_FV=?OP7VDVJ$=<9]S,3&E@KTS-A8 M+E;.Q L>7Q-MNCOV4F&.6X97A8B"PWM'M5Q&7W=VU*,<$@L+/*4^*G8?[.; M5(\N6AL;!*DF!D&4^NA#MW)(E4 &'LC3H&,T.FZ[@ND O!E)WZAQ* MQP[::'>JY^E."R&S932.0)+#QO0GO=DG=6NW6K *1][?@^6BT6;'0M82W9CY MA*;1V#*D:TOZHCJP$ 7-.:42]9LI:@X+,RQ&/!!5EH;[Q;<90/=I-"'44?S0 MB6TS;^F19E;"-ESI-27=BM6=]!T\=C2\E HSO/S/8H'0=2LT M2R(*O>L? M^6?P("AW<>_-Y3)[3VV/:#HW&"SLQ9Q6\Q;J"%4F&*4L#JSMH2 M_UC,HM/H Y\Z_(+0(R=X"YB.X*>Y!S)Q].&(!Y_^@>.O?=K0N9>5?+Z*!G=F M.(!]T>^9N(.GJR!MHE^\T1U".(OE&KY9$@9S),7J5\H.0/\M4T&4C\ M*;JK%'*FT[D*)"3SL@^E(R\NEAF,\FFH)KG%!!%NN#[&:8],&G F&N!1>,/] M/50N$YP8KJ@Y[>OW=LA8#"[ID85CO9J!4)HHNET/2Y(NG"693EE8(4*'62PV MY]:G3M]9E-?B-Y-"'=CT:3V;;@>^E"\&BK]K>"2(@"=8[+>M@[^N+^B.+?:@ M^DAIZ5][]J?&SZ*RL1Y9+=$C.ZV/OGGE^_,/GS]]O.R\>A^B#ME<$?KLG+*, M[8*!Q%^BX;R_=]V AZK<>]YF5/A-VT78=?9=0>8QLAEMO)H,[=9\,:=(F/"Q M;3 GP',"1P8>U#? U#B%'\#\DB[5!W"$P*B0I6^>VI&J1257.U"*E=HA^)'2 MN=YPN$N$&8&0U[2_%_4A)V+SX=S1I>ZZNLY3:U:;F R'A%ZWQ&3/NG&!\T)Y M>#J?K]5'WM=C[>N]]O)JF&+@ZSQWDP(BL1?0P-D>_U?K. M4%>=<;TP>YFOWAE0 M^J](?\3Y7RQ"5 IRN1I7_"R<.%6BEYF5>&C3RT]H8V!!XMFJYAQM,=>WU?95;]C0O;9/ M'?SRW#4HL6]<5VE6M2R7JLGSCI#$4T?1QI-K]K5;'872OWA*I2 KE>2;)R0' MINQJG5]\"%WM_K M&I;1!1N(&5@]H3\'.,(LF.TC(OYA<3PQ[R?]>$*J_534\G]+/^Z7R?6NLZ,BZH>-3?&IUD?'K>;-I]KH3_Y7T/$Y;8K/ M.7&(](4S"+,1A+VT&W@3MZ4YIMN4_EE\DLWR_?FQ Q%^H4-UQL:0G^I-"JE* M!66^^2KSCW^(F^2P+%3!RGO))UO$XXC)#[%2_8?-X)!>.WI7-3!+^N8EYCQ, ME6CBJMZ*)5ZWS@U4+7C^(2;E6FHW% M\;((UO,P)S%D?I7HF7.=X6E?OX+'WP]T\U%G4YRFL5J\M$B/I6*6LUJ&RM<* M=X31#%P/["G\5%A]7S$5[%:]D$LP5QI-O! 1H50 MXL@H%O[)%D!1>5E61/]_&C,6I_>U/P]C:.&5KI9A2SFY4ID-KI])_* H1\_) MT!QX@<$'19WF+&$VE)9@[D2>CMOL2K$;YEWQ:GF[4LO)A>B\]ZECWU]8GK:>@NRYZ:MNO2 M]?0K4R35,5P,.E#36]-4#6JI@ZONNG2C9 VX"%#20?J8$I7.Y0N]39(PZ:-^5[_ 8:%>[5T)LTHH3Q) M@/T]7*R?"5"#[Z=7L]C\2R6@7'U)D9UD7. WUPL M[J<#0JP_X#\_TMTR3#B0QA $H^/![QDP8,I'?$3=3 M2S=Q6_A/P(C=OMFFXI$6Z!R6.^H:+BA4BL%A0SC5I**:H\X,8 N'%63 V#0/&&:>ALOHF-;;#VL=8#+P_>++OO2:@@/5[P MX>F61F33]);.+W*32/EHM&VP"EUS>+B_%WZ%@;T-% .&KXF[C9O#TEPJKH#+ M*TM&"UXQQ$0>K+1I]TU-;)^X!N60SG=$]21@GB)*@H$E(VABN,AKAL4W0FN" MA1SYQZ'Q*@A>E-RS'2^:-=1LV(5E>X(F8[)-$LPFGL[ZU/D:&=W[5DM]M!WZ M.% .>RG?21U[ $_#5AC:8MR'^!9MR6["'1K;A2P6 F0RP@M!OH0[QHD%=$'" MXA$G==NPM;J4<;!]B #^.JSQ-FSMM?L&?\'Z?Y L;K_9\=?9T/%_0D2AV@DZ M4_C7QDG6U5?IWO4;KOZWCQ,='E'M)A7D%D,^1.)WZJ/+3X_.-_O*,&J5I6MO M5U=5J^02RVH+]=&=-H#F;GPT%#!P<.'MZC,PO'"+:' MQ..QF%C*A F*E&:,FJDKEW7Q/[:R;*]N=2M#W:*VZ[F<$KQT:@>6J) Y;;JD+]_;CLXQ.+@TK8?\-]^ ML_"*B;[MHN8>O.C]O:]]%>P]C(OO1-@D\PWU@0@\!1#OR-+.D&HC6VP!)&;8\6 ML0&4@4^8?8W"+Z'W.SX/LO)/;C3+%%KBOVKY4@)D :50X+FRU.B[&(]U83OX MVO:01V9-U>)1V<8?5G%*V^SZDHFJ4D6U:>#ARV2W)Y/_4/H!NU&!YMC]V^UY MS*(W-(1.; VG?!,)POP$AHKADT*<.?@81M/HP>==F9_R_A[_FX@]B3^([S2! MW<9_Q: -]?U1S MR&P4=@0?0<8/PL'A6]IPJ>#<=0K:&0[B4?0=MXW/49@>IRM8#[(C1:%@,-MAU M>T!P6A<[Y;%+%Y8M8(R SV!C4!')SBZZSF *.T:;>K[T=I_0 V0)/C9DT6;/ M0$9BPL11>X8&'VPBK!N>H6X]&HYMX0L.2>XS^0MO=-H1#\4PDH&GZ!XG00$!^ M7RBR>[&_!]J,8_T$P4KV'1D_ SMN@'@5T$+^N_%TFVK?U>FIT3.DP#:#&Q6Q M5" 11QZU73VJ0:B!=(I4S:[VSKIU\0..EZ0.FQ85>R'"8L2$96 '*&<5CHXA M,7G/H]RD01W[#TL;PK\;F-N(Z&;Z3*"3/0>U L\RA41B(!^8+O>_T!2FONPS M5"32'JO901F W8&2FUYOVE;[@/X5,'SP "8;@S=B\,T58MP<0*YV"2K@K)@:EW!<2K">\3UM9T ^2<7_;)-SMTZ1RCT?<8:"SF(]B+ M47:[F/-"HX/L)H]'*#W)-+H&LV-DOAZ->6M3K#]9=#4C1HO1! 'JL!01HU/P M . $>\#IQE&[@&%YBI&K\EN4>'Q;0J7#HYF2"I32@"5$61H;WW5W=L)2=*P= M")^H!7XF,QUXPERDPO_ Z?FY<-8X=V19>%B39OEG$M!T'%3W+5'+-VNI"SQD_!P5"/+9V7QF+*AK5I@G)& ML+6T"[:F&VPM[8*M&Q%LW5ISY)?=!U'&)"_9NB8"48#H[Z,8-@UFW5O, DU2 M&6<\Q1\P6\0'^2)KA&($P#("KXZ;C50F@N?)RD2,)BET86FSS*\[9B_L[Y$Q M TL2=@OQ)W"$Q;/*,?YCR'%$MUC$H,:=R$,,K/.LM@EF]#!X"3Z.4&*8:8:! M2M-P13F4R@K2<*B J_O.IA_#X;8>.K&1J&-V3SSK''G11=Y0+0^F263A!><.2X:5%HGC>D266%'^>4NJE2NUM-:4)C^2.,>5A"(; M3=.P*+M"A:5!R)4''[&PE1"Z'C'!X=C@K+N1K<5U';T43V6!B[*PAI5*L=V9 MI[F&K(H*4(X/NL<6HS;171& T+Q$7^LW1?4@QE+1*",Q@;$C%KGOZ@X&D(P1 M:>P= V5\#3NAL3%GGE6A :XEEQB\<8S\0/#*>)8%<_0FYA/ZS)@ -Q0^Q :L M['@EXVO8R8>-.?.LR@??_P@5"6!SF=5R##[B@3<%@+8SG-Q3V M=U(CZVO828V-.?.L2@V_[,FVV(HHB,B$ Y_.Y?BE(>26[#@DXVO8286-.?.L M2H4X7T/#XDV[)_'6?#\ P8<08%U0E\R$P<:<>5:% =QRMI)HV\GK MH 4JJ!P>:SS#RA-6L(LU)QZ6S#RO:)@MY.[LY TKVZ&WVY&N%=9W%D)]H2:0 MN"KUPWA&]K'S,E1:DO72ESLJ2-K?LRTJO.O:3JB-*[[0R*]X =.3^EAX41-R M#55/F4,\7=5U^]T>.TDR2UEW$T)0R>/5-)AC8^4T^WLXR]MH@7#!JJEP24W0 MJ*?)HM,!?O*QV&1>H(<_L7XYUK>$'7'6.D#5^"\1M!P?6"@<5@CBF/- MB]0!$R7_[A:D? N.L"=U>LL.C8FBCEC10ZMSS2F+W_3=\=_ S?%_A5>!__K$ M/C@UU+9EPZJ;O@+NZBIVI4;_*$L75O,0OLU&3HK.4H'S@!AZ6(.*_1P^!I.A M&:J#'/L:%^V_TP=I@Y>]P<96ZL$EG3\PJ-H1;J(:AZN4G8/*.B/]K_'^[ E$ M!C; [N]=/V+41A_L,"">C386=*EU)P%2M"A BAH"2(GIFDPV225-=YN.T=!= M@=)IH:WB]PCO[[%^3-_J#CTD8O7*\=V:%/1CSCU*FIC/8$N>X<[=B;>_Y_?, MJKX THEXFV TN^C&8$E]C3('J\.V &.WNIC87;8H8D" M;/K^C0^U$$"U2',CM0@Y3'-B8?7=+GZ=Z^ZD%E8PD&T@KR?:$1 7R'H$V8(XY(L#.@$EG?6,6_?Y> MHDF?;+!+ 7C/R>E%8,6CUF4I151FCMV M7)X IW_U28<39CD"]X.7#):'8??<(:N81L<:[G/3T74+WL.=@97!WFD7X4*7SU2$@BM5'.PJ=>);1--&AA0O)((%<7I:M^:2"0W!% M/*(EL <>#95UAXH-X,/^BRH[9/59_::I8^]@$S; MX_^T.G5$1+R]NKHS2$X M5N/X_MSE5TT?FYVM8,# .&C%H>5A%*''\+""MA+;H#G6$$D:7DLD K/^LOIT_2J8Z97W'DFV9 9&A]UYB/#\[/]<]! M9W!3A&!$@$7 _/;@ .=!R.';@U%*!%K#PC^GK5J&VV4V(?"PCAPA+@\%EOI@ MS[ 8>0 09PYY6^C3_AZU*FE]-@X>QQYU.&/3A6&5AGB]-)SG2T NPO)%ICR4 MN!P@#PCN0H?U2*G:(X6_.+ 5PON#(-!-UON K>' 93>V.>R"L^(BCG,'(5IN M=3Y&X37GO)N36\%R]$+TC> 4\/W@%\&713E3 X-53I]=[->^\+JA#[G!,_ 6 MZ]@>:6',3*)8-;.M'_3A_MZC_H2D,ERWK],=A@5(*J)5M;@\83$8_:D'7V4] MM&W''GB=8$D'&BVLIQJ8(6&#&7JV:S (.X*TH=\)K#/WC6B29S#_YA M=C S M$/3%908][PSF:Q!+]A )R)- GOP7A,GN3CX+@DD 'E';MV/#6>H>NE[!S0M? M6F)U#@/HPED_"F]\H#(M)30?F]/ KV147X!N:P';-@V"]D$_7D>L&93_5+]+ M2]&M#MXD+?15.'UQU47^Y% ZUEF8'"'2!KQYW50]])3E,8@[&N6 ?4B\ YTY M[:;A=I@[VU)!(#D,?8FR.#HH#KO+)(>,07(6 \%MAE(L_'!?A,0-WP_>^O; 9HQH.ND?'+S"32U5>L1 L35[>YBL"R$2!KGH+OS"0/7&^ 2D*K;MDK"$ MS_DWZ@[^#(QZA6::[<'*F$8"2QAN07=_3ZB1NZL;7X%$+[!N@3[M^&"D%IP- M7DV)036@^[KCSN<92B0=/0/MWSX?6\1-%Y1]'1UMFR:Q']>"83.!4$!T1'S4 MN:5 3(-UCFKT\RK+EG%K"?YLML%4\CI=9OCO[PD$229_I"[(-M9]T0KRB39/ M46-"T;!ZMF'QT4GXTGZ7+^I0.G4.I3L$GW5:&!#@(+DV);QEP.U<,AD#^<#&MR&$ST"TP+&4*$V6!^,* M\ZXL^:ZSR?+?[I@1!9H)R D6K.HQK&$5?230.?"_ O,/9)9&\5I'YQ'GIMT; MLD:Z0^EZ8('!U3%Z0GR%J2&T)Z9SNP91A86X<7>>RJ8YJ8^VP=*T?'PE,00M M"-S@(9\M%\[T,O],T$401:"Q,A^ O4AX@!.N*!LZ9P^HK!]'>!$:M*C^1]S/ M_3VF@^EQ%(HGKL0IZ$06V"?.]>(*>^V)W'SEL+#%>5RT)H6?XGOO56,88#O" M+6$%-+0'4>'%BLQ1N" -0_XH?NA1I9PR[A"E@]VT39>")NP>#6Q'_O M8'/4OXH.$) MM81#(ST6Q?$SJ&'/;SS>*L=AM7*T8A=,+!VQJ0FWC5DHX3O(Y!4\3K>(=4/A M5Q\?+;)("ERA8.&1*HN$*GP$A_=1]%-#1A<[B_V] MKNV"T/-LU\>0G0S"^)&VINHX :"Y%'R7#%!RM+O@-%$>G]5QL5HKS"<1G#D# MC]=;+4*6PSFA/4<=$CG$P\#0[/&R>U]3"-<(B0FWE6'&,]^Z 3OU*W-#"R+I M!,L=PJ95-&D?#:?O[OSHYV6K;O4FI=I/ ]=Y-W3E6>OC 2W2UB)XQ3142%22 MBW3]_>+T0*DQ1D;UVK9Y33A'0&3HB.S6XK<8&*C4T<$^[Z -86H#=/]U&AWK M0W\*O$=8OJ9WC2;"M+N\M@TK@\6T"*9@ZOKRE-K'A#F]WR^$3"<7: M\8(W.Y@'"V#2=6[(=&RW!U^C7KV@H)U$FP=_[.J'^WL_PC0Q7!]9R(_DD?O( MHHCCX7S2"0CIS3(+(#"4.%9KP@QRZ>YT@@;/B&'H7,/ M^.!8$;4D"\YUJ2IG?\\="U1S5S"8[EDW0'K.D%_,&7QIU'GX7P)%V<"D\4LSDU%+[:>"!&RPJ%W%&R0(5TYVU_3U0 M#-S,IK@SS@>"?YC2 'Y1%/Y.CE#ZU9;;?, A BS,K9IP])Z+-418A&P M$GS]RL:0.Y[AZDR3(QD>^"#U<.\IL;KJ: ,^KH=AW:N"RYC=&HXINCPM*8Y0 M:G;@5N+M8&5A_(M^=/M1-4P^I]VF>P.D8U.L,0CX2$$[=D4-_(W \X/U8J)* MW#SF;5.(FHU&P,=3"#P4BQ;WV^1(/NSIH,*Q6(X%9/;WQN24*)S%X*?*4#P9 MBU"%>71+5'Q'5DQX8\)68:E UN:O>AT;B./R0"6?Y6) +2D6NELO20'4I!0#V)7HWS+?"I)*?K2KK;P^D#;!A>R"_VOR,,8^ M%)@Q<74?#5!NF/$,ECEJH")+E^"RWWZ5,FHA@8L@?MMSD3A$8;?1T M/QPYYK"+MP:%#1'ZB/,DDOQ'D;=QZ#'DWX2J-1//.RH9 M-\W4SM#ZF%@\L3&<"P>PDX]I9CB91T_A$=<+<3X7;'(I5P3Y5YJ7SQ4Y(B7_ M4Y)KE9)6#!2);J0C*Z0>I@8%'DO%KR@_%8H&X:;<.70QS!")VXN MR9T#)G;\"RPD"QL8N[^'LTAI0"VC!OLR!;[(IPX"# BX9?"V.C\?BP,&>,U" M\%KRQ<4 %PTVXXAX/IM+,R9OFX+1V1-"'Y]']!84N9@KD-8@V15(*B$L(_F; MZ&DI6QPPS(E/PE IR+ER7B[CC,FEI.'4IX/%5RK+Y5J>YO/.=[-];^*HI36.%)D S9"9FEU_>!O!Z3!?G#[2&/>L!# MP8& .P3^4*TF,^T"!H)24^1<89KC$V5:4C1YN5BNRL5"(?HUS)(G7:5)9F<. MFSG1V!)>>:SW%&Q'H+VP3%2/S0+$R$C0#1*>X\W6P)X'3W,,[/00I9K!4_VW MAQP@\5>7U51T\1.B2D@4/(-N;3[XV:K@(S(RO]MWJ!R3/UP.1@R+:E4'KA"K M[J(Z"G?L+OFKHMQI*/&SJ\%/J\IY4J!%J3Z/RF#I43"CZ7.[V+(LQEPC'4+?P;)' MWQ+E!K:N=L=E?])M"&LS?DT#7;1CX>>Q<)*&C=,%C2%:+36E"O\I0B%42CDY M7ZPMI@Z*2J7N:(:U:WZE0V2#OZC/=1UAN&%2TP\*[Q-X>6)HGCREB,MH;[= M=R@=A8HHJ(+%T:D^H8&-$E2@&I XK#UXH1]V(HL: U!))I4N8S2.3VSMZ&8/ MZ]=Y[6MD[3.6EMTKLTR2NKI+4J>;I*[NDM2[)/7+QVFN4E7EL6C^E./XC#6RWH.%CX!DR,?#$V)#/^V7RM+%<*^;F]TYPH].(Z4@1= M)EQ/U?^,)N%4IZ#!Y0*L$U7Z0^V&6'>&U6/9/92L,PV[DUP26.[X7VWL%L+U"CV4 M>;YY!990&T^K!P",;$C;C* J5:"ZR%R(S6)%O&MAS/IYM ADB%.,G2%$(PU MN<#C!CCA^/#4'-^ ISZ)%?#DG%*$;5?*,E9U$>7;-U)WQM$C%5.CCNWJI M7;U4INGI6UHN,.URU5+%BERHYN5:KC:E6JHDEZI5N9H+[*OQ%RY4*P4KJM2* MLI*K9*Y8:A8A_U.$GVO5TM12*99. ^LS0Z52%3CD@I)?JE1J*E%V!0.[0JG, MK6]VH51)KE3*R.F6Y6*K(N6)I^M=W15*SBZ1FBMQ"H2CG"K6E M2Z3*)44NU$KSETCMY-VN0&J#J;Q @51-+E9J( 4+2TG!J<\&FQ%\_&*^%CB[ M,^[5KCAJ5QRUYN(HL(M+!;F<*XIL./RCE)-+2G5.92M!'LNVA)$KABA9)<*^6%$%9D!8N2*LHB0K@L5ZME.1^8,CB' M0]+)ILKARI'#Z MOJ" 85+.SU6/A'T Q6J<%QGG$(Y7(_G3V/D3$ZN36(R;T$050W*8IV0RM;U?[M/;:IQF2 M@(*C%;E<+8*+6XW>^$6?EJ.T!S:CU@HUN:J4)P.=8T5/!;B!1;E0&6_WB18] MS9@(* B$J2CE,K:E]@]GEJJQS/0B2 M2YK;9V#Y 1[]B4J8IM*MSFH+=N"XSQL5[T4+7119& U-U66N*/V :<9'N%<6 MFP_]GPIA#U\9O*D'RLTPLKXQ175=GRYO8$88.:SFYD,\AE%*,O<.? ML;]G&N!3F<&BBW(E7Y5KN<+N%B^]/C($Z#0YT"\;8.(+XU!^:^XT.FD2A+TJ M4^'56"*/7B:FS\2]B*DP,"KE4JA5<-%\'KV&&99QFXFM!0MGZ334Z;L0;2JE M,;KQ2.@ LE*JRH5RB8H\_/-A4FEI9N/S23P49S1$/5;@\=%RCAZ:X<-G&/W_ M]JZL.6UD"[^GRO^!2MV'Y.(8)+%.YDX5.Y@=L?IE2BL2: $M"/CUMT]W2\BQ M,TG&9,9)])08D'1T^O3ILW_N7SHO&&DH%%^?V!F8=ERPCNO%LU]-;>*X7%M3 MP;!M#,+VZ>;^3PZ9M:7R5RH0)A49\%&EHG)4'$DG*TYAOVX_+75$QP\4K.9B MSO=C;]4C87_TY4D1G$]=[V=T$)CG%#"&UDV4;K,,>YLM<:EH*V$:0UP:K"]) M;;^CK'7 =80:*=V!T>MXPC-B#PYEWPN6#_D'V E-173P'SBIL?,=UP=TC3#+ MI0'H"+F=$Z9\'R43""W ^/_D<2[BYLVSG L$QQ'"6>PA>EI2_/2=Z>/1,4;B M+B;!*'S&@WMV=#Y:Y3[.=, "7. /\'F-"]]@ U[*NY^X=CB'0NO[PJ,4%Z"0 MLQ64JAU+.X$,$30T@GAUPK][SA=<1$ ,D;*CHL(GZ F75%8(HA2"O!"<-9\FJF38(5#1@+$A/4P0E)4#2!V=UT[R M16XXH]WV/1(AQ* 4E!'F!;*-GESQ0?&O5]!>^T:(H_YBUP;C[1XICJ)$/58G M]%@OM:G/R#E9#"KH(02!ZP/<@$[%"4.KT?SEAI1K1<(,IE ,8BW4@1A0E&&I M'KQ+M>T T$R)%W7! 7A**L4#(=7]"H7Q#3$L"5P@\9S0G["/,#7H_3#:"EP, MSAN 1@54\3L"Z.R8Y%\.5XS=@%&,UKJ$7@EF(?G6:T]X=M2;-\1#Q9J,,"'^ M@C&'..0OT0FT8>&=_O[1SUTX)*6+'@7]BJN7;6E+.A4CT0)!LA!AY!&V \>T M@VZHOP]M@@-T5F"DA5#I$'T1<\T)+GAX!W10:*P6(YL(M"]% MG\'/$5P/*T^\X+:'G?D(7@6>I)!.C,M:PT&?\A C#3R UP(H, ? J%3A8#OD M6L4!/$M=Q<@9AO&*9>"U*ZBA=?-F*'DV(*Z%A@^65E4W8+^F)G$CC(=V'"(N M5JH)R*7\!R[UK@G8,P,;RHVY#VRN7,@S[R]HD?Q%H$ J&T<)*8I&4IX",=O>1NI)P).@MN3X##U=Z3$/IL-D7G#(L8(>S*^=5SD MZ8&^0D(,BI8BV6+0.@#@09]A?4E,:/@3O1[@,]&B+F0LF+9/(&<] L%*35B+ M2'\$K2=_>LO(Y/[MD7[X")@QZ!LG+!7[>+&- 5 &*74MK'ZYO =BAR)(V-LD M7187K8_3[<16 .,$L-].L2L_ D&@HXG_ZNC89E)O4Q&0#/I81+N>@LVIMY29 MR.JW/V$FM5QNWF#\X@ ^Q6"_2-5(�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end